"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_laboratory","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","age:ch1","gender:ch1","patient diagnosis:ch1","tissue:ch1","tumor stage:ch1"
"GSM3521753","Breast Cancer [SH46926_Cell3]","GSM3521753","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0211","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521753/suppl/GSM3521753_SH46926_Cell3.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521754","Breast Cancer [SH46926_Cell4]","GSM3521754","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0212","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521754/suppl/GSM3521754_SH46926_Cell4.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521755","Breast Cancer [SH46927_Cell3]","GSM3521755","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0215","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521755/suppl/GSM3521755_SH46927_Cell3.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521756","Breast Cancer [SH46927_Cell4]","GSM3521756","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0216","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521756/suppl/GSM3521756_SH46927_Cell4.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521757","Breast Cancer [SH4XE05_Cell1]","GSM3521757","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0221","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521757/suppl/GSM3521757_SH4XE05_Cell1.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521758","Breast Cancer [SH4XE07_Cell2]","GSM3521758","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0230","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521758/suppl/GSM3521758_SH4XE07_Cell2.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521759","Breast Cancer [SH4XE07_Cell3]","GSM3521759","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0231","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521759/suppl/GSM3521759_SH4XE07_Cell3.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521760","Breast Cancer [SH4XE08_Cell1]","GSM3521760","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0233","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521760/suppl/GSM3521760_SH4XE08_Cell1.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521761","Breast Cancer [SH4XE08_Cell2]","GSM3521761","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0234","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521761/suppl/GSM3521761_SH4XE08_Cell2.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521762","Breast Cancer [SH4XE08_Cell4]","GSM3521762","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0236","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521762/suppl/GSM3521762_SH4XE08_Cell4.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521763","Breast Cancer [SH4XE10_Cell3]","GSM3521763","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0239","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521763/suppl/GSM3521763_SH4XE10_Cell3.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521764","Breast Cancer [SH4XE27_Cell1]","GSM3521764","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0253","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521764/suppl/GSM3521764_SH4XE27_Cell1.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521765","Breast Cancer [SH4XE31_Cell2]","GSM3521765","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0266","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521765/suppl/GSM3521765_SH4XE31_Cell2.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521766","Breast Cancer [SH4XE31_Cell3]","GSM3521766","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0267","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521766/suppl/GSM3521766_SH4XE31_Cell3.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521767","Breast Cancer [SH4XE32_Cell2]","GSM3521767","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0270","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521767/suppl/GSM3521767_SH4XE32_Cell2.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521768","Breast Cancer [SH4XE32_Cell3]","GSM3521768","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0271","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521768/suppl/GSM3521768_SH4XE32_Cell3.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521769","Breast Cancer [SH4XE32_Cell4]","GSM3521769","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0272","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521769/suppl/GSM3521769_SH4XE32_Cell4.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521770","Breast Cancer [SH4XE34_Cell4]","GSM3521770","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0276","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521770/suppl/GSM3521770_SH4XE34_Cell4.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521771","Breast Cancer [SH4XE35_Cell1]","GSM3521771","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0277","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521771/suppl/GSM3521771_SH4XE35_Cell1.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521772","Breast Cancer [SH4XE35_Cell2]","GSM3521772","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0278","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521772/suppl/GSM3521772_SH4XE35_Cell2.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521773","Breast Cancer [SH4XX48_Cell4]","GSM3521773","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0284","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521773/suppl/GSM3521773_SH4XX48_Cell4.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521774","Breast Cancer [SH4XX50_Cell1]","GSM3521774","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0289","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521774/suppl/GSM3521774_SH4XX50_Cell1.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521775","Breast Cancer [SH4XX50_Cell3]","GSM3521775","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0291","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521775/suppl/GSM3521775_SH4XX50_Cell3.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521776","Breast Cancer [SH4XX52_Cell1]","GSM3521776","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0297","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521776/suppl/GSM3521776_SH4XX52_Cell1.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521777","Breast Cancer [SH4XX52_Cell2]","GSM3521777","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0298","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521777/suppl/GSM3521777_SH4XX52_Cell2.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521778","Breast Cancer [SH4XY02_Cell4]","GSM3521778","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0328","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521778/suppl/GSM3521778_SH4XY02_Cell4.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521779","Breast Cancer [SH4XY13_Cell4]","GSM3521779","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0356","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521779/suppl/GSM3521779_SH4XY13_Cell4.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521780","Breast Cancer [SH4XY15_Cell2]","GSM3521780","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0362","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521780/suppl/GSM3521780_SH4XY15_Cell2.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521781","Breast Cancer [SH4XY19_Cell1]","GSM3521781","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0369","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521781/suppl/GSM3521781_SH4XY19_Cell1.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3521782","Breast Cancer [SH4XY25_Cell2]","GSM3521782","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Breast Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","BC0394","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521782/suppl/GSM3521782_SH4XY25_Cell2.txt.gz","2540","uncertain","uncertain","Breast Cancer","Serum","uncertain"
"GSM3522029","Malignant bone and soft tissue tumor [SH4XX38_Cell1]","GSM3522029","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0080","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522029/suppl/GSM3522029_SH4XX38_Cell1.txt.gz","2540","49","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522063","Malignant bone and soft tissue tumor [SH4XX38_Cell3]","GSM3522063","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0122","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522063/suppl/GSM3522063_SH4XX38_Cell3.txt.gz","2540","69","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522066","Malignant bone and soft tissue tumor [SH4XX38_Cell4]","GSM3522066","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0125","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522066/suppl/GSM3522066_SH4XX38_Cell4.txt.gz","2540","51","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522071","Malignant bone and soft tissue tumor [SH4XX39_Cell3]","GSM3522071","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0133","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522071/suppl/GSM3522071_SH4XX39_Cell3.txt.gz","2540","64","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522074","Malignant bone and soft tissue tumor [SH4XX39_Cell4]","GSM3522074","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0136","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522074/suppl/GSM3522074_SH4XX39_Cell4.txt.gz","2540","66","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522086","Malignant bone and soft tissue tumor [SH4XX40_Cell3]","GSM3522086","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0150","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522086/suppl/GSM3522086_SH4XX40_Cell3.txt.gz","2540","42","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522087","Malignant bone and soft tissue tumor [SH4XX40_Cell4]","GSM3522087","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0151","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522087/suppl/GSM3522087_SH4XX40_Cell4.txt.gz","2540","77","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522088","Malignant bone and soft tissue tumor [SH4XX41_Cell1]","GSM3522088","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0152","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522088/suppl/GSM3522088_SH4XX41_Cell1.txt.gz","2540","50","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522095","Malignant bone and soft tissue tumor [SH4XX41_Cell3]","GSM3522095","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0160","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522095/suppl/GSM3522095_SH4XX41_Cell3.txt.gz","2540","56","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522112","Malignant bone and soft tissue tumor [SH4XX41_Cell4]","GSM3522112","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 86","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0180","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522112/suppl/GSM3522112_SH4XX41_Cell4.txt.gz","2540","86","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522191","Malignant bone and soft tissue tumor [SH4XX44_Cell1]","GSM3522191","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0269","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522191/suppl/GSM3522191_SH4XX44_Cell1.txt.gz","2540","31","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522282","Malignant bone and soft tissue tumor [SH4XX44_Cell2]","GSM3522282","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 10","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0370","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL18941","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522282/suppl/GSM3522282_SH4XX44_Cell2.txt.gz","2540","10","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3521783","Colorectal Cancer [SH52Q01_Cell3]","GSM3521783","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0023","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521783/suppl/GSM3521783_SH52Q01_Cell3.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521784","Colorectal Cancer [SH52Q05_Cell4]","GSM3521784","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0036","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521784/suppl/GSM3521784_SH52Q05_Cell4.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521785","Colorectal Cancer [SH52Q09_Cell1]","GSM3521785","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0037","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521785/suppl/GSM3521785_SH52Q09_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521786","Colorectal Cancer [SH52Q10_Cell2]","GSM3521786","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0042","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521786/suppl/GSM3521786_SH52Q10_Cell2.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521787","Colorectal Cancer [SH52Q25_Cell1]","GSM3521787","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0045","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521787/suppl/GSM3521787_SH52Q25_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521788","Colorectal Cancer [SH52Q29_Cell3]","GSM3521788","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0051","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521788/suppl/GSM3521788_SH52Q29_Cell3.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521789","Colorectal Cancer [SH52Q29_Cell4]","GSM3521789","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0052","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521789/suppl/GSM3521789_SH52Q29_Cell4.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521790","Colorectal Cancer [SH4ZA67_Cell1]","GSM3521790","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0057","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521790/suppl/GSM3521790_SH4ZA67_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521791","Colorectal Cancer [SH52109_Cell1]","GSM3521791","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0065","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521791/suppl/GSM3521791_SH52109_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521792","Colorectal Cancer [SH52R03_Cell4]","GSM3521792","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0076","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521792/suppl/GSM3521792_SH52R03_Cell4.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521793","Colorectal Cancer [SH52R13_Cell2]","GSM3521793","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0078","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521793/suppl/GSM3521793_SH52R13_Cell2.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521794","Colorectal Cancer [SH52R13_Cell4]","GSM3521794","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0080","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521794/suppl/GSM3521794_SH52R13_Cell4.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521795","Colorectal Cancer [SH52R25_Cell3]","GSM3521795","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0083","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521795/suppl/GSM3521795_SH52R25_Cell3.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521796","Colorectal Cancer [SH52R31_Cell3]","GSM3521796","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0091","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521796/suppl/GSM3521796_SH52R31_Cell3.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521797","Colorectal Cancer [SH52T01_Cell1]","GSM3521797","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0093","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521797/suppl/GSM3521797_SH52T01_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521798","Colorectal Cancer [SH52T02_Cell1]","GSM3521798","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0097","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521798/suppl/GSM3521798_SH52T02_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521799","Colorectal Cancer [SH52T05_Cell1]","GSM3521799","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0101","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521799/suppl/GSM3521799_SH52T05_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521800","Colorectal Cancer [SH52T05_Cell2]","GSM3521800","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0102","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521800/suppl/GSM3521800_SH52T05_Cell2.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521801","Colorectal Cancer [SH52T06_Cell2]","GSM3521801","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0106","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521801/suppl/GSM3521801_SH52T06_Cell2.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521802","Colorectal Cancer [SH52T06_Cell3]","GSM3521802","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0107","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521802/suppl/GSM3521802_SH52T06_Cell3.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521803","Colorectal Cancer [SH52T09_Cell1]","GSM3521803","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0109","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521803/suppl/GSM3521803_SH52T09_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521804","Colorectal Cancer [SH52T09_Cell2]","GSM3521804","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0110","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521804/suppl/GSM3521804_SH52T09_Cell2.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521805","Colorectal Cancer [SH52T14_Cell4]","GSM3521805","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0132","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521805/suppl/GSM3521805_SH52T14_Cell4.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521806","Colorectal Cancer [SH52T16_Cell1]","GSM3521806","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0137","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521806/suppl/GSM3521806_SH52T16_Cell1.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521807","Colorectal Cancer [SH52T16_Cell3]","GSM3521807","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0139","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521807/suppl/GSM3521807_SH52T16_Cell3.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521808","Colorectal Cancer [SH52T16_Cell4]","GSM3521808","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0140","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521808/suppl/GSM3521808_SH52T16_Cell4.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521809","Colorectal Cancer [SH52T19_Cell2]","GSM3521809","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0146","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521809/suppl/GSM3521809_SH52T19_Cell2.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521810","Colorectal Cancer [SH52T21_Cell2]","GSM3521810","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0154","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521810/suppl/GSM3521810_SH52T21_Cell2.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521811","Colorectal Cancer [SH52T22_Cell3]","GSM3521811","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0159","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521811/suppl/GSM3521811_SH52T22_Cell3.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521812","Colorectal Cancer [SH52T22_Cell4]","GSM3521812","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Colorectal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","CC0160","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521812/suppl/GSM3521812_SH52T22_Cell4.txt.gz","2540","uncertain","uncertain","Colorectal Cancer","Serum","uncertain"
"GSM3521813","Esophageal Cancer [SH56B62_Cell1]","GSM3521813","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0012","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521813/suppl/GSM3521813_SH56B62_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521814","Esophageal Cancer [SH56B63_Cell1]","GSM3521814","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0016","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521814/suppl/GSM3521814_SH56B63_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521815","Esophageal Cancer [SH56B63_Cell3]","GSM3521815","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0018","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521815/suppl/GSM3521815_SH56B63_Cell3.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521816","Esophageal Cancer [SH56B68_Cell1]","GSM3521816","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0032","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521816/suppl/GSM3521816_SH56B68_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521817","Esophageal Cancer [SH56B68_Cell4]","GSM3521817","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0035","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521817/suppl/GSM3521817_SH56B68_Cell4.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521818","Esophageal Cancer [SH56F03_Cell3]","GSM3521818","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0046","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521818/suppl/GSM3521818_SH56F03_Cell3.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521819","Esophageal Cancer [SH56F03_Cell4]","GSM3521819","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0047","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521819/suppl/GSM3521819_SH56F03_Cell4.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521820","Esophageal Cancer [SH56F05_Cell4]","GSM3521820","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0055","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521820/suppl/GSM3521820_SH56F05_Cell4.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521821","Esophageal Cancer [SH56F07_Cell1]","GSM3521821","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0060","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521821/suppl/GSM3521821_SH56F07_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521822","Esophageal Cancer [SH56F13_Cell2]","GSM3521822","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0081","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521822/suppl/GSM3521822_SH56F13_Cell2.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521823","Esophageal Cancer [SH56F13_Cell3]","GSM3521823","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0082","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521823/suppl/GSM3521823_SH56F13_Cell3.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521824","Esophageal Cancer [SH56F15_Cell1]","GSM3521824","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0088","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521824/suppl/GSM3521824_SH56F15_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521825","Esophageal Cancer [SH56F15_Cell3]","GSM3521825","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0090","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521825/suppl/GSM3521825_SH56F15_Cell3.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521826","Esophageal Cancer [SH56F16_Cell1]","GSM3521826","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0092","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521826/suppl/GSM3521826_SH56F16_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521827","Esophageal Cancer [SH56F16_Cell4]","GSM3521827","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0095","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521827/suppl/GSM3521827_SH56F16_Cell4.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521828","Esophageal Cancer [SH56F17_Cell1]","GSM3521828","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0096","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521828/suppl/GSM3521828_SH56F17_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521829","Esophageal Cancer [SH56F17_Cell3]","GSM3521829","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0098","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521829/suppl/GSM3521829_SH56F17_Cell3.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521830","Esophageal Cancer [SH56F21_Cell1]","GSM3521830","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0112","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521830/suppl/GSM3521830_SH56F21_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521831","Esophageal Cancer [SH56F21_Cell2]","GSM3521831","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0113","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521831/suppl/GSM3521831_SH56F21_Cell2.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521832","Esophageal Cancer [SH57M46_Cell2]","GSM3521832","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0121","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521832/suppl/GSM3521832_SH57M46_Cell2.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521833","Esophageal Cancer [SH57M46_Cell3]","GSM3521833","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0122","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521833/suppl/GSM3521833_SH57M46_Cell3.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521834","Esophageal Cancer [SH57M46_Cell4]","GSM3521834","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0123","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521834/suppl/GSM3521834_SH57M46_Cell4.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521835","Esophageal Cancer [SH57M53_Cell1]","GSM3521835","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0128","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521835/suppl/GSM3521835_SH57M53_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521836","Esophageal Cancer [SH57M53_Cell2]","GSM3521836","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0129","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521836/suppl/GSM3521836_SH57M53_Cell2.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521837","Esophageal Cancer [SH57M53_Cell4]","GSM3521837","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0131","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521837/suppl/GSM3521837_SH57M53_Cell4.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521838","Esophageal Cancer [SH57M60_Cell2]","GSM3521838","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0153","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521838/suppl/GSM3521838_SH57M60_Cell2.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521839","Esophageal Cancer [SH57M60_Cell4]","GSM3521839","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0155","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521839/suppl/GSM3521839_SH57M60_Cell4.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521840","Esophageal Cancer [SH57M65_Cell4]","GSM3521840","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0175","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521840/suppl/GSM3521840_SH57M65_Cell4.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521841","Esophageal Cancer [SH57N07_Cell1]","GSM3521841","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0208","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521841/suppl/GSM3521841_SH57N07_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521842","Esophageal Cancer [SH57N09_Cell1]","GSM3521842","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Esophageal Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","EC0216","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521842/suppl/GSM3521842_SH57N09_Cell1.txt.gz","2540","uncertain","uncertain","Esophageal Cancer","Serum","uncertain"
"GSM3521843","Gastric Cancer [SH59Y32_Cell2]","GSM3521843","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0213","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521843/suppl/GSM3521843_SH59Y32_Cell2.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521844","Gastric Cancer [SH59Y33_Cell2]","GSM3521844","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0217","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521844/suppl/GSM3521844_SH59Y33_Cell2.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521845","Gastric Cancer [SH59Y33_Cell3]","GSM3521845","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0218","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521845/suppl/GSM3521845_SH59Y33_Cell3.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521846","Gastric Cancer [SH59Y33_Cell4]","GSM3521846","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0219","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521846/suppl/GSM3521846_SH59Y33_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521847","Gastric Cancer [SH59Y34_Cell1]","GSM3521847","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0220","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521847/suppl/GSM3521847_SH59Y34_Cell1.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521848","Gastric Cancer [SH59Y34_Cell3]","GSM3521848","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0222","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521848/suppl/GSM3521848_SH59Y34_Cell3.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521849","Gastric Cancer [SH59Y34_Cell4]","GSM3521849","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0223","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521849/suppl/GSM3521849_SH59Y34_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521850","Gastric Cancer [SH59Y35_Cell3]","GSM3521850","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0226","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521850/suppl/GSM3521850_SH59Y35_Cell3.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521851","Gastric Cancer [SH59Y40_Cell1]","GSM3521851","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0240","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521851/suppl/GSM3521851_SH59Y40_Cell1.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521852","Gastric Cancer [SH59Y40_Cell3]","GSM3521852","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0242","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521852/suppl/GSM3521852_SH59Y40_Cell3.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521853","Gastric Cancer [SH59Y41_Cell2]","GSM3521853","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0245","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521853/suppl/GSM3521853_SH59Y41_Cell2.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521854","Gastric Cancer [SH59Y41_Cell4]","GSM3521854","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0247","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521854/suppl/GSM3521854_SH59Y41_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521855","Gastric Cancer [SH59Y42_Cell3]","GSM3521855","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0250","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521855/suppl/GSM3521855_SH59Y42_Cell3.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521856","Gastric Cancer [SH59Y42_Cell4]","GSM3521856","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0251","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521856/suppl/GSM3521856_SH59Y42_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521857","Gastric Cancer [SH59Y43_Cell1]","GSM3521857","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0252","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521857/suppl/GSM3521857_SH59Y43_Cell1.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521858","Gastric Cancer [SH59Y43_Cell3]","GSM3521858","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0254","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521858/suppl/GSM3521858_SH59Y43_Cell3.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521859","Gastric Cancer [SH59Y44_Cell2]","GSM3521859","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0257","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521859/suppl/GSM3521859_SH59Y44_Cell2.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521860","Gastric Cancer [SH59Y44_Cell3]","GSM3521860","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0258","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521860/suppl/GSM3521860_SH59Y44_Cell3.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521861","Gastric Cancer [SH59Y44_Cell4]","GSM3521861","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0259","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521861/suppl/GSM3521861_SH59Y44_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521862","Gastric Cancer [SH59Y45_Cell1]","GSM3521862","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0260","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521862/suppl/GSM3521862_SH59Y45_Cell1.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521863","Gastric Cancer [SH59Y45_Cell2]","GSM3521863","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0261","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521863/suppl/GSM3521863_SH59Y45_Cell2.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521864","Gastric Cancer [SH59Y48_Cell4]","GSM3521864","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0275","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521864/suppl/GSM3521864_SH59Y48_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521865","Gastric Cancer [SH59Y49_Cell4]","GSM3521865","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0279","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521865/suppl/GSM3521865_SH59Y49_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521866","Gastric Cancer [SH59Y51_Cell2]","GSM3521866","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0281","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521866/suppl/GSM3521866_SH59Y51_Cell2.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521867","Gastric Cancer [SH59Y51_Cell4]","GSM3521867","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0283","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521867/suppl/GSM3521867_SH59Y51_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521868","Gastric Cancer [SH59Y52_Cell4]","GSM3521868","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0287","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521868/suppl/GSM3521868_SH59Y52_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521869","Gastric Cancer [SH59Y53_Cell1]","GSM3521869","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0288","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521869/suppl/GSM3521869_SH59Y53_Cell1.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521870","Gastric Cancer [SH59Y54_Cell4]","GSM3521870","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0295","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521870/suppl/GSM3521870_SH59Y54_Cell4.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521871","Gastric Cancer [SH59Y56_Cell1]","GSM3521871","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0296","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521871/suppl/GSM3521871_SH59Y56_Cell1.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521872","Gastric Cancer [SH59Y57_Cell1]","GSM3521872","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Gastric Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GC0300","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521872/suppl/GSM3521872_SH59Y57_Cell1.txt.gz","2540","uncertain","uncertain","Gastric Cancer","Serum","uncertain"
"GSM3521873","Glioma [SH51914_Cell2]","GSM3521873","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0002","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521873/suppl/GSM3521873_SH51914_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521874","Glioma [SH51914_Cell3]","GSM3521874","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0003","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521874/suppl/GSM3521874_SH51914_Cell3.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521875","Glioma [SH51916_Cell1]","GSM3521875","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0009","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521875/suppl/GSM3521875_SH51916_Cell1.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521876","Glioma [SH51919_Cell1]","GSM3521876","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0021","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521876/suppl/GSM3521876_SH51919_Cell1.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521877","Glioma [SH51919_Cell2]","GSM3521877","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0022","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521877/suppl/GSM3521877_SH51919_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521878","Glioma [SH51921_Cell4]","GSM3521878","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0028","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521878/suppl/GSM3521878_SH51921_Cell4.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521879","Glioma [SH51924_Cell4]","GSM3521879","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0040","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521879/suppl/GSM3521879_SH51924_Cell4.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521880","Glioma [SH51925_Cell2]","GSM3521880","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0042","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521880/suppl/GSM3521880_SH51925_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521881","Glioma [SH51926_Cell2]","GSM3521881","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0046","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521881/suppl/GSM3521881_SH51926_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521882","Glioma [SH51933_Cell1]","GSM3521882","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0069","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521882/suppl/GSM3521882_SH51933_Cell1.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521883","Glioma [SH51933_Cell4]","GSM3521883","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0072","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521883/suppl/GSM3521883_SH51933_Cell4.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521884","Glioma [SH51934_Cell1]","GSM3521884","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0073","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521884/suppl/GSM3521884_SH51934_Cell1.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521885","Glioma [SH51934_Cell2]","GSM3521885","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0074","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521885/suppl/GSM3521885_SH51934_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521886","Glioma [SH4ZJ50_Cell1]","GSM3521886","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0081","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521886/suppl/GSM3521886_SH4ZJ50_Cell1.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521887","Glioma [SH4ZJ50_Cell4]","GSM3521887","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0084","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521887/suppl/GSM3521887_SH4ZJ50_Cell4.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521888","Glioma [SH4ZP65_Cell3]","GSM3521888","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0087","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521888/suppl/GSM3521888_SH4ZP65_Cell3.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521889","Glioma [SH51938_Cell1]","GSM3521889","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0101","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521889/suppl/GSM3521889_SH51938_Cell1.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521890","Glioma [SH51939_Cell2]","GSM3521890","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0106","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521890/suppl/GSM3521890_SH51939_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521891","Glioma [SH51941_Cell2]","GSM3521891","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0110","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521891/suppl/GSM3521891_SH51941_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521892","Glioma [SH51952_Cell4]","GSM3521892","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0120","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521892/suppl/GSM3521892_SH51952_Cell4.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521893","Glioma [SH51D23_Cell4]","GSM3521893","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0128","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521893/suppl/GSM3521893_SH51D23_Cell4.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521894","Glioma [SH51D42_Cell4]","GSM3521894","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0136","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521894/suppl/GSM3521894_SH51D42_Cell4.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521895","Glioma [SH51G66_Cell1]","GSM3521895","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0145","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521895/suppl/GSM3521895_SH51G66_Cell1.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521896","Glioma [SH51G66_Cell2]","GSM3521896","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0146","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521896/suppl/GSM3521896_SH51G66_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521897","Glioma [SH51G66_Cell3]","GSM3521897","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0147","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521897/suppl/GSM3521897_SH51G66_Cell3.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521898","Glioma [SH51L49_Cell2]","GSM3521898","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0150","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521898/suppl/GSM3521898_SH51L49_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521899","Glioma [SH51M67_Cell2]","GSM3521899","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0162","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521899/suppl/GSM3521899_SH51M67_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521900","Glioma [SH51P02_Cell1]","GSM3521900","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0169","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521900/suppl/GSM3521900_SH51P02_Cell1.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521901","Glioma [SH51P04_Cell3]","GSM3521901","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0176","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521901/suppl/GSM3521901_SH51P04_Cell3.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521902","Glioma [SH51P08_Cell2]","GSM3521902","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Glioma","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GL0183","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521902/suppl/GSM3521902_SH51P08_Cell2.txt.gz","2540","uncertain","uncertain","Glioma","Serum","uncertain"
"GSM3521903","HCC [SH54N29_Cell1]","GSM3521903","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0017","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521903/suppl/GSM3521903_SH54N29_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521904","HCC [SH54N29_Cell4]","GSM3521904","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0020","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521904/suppl/GSM3521904_SH54N29_Cell4.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521905","HCC [SH54N32_Cell1]","GSM3521905","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0025","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521905/suppl/GSM3521905_SH54N32_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521906","HCC [SH54N33_Cell1]","GSM3521906","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0029","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521906/suppl/GSM3521906_SH54N33_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521907","HCC [SH54N33_Cell2]","GSM3521907","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0030","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521907/suppl/GSM3521907_SH54N33_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521908","HCC [SH54N33_Cell3]","GSM3521908","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0031","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521908/suppl/GSM3521908_SH54N33_Cell3.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521909","HCC [SH54N34_Cell1]","GSM3521909","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0033","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521909/suppl/GSM3521909_SH54N34_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521910","HCC [SH54N36_Cell3]","GSM3521910","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0043","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521910/suppl/GSM3521910_SH54N36_Cell3.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521911","HCC [SH54N38_Cell1]","GSM3521911","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0049","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521911/suppl/GSM3521911_SH54N38_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521912","HCC [SH54N38_Cell2]","GSM3521912","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0050","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521912/suppl/GSM3521912_SH54N38_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521913","HCC [SH54N40_Cell1]","GSM3521913","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0053","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521913/suppl/GSM3521913_SH54N40_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521914","HCC [SH54N41_Cell3]","GSM3521914","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0059","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521914/suppl/GSM3521914_SH54N41_Cell3.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521915","HCC [SH54N43_Cell3]","GSM3521915","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0063","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521915/suppl/GSM3521915_SH54N43_Cell3.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521916","HCC [SH54N45_Cell2]","GSM3521916","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0070","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521916/suppl/GSM3521916_SH54N45_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521917","HCC [SH54N51_Cell1]","GSM3521917","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0073","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521917/suppl/GSM3521917_SH54N51_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521918","HCC [SH54N55_Cell3]","GSM3521918","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0087","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521918/suppl/GSM3521918_SH54N55_Cell3.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521919","HCC [SH54N57_Cell2]","GSM3521919","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0094","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521919/suppl/GSM3521919_SH54N57_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521920","HCC [SH55T23_Cell1]","GSM3521920","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0105","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521920/suppl/GSM3521920_SH55T23_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521921","HCC [SH55T25_Cell3]","GSM3521921","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0115","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521921/suppl/GSM3521921_SH55T25_Cell3.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521922","HCC [SH55T26_Cell1]","GSM3521922","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0117","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521922/suppl/GSM3521922_SH55T26_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521923","HCC [SH55T26_Cell2]","GSM3521923","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0118","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521923/suppl/GSM3521923_SH55T26_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521924","HCC [SH55T28_Cell1]","GSM3521924","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0125","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521924/suppl/GSM3521924_SH55T28_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521925","HCC [SH55T33_Cell2]","GSM3521925","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0134","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521925/suppl/GSM3521925_SH55T33_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521926","HCC [SH55T35_Cell2]","GSM3521926","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0138","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521926/suppl/GSM3521926_SH55T35_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521927","HCC [SH55T36_Cell1]","GSM3521927","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0141","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521927/suppl/GSM3521927_SH55T36_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521928","HCC [SH55T38_Cell2]","GSM3521928","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0150","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521928/suppl/GSM3521928_SH55T38_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521929","HCC [SH55T38_Cell4]","GSM3521929","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0152","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521929/suppl/GSM3521929_SH55T38_Cell4.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521930","HCC [SH56964_Cell1]","GSM3521930","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0156","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521930/suppl/GSM3521930_SH56964_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521931","HCC [SH55T41_Cell1]","GSM3521931","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0157","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521931/suppl/GSM3521931_SH55T41_Cell1.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521932","HCC [SH55T41_Cell2]","GSM3521932","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: HCC","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","HC0158","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521932/suppl/GSM3521932_SH55T41_Cell2.txt.gz","2540","uncertain","uncertain","HCC","Serum","uncertain"
"GSM3521933","Lung Cancer [SH59Q28_Cell4]","GSM3521933","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0214","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521933/suppl/GSM3521933_SH59Q28_Cell4.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521934","Lung Cancer [SH59Q32_Cell2]","GSM3521934","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0224","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521934/suppl/GSM3521934_SH59Q32_Cell2.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521935","Lung Cancer [SH59Q32_Cell3]","GSM3521935","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0225","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521935/suppl/GSM3521935_SH59Q32_Cell3.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521936","Lung Cancer [SH59Q33_Cell1]","GSM3521936","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0227","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521936/suppl/GSM3521936_SH59Q33_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521937","Lung Cancer [SH59Q36_Cell1]","GSM3521937","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0232","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521937/suppl/GSM3521937_SH59Q36_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521938","Lung Cancer [SH59Q36_Cell3]","GSM3521938","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0235","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521938/suppl/GSM3521938_SH59Q36_Cell3.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521939","Lung Cancer [SH59Q38_Cell1]","GSM3521939","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0237","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521939/suppl/GSM3521939_SH59Q38_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521940","Lung Cancer [SH59Q38_Cell2]","GSM3521940","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0238","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521940/suppl/GSM3521940_SH59Q38_Cell2.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521941","Lung Cancer [SH59Q39_Cell1]","GSM3521941","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0241","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521941/suppl/GSM3521941_SH59Q39_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521942","Lung Cancer [SH59Q39_Cell3]","GSM3521942","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0243","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521942/suppl/GSM3521942_SH59Q39_Cell3.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521943","Lung Cancer [SH59Q39_Cell4]","GSM3521943","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0244","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521943/suppl/GSM3521943_SH59Q39_Cell4.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521944","Lung Cancer [SH59Q40_Cell2]","GSM3521944","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0246","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521944/suppl/GSM3521944_SH59Q40_Cell2.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521945","Lung Cancer [SH59Q40_Cell4]","GSM3521945","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0248","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521945/suppl/GSM3521945_SH59Q40_Cell4.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521946","Lung Cancer [SH59Q41_Cell1]","GSM3521946","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0249","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521946/suppl/GSM3521946_SH59Q41_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521947","Lung Cancer [SH59Q42_Cell3]","GSM3521947","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0255","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521947/suppl/GSM3521947_SH59Q42_Cell3.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521948","Lung Cancer [SH59Q45_Cell3]","GSM3521948","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0263","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521948/suppl/GSM3521948_SH59Q45_Cell3.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521949","Lung Cancer [SH59Q45_Cell4]","GSM3521949","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0264","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521949/suppl/GSM3521949_SH59Q45_Cell4.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521950","Lung Cancer [SH59Q46_Cell1]","GSM3521950","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0265","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521950/suppl/GSM3521950_SH59Q46_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521951","Lung Cancer [SH59Q46_Cell4]","GSM3521951","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0268","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521951/suppl/GSM3521951_SH59Q46_Cell4.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521952","Lung Cancer [SH59Q48_Cell1]","GSM3521952","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0273","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521952/suppl/GSM3521952_SH59Q48_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521953","Lung Cancer [SH59Q48_Cell2]","GSM3521953","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0274","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521953/suppl/GSM3521953_SH59Q48_Cell2.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521954","Lung Cancer [SH59Q49_Cell4]","GSM3521954","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0280","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521954/suppl/GSM3521954_SH59Q49_Cell4.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521955","Lung Cancer [SH59X32_Cell2]","GSM3521955","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0282","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521955/suppl/GSM3521955_SH59X32_Cell2.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521956","Lung Cancer [SH59X33_Cell1]","GSM3521956","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0285","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521956/suppl/GSM3521956_SH59X33_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521957","Lung Cancer [SH59X33_Cell2]","GSM3521957","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0286","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521957/suppl/GSM3521957_SH59X33_Cell2.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521958","Lung Cancer [SH59X34_Cell1]","GSM3521958","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0290","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521958/suppl/GSM3521958_SH59X34_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521959","Lung Cancer [SH57Y51_Cell2]","GSM3521959","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0292","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521959/suppl/GSM3521959_SH57Y51_Cell2.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521960","Lung Cancer [SH57Y51_Cell3]","GSM3521960","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0293","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521960/suppl/GSM3521960_SH57Y51_Cell3.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521961","Lung Cancer [SH57Y55_Cell1]","GSM3521961","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0299","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521961/suppl/GSM3521961_SH57Y55_Cell1.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521962","Lung Cancer [SH58L01_Cell3]","GSM3521962","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Lung Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","LK0329","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521962/suppl/GSM3521962_SH58L01_Cell3.txt.gz","2540","uncertain","uncertain","Lung Cancer","Serum","uncertain"
"GSM3521963","Pancreatic Cancer [SH51P61_Cell4]","GSM3521963","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0014","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521963/suppl/GSM3521963_SH51P61_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521964","Pancreatic Cancer [SH51P65_Cell1]","GSM3521964","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0015","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521964/suppl/GSM3521964_SH51P65_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521965","Pancreatic Cancer [SH51Q09_Cell2]","GSM3521965","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0024","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521965/suppl/GSM3521965_SH51Q09_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521966","Pancreatic Cancer [SH51Q09_Cell4]","GSM3521966","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0026","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521966/suppl/GSM3521966_SH51Q09_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521967","Pancreatic Cancer [SH51Q16_Cell1]","GSM3521967","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0027","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521967/suppl/GSM3521967_SH51Q16_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521968","Pancreatic Cancer [SH51Q16_Cell2]","GSM3521968","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0028","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521968/suppl/GSM3521968_SH51Q16_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521969","Pancreatic Cancer [SH51Q17_Cell4]","GSM3521969","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0034","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521969/suppl/GSM3521969_SH51Q17_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521970","Pancreatic Cancer [SH51Q37_Cell2]","GSM3521970","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0048","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521970/suppl/GSM3521970_SH51Q37_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521971","Pancreatic Cancer [SH51Q45_Cell4]","GSM3521971","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0054","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521971/suppl/GSM3521971_SH51Q45_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521972","Pancreatic Cancer [SH51Q49_Cell2]","GSM3521972","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0056","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521972/suppl/GSM3521972_SH51Q49_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521973","Pancreatic Cancer [SH51Q55_Cell4]","GSM3521973","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0062","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521973/suppl/GSM3521973_SH51Q55_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521974","Pancreatic Cancer [SH51Q57_Cell2]","GSM3521974","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0064","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521974/suppl/GSM3521974_SH51Q57_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521975","Pancreatic Cancer [SH51Q57_Cell4]","GSM3521975","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0066","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521975/suppl/GSM3521975_SH51Q57_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521976","Pancreatic Cancer [SH51Q63_Cell1]","GSM3521976","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0067","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521976/suppl/GSM3521976_SH51Q63_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521977","Pancreatic Cancer [SH51Q63_Cell2]","GSM3521977","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0068","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521977/suppl/GSM3521977_SH51Q63_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521978","Pancreatic Cancer [SH51Q65_Cell4]","GSM3521978","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0074","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521978/suppl/GSM3521978_SH51Q65_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521979","Pancreatic Cancer [SH51T03_Cell2]","GSM3521979","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0084","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521979/suppl/GSM3521979_SH51T03_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521980","Pancreatic Cancer [SH51T11_Cell1]","GSM3521980","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0099","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521980/suppl/GSM3521980_SH51T11_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521981","Pancreatic Cancer [SH51T15_Cell1]","GSM3521981","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0111","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521981/suppl/GSM3521981_SH51T15_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521982","Pancreatic Cancer [SH51T15_Cell4]","GSM3521982","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0114","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521982/suppl/GSM3521982_SH51T15_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521983","Pancreatic Cancer [SH51T21_Cell2]","GSM3521983","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0120","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521983/suppl/GSM3521983_SH51T21_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521984","Pancreatic Cancer [SH51T22_Cell2]","GSM3521984","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0124","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521984/suppl/GSM3521984_SH51T22_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521985","Pancreatic Cancer [SH51T23_Cell1]","GSM3521985","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0127","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521985/suppl/GSM3521985_SH51T23_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521986","Pancreatic Cancer [SH51T23_Cell4]","GSM3521986","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0130","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521986/suppl/GSM3521986_SH51T23_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521987","Pancreatic Cancer [SH51T25_Cell3]","GSM3521987","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0133","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521987/suppl/GSM3521987_SH51T25_Cell3.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521988","Pancreatic Cancer [SH51T26_Cell1]","GSM3521988","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0135","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521988/suppl/GSM3521988_SH51T26_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521989","Pancreatic Cancer [SH51T26_Cell2]","GSM3521989","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0136","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521989/suppl/GSM3521989_SH51T26_Cell2.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521990","Pancreatic Cancer [SH51T27_Cell4]","GSM3521990","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0142","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521990/suppl/GSM3521990_SH51T27_Cell4.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521991","Pancreatic Cancer [SH51T29_Cell1]","GSM3521991","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0147","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521991/suppl/GSM3521991_SH51T29_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521992","Pancreatic Cancer [SH51T31_Cell1]","GSM3521992","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Pancreatic Cancer","gender: uncertain","tumor stage: uncertain","age: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","PC0151","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521992/suppl/GSM3521992_SH51T31_Cell1.txt.gz","2540","uncertain","uncertain","Pancreatic Cancer","Serum","uncertain"
"GSM3521993","Intermediate bone and soft tissue tumor [SH59Q50_Cell1]","GSM3521993","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0041","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521993/suppl/GSM3521993_SH59Q50_Cell1.txt.gz","2540","33","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3521994","Intermediate bone and soft tissue tumor [SH59Q50_Cell2]","GSM3521994","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0042","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521994/suppl/GSM3521994_SH59Q50_Cell2.txt.gz","2540","50","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3521995","Intermediate bone and soft tissue tumor [SH59Q50_Cell3]","GSM3521995","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0043","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521995/suppl/GSM3521995_SH59Q50_Cell3.txt.gz","2540","36","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3521996","Intermediate bone and soft tissue tumor [SH59Q50_Cell4]","GSM3521996","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0044","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521996/suppl/GSM3521996_SH59Q50_Cell4.txt.gz","2540","40","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3521997","Intermediate bone and soft tissue tumor [SH59Q51_Cell3]","GSM3521997","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0047","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521997/suppl/GSM3521997_SH59Q51_Cell3.txt.gz","2540","49","Female","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3521998","Malignant bone and soft tissue tumor [SH59Q51_Cell4]","GSM3521998","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0048","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521998/suppl/GSM3521998_SH59Q51_Cell4.txt.gz","2540","49","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3521999","Malignant bone and soft tissue tumor [SH59Q52_Cell1]","GSM3521999","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0049","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3521nnn/GSM3521999/suppl/GSM3521999_SH59Q52_Cell1.txt.gz","2540","49","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522000","Intermediate bone and soft tissue tumor [SH59Q52_Cell2]","GSM3522000","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0050","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522000/suppl/GSM3522000_SH59Q52_Cell2.txt.gz","2540","36","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522001","Intermediate bone and soft tissue tumor [SH59Q52_Cell3]","GSM3522001","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIA","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0051","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522001/suppl/GSM3522001_SH59Q52_Cell3.txt.gz","2540","27","Female","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522002","Malignant bone and soft tissue tumor [SH59Q52_Cell4]","GSM3522002","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0052","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522002/suppl/GSM3522002_SH59Q52_Cell4.txt.gz","2540","19","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522003","Malignant bone and soft tissue tumor [SH59Q53_Cell1]","GSM3522003","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0053","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522003/suppl/GSM3522003_SH59Q53_Cell1.txt.gz","2540","36","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522004","Malignant bone and soft tissue tumor [SH59Q53_Cell2]","GSM3522004","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0054","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522004/suppl/GSM3522004_SH59Q53_Cell2.txt.gz","2540","59","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522005","Malignant bone and soft tissue tumor [SH59Q53_Cell3]","GSM3522005","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0055","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522005/suppl/GSM3522005_SH59Q53_Cell3.txt.gz","2540","69","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522006","Malignant bone and soft tissue tumor [SH59Q53_Cell4]","GSM3522006","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0056","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522006/suppl/GSM3522006_SH59Q53_Cell4.txt.gz","2540","69","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522007","Malignant bone and soft tissue tumor [SH59Q54_Cell1]","GSM3522007","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0057","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522007/suppl/GSM3522007_SH59Q54_Cell1.txt.gz","2540","64","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522008","Malignant bone and soft tissue tumor [SH59Q54_Cell2]","GSM3522008","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0058","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522008/suppl/GSM3522008_SH59Q54_Cell2.txt.gz","2540","36","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522009","Malignant bone and soft tissue tumor [SH59Q54_Cell3]","GSM3522009","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0059","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522009/suppl/GSM3522009_SH59Q54_Cell3.txt.gz","2540","30","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522010","Malignant bone and soft tissue tumor [SH59Q54_Cell4]","GSM3522010","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 92","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0060","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522010/suppl/GSM3522010_SH59Q54_Cell4.txt.gz","2540","92","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522011","Malignant bone and soft tissue tumor [SH59Q55_Cell1]","GSM3522011","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0061","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522011/suppl/GSM3522011_SH59Q55_Cell1.txt.gz","2540","31","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522012","Malignant bone and soft tissue tumor [SH59Q55_Cell2]","GSM3522012","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0062","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522012/suppl/GSM3522012_SH59Q55_Cell2.txt.gz","2540","48","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522013","Malignant bone and soft tissue tumor [SH59Q55_Cell3]","GSM3522013","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0063","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522013/suppl/GSM3522013_SH59Q55_Cell3.txt.gz","2540","74","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522014","Malignant bone and soft tissue tumor [SH59Q55_Cell4]","GSM3522014","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0064","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522014/suppl/GSM3522014_SH59Q55_Cell4.txt.gz","2540","74","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522015","Malignant bone and soft tissue tumor [SH59Q57_Cell1]","GSM3522015","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0065","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522015/suppl/GSM3522015_SH59Q57_Cell1.txt.gz","2540","26","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522016","Malignant bone and soft tissue tumor [SH59Q57_Cell2]","GSM3522016","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0066","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522016/suppl/GSM3522016_SH59Q57_Cell2.txt.gz","2540","38","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522017","Malignant bone and soft tissue tumor [SH59Q57_Cell3]","GSM3522017","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0067","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522017/suppl/GSM3522017_SH59Q57_Cell3.txt.gz","2540","29","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522018","Malignant bone and soft tissue tumor [SH59Q57_Cell4]","GSM3522018","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0068","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522018/suppl/GSM3522018_SH59Q57_Cell4.txt.gz","2540","34","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522019","Malignant bone and soft tissue tumor [SH59Q58_Cell2]","GSM3522019","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0070","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522019/suppl/GSM3522019_SH59Q58_Cell2.txt.gz","2540","59","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522020","Intermediate bone and soft tissue tumor [SH59Q58_Cell3]","GSM3522020","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0071","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522020/suppl/GSM3522020_SH59Q58_Cell3.txt.gz","2540","36","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522021","Intermediate bone and soft tissue tumor [SH59Q58_Cell4]","GSM3522021","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0072","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522021/suppl/GSM3522021_SH59Q58_Cell4.txt.gz","2540","38","Male","Intermediate bone and soft tissue tumor","Serum","StageIIB"
"GSM3522022","Intermediate bone and soft tissue tumor [SH59Q59_Cell1]","GSM3522022","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0073","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522022/suppl/GSM3522022_SH59Q59_Cell1.txt.gz","2540","29","Male","Intermediate bone and soft tissue tumor","Serum","StageIIA"
"GSM3522023","Intermediate bone and soft tissue tumor [SH59Q59_Cell2]","GSM3522023","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0074","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522023/suppl/GSM3522023_SH59Q59_Cell2.txt.gz","2540","35","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522024","Malignant bone and soft tissue tumor [SH59Q59_Cell3]","GSM3522024","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0075","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522024/suppl/GSM3522024_SH59Q59_Cell3.txt.gz","2540","27","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522025","Malignant bone and soft tissue tumor [SH59Q59_Cell4]","GSM3522025","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0076","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522025/suppl/GSM3522025_SH59Q59_Cell4.txt.gz","2540","41","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522026","Malignant bone and soft tissue tumor [SH59Q60_Cell1]","GSM3522026","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageX","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0077","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522026/suppl/GSM3522026_SH59Q60_Cell1.txt.gz","2540","32","Male","Malignant bone and soft tissue tumor","Serum","StageX"
"GSM3522027","Malignant bone and soft tissue tumor [SH59Q60_Cell2]","GSM3522027","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0078","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522027/suppl/GSM3522027_SH59Q60_Cell2.txt.gz","2540","49","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522028","Malignant bone and soft tissue tumor [SH59Q60_Cell3]","GSM3522028","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0079","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522028/suppl/GSM3522028_SH59Q60_Cell3.txt.gz","2540","28","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522030","Malignant bone and soft tissue tumor [SH59Q60_Cell4]","GSM3522030","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0081","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522030/suppl/GSM3522030_SH59Q60_Cell4.txt.gz","2540","15","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522031","Malignant bone and soft tissue tumor [SH59Q61_Cell1]","GSM3522031","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0082","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522031/suppl/GSM3522031_SH59Q61_Cell1.txt.gz","2540","21","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522032","Malignant bone and soft tissue tumor [SH59Q61_Cell2]","GSM3522032","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0083","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522032/suppl/GSM3522032_SH59Q61_Cell2.txt.gz","2540","12","Male","Malignant bone and soft tissue tumor","Serum","StageIVA"
"GSM3522033","Malignant bone and soft tissue tumor [SH59Q61_Cell3]","GSM3522033","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVA","age: 8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0084","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522033/suppl/GSM3522033_SH59Q61_Cell3.txt.gz","2540","8","Male","Malignant bone and soft tissue tumor","Serum","StageIVA"
"GSM3522034","Malignant bone and soft tissue tumor [SH59Q61_Cell4]","GSM3522034","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0085","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522034/suppl/GSM3522034_SH59Q61_Cell4.txt.gz","2540","12","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522035","Malignant bone and soft tissue tumor [SH59Q62_Cell1]","GSM3522035","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 9","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0086","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522035/suppl/GSM3522035_SH59Q62_Cell1.txt.gz","2540","9","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522036","Malignant bone and soft tissue tumor [SH59Q62_Cell2]","GSM3522036","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0087","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522036/suppl/GSM3522036_SH59Q62_Cell2.txt.gz","2540","18","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522037","Malignant bone and soft tissue tumor [SH59Q62_Cell3]","GSM3522037","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0088","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522037/suppl/GSM3522037_SH59Q62_Cell3.txt.gz","2540","18","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522038","Malignant bone and soft tissue tumor [SH59Q62_Cell4]","GSM3522038","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0089","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522038/suppl/GSM3522038_SH59Q62_Cell4.txt.gz","2540","30","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522039","Malignant bone and soft tissue tumor [SH59Q63_Cell1]","GSM3522039","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0090","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522039/suppl/GSM3522039_SH59Q63_Cell1.txt.gz","2540","17","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522040","Malignant bone and soft tissue tumor [SH59Q63_Cell2]","GSM3522040","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIVB","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0091","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522040/suppl/GSM3522040_SH59Q63_Cell2.txt.gz","2540","44","Female","Malignant bone and soft tissue tumor","Serum","StageIVB"
"GSM3522041","Malignant bone and soft tissue tumor [SH59Q63_Cell4]","GSM3522041","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIVB","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0093","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522041/suppl/GSM3522041_SH59Q63_Cell4.txt.gz","2540","29","Female","Malignant bone and soft tissue tumor","Serum","StageIVB"
"GSM3522042","Malignant bone and soft tissue tumor [SH59Q64_Cell1]","GSM3522042","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVB","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0094","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522042/suppl/GSM3522042_SH59Q64_Cell1.txt.gz","2540","51","Male","Malignant bone and soft tissue tumor","Serum","StageIVB"
"GSM3522043","Malignant bone and soft tissue tumor [SH59Q64_Cell2]","GSM3522043","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIVB","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0095","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522043/suppl/GSM3522043_SH59Q64_Cell2.txt.gz","2540","12","Female","Malignant bone and soft tissue tumor","Serum","StageIVB"
"GSM3522044","Malignant bone and soft tissue tumor [SH59Q64_Cell3]","GSM3522044","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0096","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522044/suppl/GSM3522044_SH59Q64_Cell3.txt.gz","2540","36","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522045","Malignant bone and soft tissue tumor [SH59Q64_Cell4]","GSM3522045","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0097","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522045/suppl/GSM3522045_SH59Q64_Cell4.txt.gz","2540","15","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522046","Malignant bone and soft tissue tumor [SH59W01_Cell1]","GSM3522046","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0098","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522046/suppl/GSM3522046_SH59W01_Cell1.txt.gz","2540","65","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522047","Malignant bone and soft tissue tumor [SH59W01_Cell2]","GSM3522047","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0099","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522047/suppl/GSM3522047_SH59W01_Cell2.txt.gz","2540","28","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522048","Malignant bone and soft tissue tumor [SH59W01_Cell3]","GSM3522048","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0100","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522048/suppl/GSM3522048_SH59W01_Cell3.txt.gz","2540","47","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522049","Malignant bone and soft tissue tumor [SH59W02_Cell1]","GSM3522049","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0103","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522049/suppl/GSM3522049_SH59W02_Cell1.txt.gz","2540","15","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522050","Malignant bone and soft tissue tumor [SH59W02_Cell2]","GSM3522050","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0104","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522050/suppl/GSM3522050_SH59W02_Cell2.txt.gz","2540","29","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522051","Malignant bone and soft tissue tumor [SH59W02_Cell3]","GSM3522051","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0105","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522051/suppl/GSM3522051_SH59W02_Cell3.txt.gz","2540","36","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522052","Malignant bone and soft tissue tumor [SH59W02_Cell4]","GSM3522052","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0106","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522052/suppl/GSM3522052_SH59W02_Cell4.txt.gz","2540","48","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522053","Malignant bone and soft tissue tumor [SH59W03_Cell1]","GSM3522053","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0107","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522053/suppl/GSM3522053_SH59W03_Cell1.txt.gz","2540","15","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522054","Malignant bone and soft tissue tumor [SH59W03_Cell2]","GSM3522054","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0108","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522054/suppl/GSM3522054_SH59W03_Cell2.txt.gz","2540","45","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522055","Malignant bone and soft tissue tumor [SH59W03_Cell3]","GSM3522055","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0109","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522055/suppl/GSM3522055_SH59W03_Cell3.txt.gz","2540","65","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522056","Malignant bone and soft tissue tumor [SH59W03_Cell4]","GSM3522056","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0112","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522056/suppl/GSM3522056_SH59W03_Cell4.txt.gz","2540","65","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522057","Malignant bone and soft tissue tumor [SH59W04_Cell2]","GSM3522057","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0114","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522057/suppl/GSM3522057_SH59W04_Cell2.txt.gz","2540","48","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522058","Malignant bone and soft tissue tumor [SH59W04_Cell3]","GSM3522058","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIA","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0116","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522058/suppl/GSM3522058_SH59W04_Cell3.txt.gz","2540","77","Female","Malignant bone and soft tissue tumor","Serum","StageIA"
"GSM3522059","Malignant bone and soft tissue tumor [SH59W04_Cell4]","GSM3522059","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0117","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522059/suppl/GSM3522059_SH59W04_Cell4.txt.gz","2540","60","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522060","Malignant bone and soft tissue tumor [SH59W05_Cell1]","GSM3522060","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0118","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522060/suppl/GSM3522060_SH59W05_Cell1.txt.gz","2540","68","Male","Malignant bone and soft tissue tumor","Serum","StageIA"
"GSM3522061","Malignant bone and soft tissue tumor [SH59W05_Cell2]","GSM3522061","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0119","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522061/suppl/GSM3522061_SH59W05_Cell2.txt.gz","2540","44","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522062","Malignant bone and soft tissue tumor [SH59W05_Cell3]","GSM3522062","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0120","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522062/suppl/GSM3522062_SH59W05_Cell3.txt.gz","2540","38","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522064","Malignant bone and soft tissue tumor [SH59W06_Cell1]","GSM3522064","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0123","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522064/suppl/GSM3522064_SH59W06_Cell1.txt.gz","2540","47","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522065","Malignant bone and soft tissue tumor [SH59W06_Cell2]","GSM3522065","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0124","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522065/suppl/GSM3522065_SH59W06_Cell2.txt.gz","2540","59","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522067","Malignant bone and soft tissue tumor [SH59W06_Cell3]","GSM3522067","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0126","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522067/suppl/GSM3522067_SH59W06_Cell3.txt.gz","2540","65","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522068","Malignant bone and soft tissue tumor [SH59W06_Cell4]","GSM3522068","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0127","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522068/suppl/GSM3522068_SH59W06_Cell4.txt.gz","2540","59","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522069","Malignant bone and soft tissue tumor [SH59W07_Cell1]","GSM3522069","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0128","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522069/suppl/GSM3522069_SH59W07_Cell1.txt.gz","2540","41","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522070","Malignant bone and soft tissue tumor [SH59W07_Cell3]","GSM3522070","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0131","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522070/suppl/GSM3522070_SH59W07_Cell3.txt.gz","2540","53","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522072","Malignant bone and soft tissue tumor [SH59W07_Cell4]","GSM3522072","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0134","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522072/suppl/GSM3522072_SH59W07_Cell4.txt.gz","2540","63","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522073","Malignant bone and soft tissue tumor [SH59W09_Cell1]","GSM3522073","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0135","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522073/suppl/GSM3522073_SH59W09_Cell1.txt.gz","2540","55","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522075","Malignant bone and soft tissue tumor [SH59W09_Cell2]","GSM3522075","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0137","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522075/suppl/GSM3522075_SH59W09_Cell2.txt.gz","2540","53","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522076","Malignant bone and soft tissue tumor [SH59W09_Cell3]","GSM3522076","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0138","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522076/suppl/GSM3522076_SH59W09_Cell3.txt.gz","2540","50","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522077","Malignant bone and soft tissue tumor [SH59W09_Cell4]","GSM3522077","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0139","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522077/suppl/GSM3522077_SH59W09_Cell4.txt.gz","2540","72","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522078","Malignant bone and soft tissue tumor [SH59W10_Cell1]","GSM3522078","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0140","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522078/suppl/GSM3522078_SH59W10_Cell1.txt.gz","2540","66","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522079","Malignant bone and soft tissue tumor [SH59W10_Cell2]","GSM3522079","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 89","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0141","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522079/suppl/GSM3522079_SH59W10_Cell2.txt.gz","2540","89","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522080","Malignant bone and soft tissue tumor [SH59W10_Cell3]","GSM3522080","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0142","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522080/suppl/GSM3522080_SH59W10_Cell3.txt.gz","2540","68","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522081","Malignant bone and soft tissue tumor [SH59W10_Cell4]","GSM3522081","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0143","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522081/suppl/GSM3522081_SH59W10_Cell4.txt.gz","2540","60","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522082","Malignant bone and soft tissue tumor [SH59W11_Cell1]","GSM3522082","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0144","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522082/suppl/GSM3522082_SH59W11_Cell1.txt.gz","2540","35","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522083","Malignant bone and soft tissue tumor [SH59W11_Cell2]","GSM3522083","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0145","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522083/suppl/GSM3522083_SH59W11_Cell2.txt.gz","2540","68","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522084","Malignant bone and soft tissue tumor [SH59W11_Cell3]","GSM3522084","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0146","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522084/suppl/GSM3522084_SH59W11_Cell3.txt.gz","2540","56","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522085","Malignant bone and soft tissue tumor [SH59W11_Cell4]","GSM3522085","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0148","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522085/suppl/GSM3522085_SH59W11_Cell4.txt.gz","2540","62","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522089","Malignant bone and soft tissue tumor [SH59W12_Cell1]","GSM3522089","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0153","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522089/suppl/GSM3522089_SH59W12_Cell1.txt.gz","2540","38","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522090","Malignant bone and soft tissue tumor [SH59W12_Cell2]","GSM3522090","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0154","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522090/suppl/GSM3522090_SH59W12_Cell2.txt.gz","2540","33","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522091","Malignant bone and soft tissue tumor [SH59W12_Cell3]","GSM3522091","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0155","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522091/suppl/GSM3522091_SH59W12_Cell3.txt.gz","2540","64","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522092","Malignant bone and soft tissue tumor [SH59W12_Cell4]","GSM3522092","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0157","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522092/suppl/GSM3522092_SH59W12_Cell4.txt.gz","2540","50","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522093","Malignant bone and soft tissue tumor [SH59W13_Cell1]","GSM3522093","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0158","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522093/suppl/GSM3522093_SH59W13_Cell1.txt.gz","2540","44","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522094","Malignant bone and soft tissue tumor [SH59W13_Cell2]","GSM3522094","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0159","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522094/suppl/GSM3522094_SH59W13_Cell2.txt.gz","2540","65","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522096","Malignant bone and soft tissue tumor [SH59W13_Cell3]","GSM3522096","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0161","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522096/suppl/GSM3522096_SH59W13_Cell3.txt.gz","2540","49","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522097","Malignant bone and soft tissue tumor [SH59W13_Cell4]","GSM3522097","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0162","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522097/suppl/GSM3522097_SH59W13_Cell4.txt.gz","2540","59","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522098","Malignant bone and soft tissue tumor [SH59W14_Cell1]","GSM3522098","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0163","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522098/suppl/GSM3522098_SH59W14_Cell1.txt.gz","2540","63","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522099","Malignant bone and soft tissue tumor [SH59W14_Cell2]","GSM3522099","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0164","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522099/suppl/GSM3522099_SH59W14_Cell2.txt.gz","2540","61","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522100","Malignant bone and soft tissue tumor [SH59W14_Cell3]","GSM3522100","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0165","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522100/suppl/GSM3522100_SH59W14_Cell3.txt.gz","2540","47","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522101","Malignant bone and soft tissue tumor [SH59W14_Cell4]","GSM3522101","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0166","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522101/suppl/GSM3522101_SH59W14_Cell4.txt.gz","2540","55","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522102","Malignant bone and soft tissue tumor [SH59W15_Cell1]","GSM3522102","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0167","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522102/suppl/GSM3522102_SH59W15_Cell1.txt.gz","2540","77","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522103","Malignant bone and soft tissue tumor [SH59W15_Cell2]","GSM3522103","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0168","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522103/suppl/GSM3522103_SH59W15_Cell2.txt.gz","2540","67","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522104","Malignant bone and soft tissue tumor [SH59W15_Cell3]","GSM3522104","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0169","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522104/suppl/GSM3522104_SH59W15_Cell3.txt.gz","2540","71","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522105","Malignant bone and soft tissue tumor [SH59W15_Cell4]","GSM3522105","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 79","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0172","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522105/suppl/GSM3522105_SH59W15_Cell4.txt.gz","2540","79","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522106","Malignant bone and soft tissue tumor [SH59W16_Cell1]","GSM3522106","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 70","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0173","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522106/suppl/GSM3522106_SH59W16_Cell1.txt.gz","2540","70","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522107","Malignant bone and soft tissue tumor [SH59W16_Cell2]","GSM3522107","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0174","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522107/suppl/GSM3522107_SH59W16_Cell2.txt.gz","2540","59","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522108","Malignant bone and soft tissue tumor [SH59W16_Cell3]","GSM3522108","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0175","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522108/suppl/GSM3522108_SH59W16_Cell3.txt.gz","2540","53","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522109","Malignant bone and soft tissue tumor [SH59W17_Cell1]","GSM3522109","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0177","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522109/suppl/GSM3522109_SH59W17_Cell1.txt.gz","2540","55","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522110","Malignant bone and soft tissue tumor [SH59W17_Cell2]","GSM3522110","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0178","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522110/suppl/GSM3522110_SH59W17_Cell2.txt.gz","2540","64","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522111","Malignant bone and soft tissue tumor [SH59W17_Cell3]","GSM3522111","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0179","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522111/suppl/GSM3522111_SH59W17_Cell3.txt.gz","2540","69","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522113","Malignant bone and soft tissue tumor [SH59W17_Cell4]","GSM3522113","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0181","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522113/suppl/GSM3522113_SH59W17_Cell4.txt.gz","2540","75","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522114","Malignant bone and soft tissue tumor [SH59W18_Cell1]","GSM3522114","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0182","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522114/suppl/GSM3522114_SH59W18_Cell1.txt.gz","2540","54","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522115","Malignant bone and soft tissue tumor [SH59W18_Cell2]","GSM3522115","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0183","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522115/suppl/GSM3522115_SH59W18_Cell2.txt.gz","2540","75","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522116","Malignant bone and soft tissue tumor [SH59W18_Cell3]","GSM3522116","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0184","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522116/suppl/GSM3522116_SH59W18_Cell3.txt.gz","2540","63","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522117","Malignant bone and soft tissue tumor [SH59W18_Cell4]","GSM3522117","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0185","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522117/suppl/GSM3522117_SH59W18_Cell4.txt.gz","2540","66","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522118","Intermediate bone and soft tissue tumor [SH59W19_Cell1]","GSM3522118","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0186","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522118/suppl/GSM3522118_SH59W19_Cell1.txt.gz","2540","77","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522119","Malignant bone and soft tissue tumor [SH59W19_Cell2]","GSM3522119","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0187","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522119/suppl/GSM3522119_SH59W19_Cell2.txt.gz","2540","44","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522120","Malignant bone and soft tissue tumor [SH59W19_Cell3]","GSM3522120","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0188","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522120/suppl/GSM3522120_SH59W19_Cell3.txt.gz","2540","71","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522121","Malignant bone and soft tissue tumor [SH59W19_Cell4]","GSM3522121","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0191","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522121/suppl/GSM3522121_SH59W19_Cell4.txt.gz","2540","67","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522122","Malignant bone and soft tissue tumor [SH59W21_Cell1]","GSM3522122","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0192","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522122/suppl/GSM3522122_SH59W21_Cell1.txt.gz","2540","36","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522123","Malignant bone and soft tissue tumor [SH59W21_Cell2]","GSM3522123","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0193","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522123/suppl/GSM3522123_SH59W21_Cell2.txt.gz","2540","41","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522124","Malignant bone and soft tissue tumor [SH59W21_Cell3]","GSM3522124","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0194","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522124/suppl/GSM3522124_SH59W21_Cell3.txt.gz","2540","41","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522125","Malignant bone and soft tissue tumor [SH59W21_Cell4]","GSM3522125","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0195","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522125/suppl/GSM3522125_SH59W21_Cell4.txt.gz","2540","60","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522126","Malignant bone and soft tissue tumor [SH59W22_Cell1]","GSM3522126","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0196","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522126/suppl/GSM3522126_SH59W22_Cell1.txt.gz","2540","56","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522127","Malignant bone and soft tissue tumor [SH59W22_Cell2]","GSM3522127","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0197","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522127/suppl/GSM3522127_SH59W22_Cell2.txt.gz","2540","33","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522128","Malignant bone and soft tissue tumor [SH59W22_Cell3]","GSM3522128","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0198","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522128/suppl/GSM3522128_SH59W22_Cell3.txt.gz","2540","33","Male","Malignant bone and soft tissue tumor","Serum","StageIA"
"GSM3522129","Malignant bone and soft tissue tumor [SH59W22_Cell4]","GSM3522129","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0199","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522129/suppl/GSM3522129_SH59W22_Cell4.txt.gz","2540","55","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522130","Malignant bone and soft tissue tumor [SH59W23_Cell1]","GSM3522130","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0200","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522130/suppl/GSM3522130_SH59W23_Cell1.txt.gz","2540","65","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522131","Malignant bone and soft tissue tumor [SH59W23_Cell2]","GSM3522131","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0201","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522131/suppl/GSM3522131_SH59W23_Cell2.txt.gz","2540","42","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522132","Malignant bone and soft tissue tumor [SH59W23_Cell3]","GSM3522132","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0202","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522132/suppl/GSM3522132_SH59W23_Cell3.txt.gz","2540","40","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522133","Malignant bone and soft tissue tumor [SH59W23_Cell4]","GSM3522133","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0203","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522133/suppl/GSM3522133_SH59W23_Cell4.txt.gz","2540","38","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522134","Malignant bone and soft tissue tumor [SH59W24_Cell1]","GSM3522134","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0204","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522134/suppl/GSM3522134_SH59W24_Cell1.txt.gz","2540","30","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522135","Malignant bone and soft tissue tumor [SH59W24_Cell2]","GSM3522135","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0205","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522135/suppl/GSM3522135_SH59W24_Cell2.txt.gz","2540","21","Male","Malignant bone and soft tissue tumor","Serum","StageIA"
"GSM3522136","Malignant bone and soft tissue tumor [SH59W24_Cell3]","GSM3522136","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0206","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522136/suppl/GSM3522136_SH59W24_Cell3.txt.gz","2540","54","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522137","Malignant bone and soft tissue tumor [SH59W24_Cell4]","GSM3522137","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0207","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522137/suppl/GSM3522137_SH59W24_Cell4.txt.gz","2540","37","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522138","Malignant bone and soft tissue tumor [SH59W25_Cell1]","GSM3522138","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0208","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522138/suppl/GSM3522138_SH59W25_Cell1.txt.gz","2540","48","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522139","Malignant bone and soft tissue tumor [SH59W25_Cell2]","GSM3522139","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0209","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522139/suppl/GSM3522139_SH59W25_Cell2.txt.gz","2540","51","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522140","Malignant bone and soft tissue tumor [SH59W25_Cell4]","GSM3522140","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageX","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0213","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522140/suppl/GSM3522140_SH59W25_Cell4.txt.gz","2540","47","Female","Malignant bone and soft tissue tumor","Serum","StageX"
"GSM3522141","Malignant bone and soft tissue tumor [SH59W26_Cell1]","GSM3522141","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 16","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0214","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522141/suppl/GSM3522141_SH59W26_Cell1.txt.gz","2540","16","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522142","Malignant bone and soft tissue tumor [SH59W26_Cell2]","GSM3522142","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0215","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522142/suppl/GSM3522142_SH59W26_Cell2.txt.gz","2540","49","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522143","Malignant bone and soft tissue tumor [SH59W26_Cell3]","GSM3522143","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0216","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522143/suppl/GSM3522143_SH59W26_Cell3.txt.gz","2540","35","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522144","Malignant bone and soft tissue tumor [SH59W26_Cell4]","GSM3522144","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0217","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522144/suppl/GSM3522144_SH59W26_Cell4.txt.gz","2540","77","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522145","Malignant bone and soft tissue tumor [SH59W27_Cell1]","GSM3522145","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0218","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522145/suppl/GSM3522145_SH59W27_Cell1.txt.gz","2540","65","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522146","Malignant bone and soft tissue tumor [SH59W27_Cell2]","GSM3522146","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0219","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522146/suppl/GSM3522146_SH59W27_Cell2.txt.gz","2540","52","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522147","Malignant bone and soft tissue tumor [SH59W27_Cell3]","GSM3522147","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0220","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522147/suppl/GSM3522147_SH59W27_Cell3.txt.gz","2540","46","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522148","Malignant bone and soft tissue tumor [SH59W27_Cell4]","GSM3522148","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0221","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522148/suppl/GSM3522148_SH59W27_Cell4.txt.gz","2540","29","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522149","Intermediate bone and soft tissue tumor [SH59W28_Cell1]","GSM3522149","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0222","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522149/suppl/GSM3522149_SH59W28_Cell1.txt.gz","2540","78","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522150","Intermediate bone and soft tissue tumor [SH59W28_Cell2]","GSM3522150","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 76","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0223","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522150/suppl/GSM3522150_SH59W28_Cell2.txt.gz","2540","76","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522151","Intermediate bone and soft tissue tumor [SH59W28_Cell3]","GSM3522151","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0224","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522151/suppl/GSM3522151_SH59W28_Cell3.txt.gz","2540","52","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522152","Intermediate bone and soft tissue tumor [SH59W28_Cell4]","GSM3522152","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 85","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0225","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522152/suppl/GSM3522152_SH59W28_Cell4.txt.gz","2540","85","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522153","Intermediate bone and soft tissue tumor [SH59W29_Cell1]","GSM3522153","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0226","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522153/suppl/GSM3522153_SH59W29_Cell1.txt.gz","2540","61","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522154","Intermediate bone and soft tissue tumor [SH59W29_Cell3]","GSM3522154","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0228","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522154/suppl/GSM3522154_SH59W29_Cell3.txt.gz","2540","62","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522155","Intermediate bone and soft tissue tumor [SH59W29_Cell4]","GSM3522155","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0229","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522155/suppl/GSM3522155_SH59W29_Cell4.txt.gz","2540","60","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522156","Intermediate bone and soft tissue tumor [SH59W30_Cell1]","GSM3522156","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0230","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522156/suppl/GSM3522156_SH59W30_Cell1.txt.gz","2540","46","Female","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522157","Intermediate bone and soft tissue tumor [SH59W30_Cell2]","GSM3522157","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0231","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522157/suppl/GSM3522157_SH59W30_Cell2.txt.gz","2540","62","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522158","Intermediate bone and soft tissue tumor [SH59W30_Cell3]","GSM3522158","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0232","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522158/suppl/GSM3522158_SH59W30_Cell3.txt.gz","2540","68","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522159","Intermediate bone and soft tissue tumor [SH59W30_Cell4]","GSM3522159","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0233","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522159/suppl/GSM3522159_SH59W30_Cell4.txt.gz","2540","66","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522160","Intermediate bone and soft tissue tumor [SH59W31_Cell1]","GSM3522160","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0234","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522160/suppl/GSM3522160_SH59W31_Cell1.txt.gz","2540","65","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522161","Intermediate bone and soft tissue tumor [SH59W31_Cell2]","GSM3522161","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0235","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522161/suppl/GSM3522161_SH59W31_Cell2.txt.gz","2540","59","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522162","Intermediate bone and soft tissue tumor [SH59W31_Cell3]","GSM3522162","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0236","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522162/suppl/GSM3522162_SH59W31_Cell3.txt.gz","2540","75","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522163","Intermediate bone and soft tissue tumor [SH59W31_Cell4]","GSM3522163","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0237","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522163/suppl/GSM3522163_SH59W31_Cell4.txt.gz","2540","61","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522164","Intermediate bone and soft tissue tumor [SH59W32_Cell1]","GSM3522164","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0238","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522164/suppl/GSM3522164_SH59W32_Cell1.txt.gz","2540","50","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522165","Intermediate bone and soft tissue tumor [SH59W32_Cell2]","GSM3522165","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0239","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522165/suppl/GSM3522165_SH59W32_Cell2.txt.gz","2540","62","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522166","Intermediate bone and soft tissue tumor [SH59W32_Cell3]","GSM3522166","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0240","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522166/suppl/GSM3522166_SH59W32_Cell3.txt.gz","2540","55","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522167","Intermediate bone and soft tissue tumor [SH59W32_Cell4]","GSM3522167","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0241","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522167/suppl/GSM3522167_SH59W32_Cell4.txt.gz","2540","67","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522168","Intermediate bone and soft tissue tumor [SH59W33_Cell1]","GSM3522168","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0242","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522168/suppl/GSM3522168_SH59W33_Cell1.txt.gz","2540","49","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522169","Intermediate bone and soft tissue tumor [SH59W33_Cell2]","GSM3522169","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0243","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522169/suppl/GSM3522169_SH59W33_Cell2.txt.gz","2540","59","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522170","Intermediate bone and soft tissue tumor [SH59W33_Cell3]","GSM3522170","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0244","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522170/suppl/GSM3522170_SH59W33_Cell3.txt.gz","2540","63","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522171","Intermediate bone and soft tissue tumor [SH59W33_Cell4]","GSM3522171","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0245","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522171/suppl/GSM3522171_SH59W33_Cell4.txt.gz","2540","30","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522172","Intermediate bone and soft tissue tumor [SH59W34_Cell1]","GSM3522172","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0246","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522172/suppl/GSM3522172_SH59W34_Cell1.txt.gz","2540","61","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522173","Intermediate bone and soft tissue tumor [SH59W34_Cell2]","GSM3522173","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 84","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0247","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522173/suppl/GSM3522173_SH59W34_Cell2.txt.gz","2540","84","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522174","Intermediate bone and soft tissue tumor [SH59W34_Cell3]","GSM3522174","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0248","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522174/suppl/GSM3522174_SH59W34_Cell3.txt.gz","2540","44","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522175","Intermediate bone and soft tissue tumor [SH59W34_Cell4]","GSM3522175","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0249","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522175/suppl/GSM3522175_SH59W34_Cell4.txt.gz","2540","60","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522176","Intermediate bone and soft tissue tumor [SH59W37_Cell1]","GSM3522176","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0252","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522176/suppl/GSM3522176_SH59W37_Cell1.txt.gz","2540","62","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522177","Intermediate bone and soft tissue tumor [SH59W37_Cell2]","GSM3522177","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0253","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522177/suppl/GSM3522177_SH59W37_Cell2.txt.gz","2540","44","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522178","Intermediate bone and soft tissue tumor [SH59W37_Cell3]","GSM3522178","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0254","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522178/suppl/GSM3522178_SH59W37_Cell3.txt.gz","2540","59","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522179","Intermediate bone and soft tissue tumor [SH59W37_Cell4]","GSM3522179","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0255","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522179/suppl/GSM3522179_SH59W37_Cell4.txt.gz","2540","61","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522180","Intermediate bone and soft tissue tumor [SH59W38_Cell1]","GSM3522180","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0257","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522180/suppl/GSM3522180_SH59W38_Cell1.txt.gz","2540","47","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522181","Intermediate bone and soft tissue tumor [SH59W38_Cell2]","GSM3522181","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0258","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522181/suppl/GSM3522181_SH59W38_Cell2.txt.gz","2540","43","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522182","Intermediate bone and soft tissue tumor [SH59W38_Cell3]","GSM3522182","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0259","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522182/suppl/GSM3522182_SH59W38_Cell3.txt.gz","2540","45","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522183","Intermediate bone and soft tissue tumor [SH59W38_Cell4]","GSM3522183","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0260","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522183/suppl/GSM3522183_SH59W38_Cell4.txt.gz","2540","65","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522184","Intermediate bone and soft tissue tumor [SH59W39_Cell1]","GSM3522184","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0261","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522184/suppl/GSM3522184_SH59W39_Cell1.txt.gz","2540","68","Male","Intermediate bone and soft tissue tumor","Serum","StageIV"
"GSM3522185","Intermediate bone and soft tissue tumor [SH59W39_Cell2]","GSM3522185","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0262","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522185/suppl/GSM3522185_SH59W39_Cell2.txt.gz","2540","64","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522186","Intermediate bone and soft tissue tumor [SH59W39_Cell3]","GSM3522186","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0263","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522186/suppl/GSM3522186_SH59W39_Cell3.txt.gz","2540","44","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522187","Intermediate bone and soft tissue tumor [SH59W39_Cell4]","GSM3522187","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 79","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0264","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522187/suppl/GSM3522187_SH59W39_Cell4.txt.gz","2540","79","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522188","Malignant bone and soft tissue tumor [SH59W40_Cell1]","GSM3522188","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0266","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522188/suppl/GSM3522188_SH59W40_Cell1.txt.gz","2540","12","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522189","Malignant bone and soft tissue tumor [SH59W40_Cell2]","GSM3522189","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0267","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522189/suppl/GSM3522189_SH59W40_Cell2.txt.gz","2540","25","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522190","Malignant bone and soft tissue tumor [SH59W40_Cell3]","GSM3522190","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0268","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522190/suppl/GSM3522190_SH59W40_Cell3.txt.gz","2540","57","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522192","Malignant bone and soft tissue tumor [SH59W40_Cell4]","GSM3522192","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0270","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522192/suppl/GSM3522192_SH59W40_Cell4.txt.gz","2540","54","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522193","Malignant bone and soft tissue tumor [SH59W41_Cell1]","GSM3522193","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0271","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522193/suppl/GSM3522193_SH59W41_Cell1.txt.gz","2540","71","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522194","Malignant bone and soft tissue tumor [SH59W41_Cell2]","GSM3522194","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0272","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522194/suppl/GSM3522194_SH59W41_Cell2.txt.gz","2540","68","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522195","Malignant bone and soft tissue tumor [SH59W41_Cell3]","GSM3522195","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0273","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522195/suppl/GSM3522195_SH59W41_Cell3.txt.gz","2540","41","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522196","Malignant bone and soft tissue tumor [SH59W41_Cell4]","GSM3522196","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0274","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522196/suppl/GSM3522196_SH59W41_Cell4.txt.gz","2540","34","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522197","Malignant bone and soft tissue tumor [SH59W42_Cell1]","GSM3522197","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0275","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522197/suppl/GSM3522197_SH59W42_Cell1.txt.gz","2540","52","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522198","Malignant bone and soft tissue tumor [SH59W42_Cell2]","GSM3522198","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0276","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522198/suppl/GSM3522198_SH59W42_Cell2.txt.gz","2540","64","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522199","Malignant bone and soft tissue tumor [SH59W42_Cell4]","GSM3522199","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0278","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522199/suppl/GSM3522199_SH59W42_Cell4.txt.gz","2540","63","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522200","Malignant bone and soft tissue tumor [SH59W43_Cell1]","GSM3522200","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0279","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522200/suppl/GSM3522200_SH59W43_Cell1.txt.gz","2540","50","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522201","Malignant bone and soft tissue tumor [SH59W43_Cell2]","GSM3522201","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0280","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522201/suppl/GSM3522201_SH59W43_Cell2.txt.gz","2540","78","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522202","Malignant bone and soft tissue tumor [SH59W43_Cell3]","GSM3522202","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0281","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522202/suppl/GSM3522202_SH59W43_Cell3.txt.gz","2540","44","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522203","Malignant bone and soft tissue tumor [SH59W43_Cell4]","GSM3522203","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0282","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522203/suppl/GSM3522203_SH59W43_Cell4.txt.gz","2540","48","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522204","Malignant bone and soft tissue tumor [SH59W44_Cell1]","GSM3522204","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0283","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522204/suppl/GSM3522204_SH59W44_Cell1.txt.gz","2540","65","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522205","Malignant bone and soft tissue tumor [SH59W44_Cell2]","GSM3522205","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0284","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522205/suppl/GSM3522205_SH59W44_Cell2.txt.gz","2540","72","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522206","Malignant bone and soft tissue tumor [SH59W44_Cell3]","GSM3522206","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0285","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522206/suppl/GSM3522206_SH59W44_Cell3.txt.gz","2540","38","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522207","Malignant bone and soft tissue tumor [SH59W44_Cell4]","GSM3522207","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0286","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522207/suppl/GSM3522207_SH59W44_Cell4.txt.gz","2540","54","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522208","Malignant bone and soft tissue tumor [SH59W46_Cell1]","GSM3522208","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0287","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522208/suppl/GSM3522208_SH59W46_Cell1.txt.gz","2540","69","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522209","Malignant bone and soft tissue tumor [SH59W46_Cell2]","GSM3522209","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0288","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522209/suppl/GSM3522209_SH59W46_Cell2.txt.gz","2540","67","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522210","Malignant bone and soft tissue tumor [SH59W46_Cell3]","GSM3522210","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 83","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0290","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522210/suppl/GSM3522210_SH59W46_Cell3.txt.gz","2540","83","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522211","Malignant bone and soft tissue tumor [SH59W47_Cell2]","GSM3522211","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0293","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522211/suppl/GSM3522211_SH59W47_Cell2.txt.gz","2540","62","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522212","Malignant bone and soft tissue tumor [SH59W47_Cell3]","GSM3522212","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0294","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522212/suppl/GSM3522212_SH59W47_Cell3.txt.gz","2540","37","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522213","Malignant bone and soft tissue tumor [SH59W47_Cell4]","GSM3522213","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 76","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0295","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522213/suppl/GSM3522213_SH59W47_Cell4.txt.gz","2540","76","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522214","Malignant bone and soft tissue tumor [SH59W48_Cell1]","GSM3522214","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0296","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522214/suppl/GSM3522214_SH59W48_Cell1.txt.gz","2540","72","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522215","Malignant bone and soft tissue tumor [SH59W48_Cell2]","GSM3522215","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0297","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522215/suppl/GSM3522215_SH59W48_Cell2.txt.gz","2540","43","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522216","Malignant bone and soft tissue tumor [SH59W48_Cell3]","GSM3522216","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0298","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522216/suppl/GSM3522216_SH59W48_Cell3.txt.gz","2540","57","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522217","Malignant bone and soft tissue tumor [SH59W48_Cell4]","GSM3522217","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0299","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522217/suppl/GSM3522217_SH59W48_Cell4.txt.gz","2540","54","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522218","Malignant bone and soft tissue tumor [SH59W49_Cell1]","GSM3522218","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0300","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522218/suppl/GSM3522218_SH59W49_Cell1.txt.gz","2540","64","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522219","Malignant bone and soft tissue tumor [SH59W49_Cell2]","GSM3522219","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 79","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0301","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522219/suppl/GSM3522219_SH59W49_Cell2.txt.gz","2540","79","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522220","Malignant bone and soft tissue tumor [SH59W49_Cell3]","GSM3522220","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0302","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522220/suppl/GSM3522220_SH59W49_Cell3.txt.gz","2540","75","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522221","Malignant bone and soft tissue tumor [SH59W49_Cell4]","GSM3522221","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 76","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0303","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522221/suppl/GSM3522221_SH59W49_Cell4.txt.gz","2540","76","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522222","Malignant bone and soft tissue tumor [SH59W50_Cell1]","GSM3522222","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 88","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0304","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522222/suppl/GSM3522222_SH59W50_Cell1.txt.gz","2540","88","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522223","Malignant bone and soft tissue tumor [SH59W50_Cell2]","GSM3522223","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0305","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522223/suppl/GSM3522223_SH59W50_Cell2.txt.gz","2540","72","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522224","Malignant bone and soft tissue tumor [SH59W50_Cell3]","GSM3522224","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0306","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522224/suppl/GSM3522224_SH59W50_Cell3.txt.gz","2540","56","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522225","Malignant bone and soft tissue tumor [SH59W50_Cell4]","GSM3522225","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0307","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522225/suppl/GSM3522225_SH59W50_Cell4.txt.gz","2540","63","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522226","Malignant bone and soft tissue tumor [SH59W51_Cell1]","GSM3522226","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0308","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522226/suppl/GSM3522226_SH59W51_Cell1.txt.gz","2540","48","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522227","Malignant bone and soft tissue tumor [SH59W51_Cell2]","GSM3522227","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0309","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522227/suppl/GSM3522227_SH59W51_Cell2.txt.gz","2540","56","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522228","Malignant bone and soft tissue tumor [SH59W51_Cell3]","GSM3522228","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0310","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522228/suppl/GSM3522228_SH59W51_Cell3.txt.gz","2540","45","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522229","Malignant bone and soft tissue tumor [SH59W51_Cell4]","GSM3522229","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0311","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522229/suppl/GSM3522229_SH59W51_Cell4.txt.gz","2540","37","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522230","Malignant bone and soft tissue tumor [SH59W52_Cell1]","GSM3522230","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0312","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522230/suppl/GSM3522230_SH59W52_Cell1.txt.gz","2540","68","Female","Malignant bone and soft tissue tumor","Serum","StageIA"
"GSM3522231","Malignant bone and soft tissue tumor [SH59W52_Cell3]","GSM3522231","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 70","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0314","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522231/suppl/GSM3522231_SH59W52_Cell3.txt.gz","2540","70","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522232","Malignant bone and soft tissue tumor [SH59W53_Cell1]","GSM3522232","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0316","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522232/suppl/GSM3522232_SH59W53_Cell1.txt.gz","2540","40","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522233","Malignant bone and soft tissue tumor [SH59W53_Cell2]","GSM3522233","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0317","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522233/suppl/GSM3522233_SH59W53_Cell2.txt.gz","2540","73","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522234","Malignant bone and soft tissue tumor [SH59W53_Cell3]","GSM3522234","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0318","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522234/suppl/GSM3522234_SH59W53_Cell3.txt.gz","2540","61","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522235","Malignant bone and soft tissue tumor [SH59W53_Cell4]","GSM3522235","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0319","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522235/suppl/GSM3522235_SH59W53_Cell4.txt.gz","2540","75","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522236","Malignant bone and soft tissue tumor [SH59W54_Cell1]","GSM3522236","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0320","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522236/suppl/GSM3522236_SH59W54_Cell1.txt.gz","2540","73","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522237","Malignant bone and soft tissue tumor [SH59W54_Cell2]","GSM3522237","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 97","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0321","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522237/suppl/GSM3522237_SH59W54_Cell2.txt.gz","2540","97","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522238","Malignant bone and soft tissue tumor [SH59W54_Cell3]","GSM3522238","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0322","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522238/suppl/GSM3522238_SH59W54_Cell3.txt.gz","2540","77","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522239","Malignant bone and soft tissue tumor [SH59W54_Cell4]","GSM3522239","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0323","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522239/suppl/GSM3522239_SH59W54_Cell4.txt.gz","2540","63","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522240","Malignant bone and soft tissue tumor [SH59W55_Cell1]","GSM3522240","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0324","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522240/suppl/GSM3522240_SH59W55_Cell1.txt.gz","2540","69","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522241","Malignant bone and soft tissue tumor [SH59W55_Cell2]","GSM3522241","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0325","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522241/suppl/GSM3522241_SH59W55_Cell2.txt.gz","2540","57","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522242","Malignant bone and soft tissue tumor [SH59W55_Cell3]","GSM3522242","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0326","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522242/suppl/GSM3522242_SH59W55_Cell3.txt.gz","2540","66","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522243","Malignant bone and soft tissue tumor [SH59W55_Cell4]","GSM3522243","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 86","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0327","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522243/suppl/GSM3522243_SH59W55_Cell4.txt.gz","2540","86","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522244","Malignant bone and soft tissue tumor [SH59W56_Cell2]","GSM3522244","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0329","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522244/suppl/GSM3522244_SH59W56_Cell2.txt.gz","2540","73","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522245","Malignant bone and soft tissue tumor [SH59W56_Cell3]","GSM3522245","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0330","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522245/suppl/GSM3522245_SH59W56_Cell3.txt.gz","2540","66","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522246","Malignant bone and soft tissue tumor [SH59W56_Cell4]","GSM3522246","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0331","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522246/suppl/GSM3522246_SH59W56_Cell4.txt.gz","2540","58","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522247","Malignant bone and soft tissue tumor [SH59W57_Cell1]","GSM3522247","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0332","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522247/suppl/GSM3522247_SH59W57_Cell1.txt.gz","2540","65","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522248","Malignant bone and soft tissue tumor [SH59W57_Cell2]","GSM3522248","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0333","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522248/suppl/GSM3522248_SH59W57_Cell2.txt.gz","2540","59","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522249","Malignant bone and soft tissue tumor [SH59W57_Cell3]","GSM3522249","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0334","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522249/suppl/GSM3522249_SH59W57_Cell3.txt.gz","2540","69","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522250","Malignant bone and soft tissue tumor [SH59W57_Cell4]","GSM3522250","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageX","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0335","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522250/suppl/GSM3522250_SH59W57_Cell4.txt.gz","2540","62","Female","Malignant bone and soft tissue tumor","Serum","StageX"
"GSM3522251","Malignant bone and soft tissue tumor [SH59W58_Cell1]","GSM3522251","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0336","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522251/suppl/GSM3522251_SH59W58_Cell1.txt.gz","2540","61","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522252","Malignant bone and soft tissue tumor [SH59W58_Cell2]","GSM3522252","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0337","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522252/suppl/GSM3522252_SH59W58_Cell2.txt.gz","2540","69","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522253","Malignant bone and soft tissue tumor [SH59W58_Cell3]","GSM3522253","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0338","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522253/suppl/GSM3522253_SH59W58_Cell3.txt.gz","2540","73","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522254","Malignant bone and soft tissue tumor [SH59W58_Cell4]","GSM3522254","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0339","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522254/suppl/GSM3522254_SH59W58_Cell4.txt.gz","2540","77","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522255","Malignant bone and soft tissue tumor [SH59W59_Cell1]","GSM3522255","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0340","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522255/suppl/GSM3522255_SH59W59_Cell1.txt.gz","2540","64","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522256","Malignant bone and soft tissue tumor [SH59W59_Cell2]","GSM3522256","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0341","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522256/suppl/GSM3522256_SH59W59_Cell2.txt.gz","2540","71","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522257","Malignant bone and soft tissue tumor [SH59W59_Cell3]","GSM3522257","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0342","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522257/suppl/GSM3522257_SH59W59_Cell3.txt.gz","2540","58","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522258","Malignant bone and soft tissue tumor [SH59W59_Cell4]","GSM3522258","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0343","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522258/suppl/GSM3522258_SH59W59_Cell4.txt.gz","2540","73","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522259","Malignant bone and soft tissue tumor [SH59W60_Cell1]","GSM3522259","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0344","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522259/suppl/GSM3522259_SH59W60_Cell1.txt.gz","2540","61","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522260","Malignant bone and soft tissue tumor [SH59W60_Cell2]","GSM3522260","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0345","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522260/suppl/GSM3522260_SH59W60_Cell2.txt.gz","2540","71","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522261","Malignant bone and soft tissue tumor [SH59W60_Cell3]","GSM3522261","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 86","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0346","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522261/suppl/GSM3522261_SH59W60_Cell3.txt.gz","2540","86","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522262","Malignant bone and soft tissue tumor [SH59W60_Cell4]","GSM3522262","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 83","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0347","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522262/suppl/GSM3522262_SH59W60_Cell4.txt.gz","2540","83","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522263","Malignant bone and soft tissue tumor [SH59W61_Cell1]","GSM3522263","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0348","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522263/suppl/GSM3522263_SH59W61_Cell1.txt.gz","2540","65","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522264","Malignant bone and soft tissue tumor [SH59W61_Cell2]","GSM3522264","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 81","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0349","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522264/suppl/GSM3522264_SH59W61_Cell2.txt.gz","2540","81","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522265","Malignant bone and soft tissue tumor [SH59W61_Cell3]","GSM3522265","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0350","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522265/suppl/GSM3522265_SH59W61_Cell3.txt.gz","2540","61","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522266","Malignant bone and soft tissue tumor [SH59W61_Cell4]","GSM3522266","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0351","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522266/suppl/GSM3522266_SH59W61_Cell4.txt.gz","2540","51","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522267","Malignant bone and soft tissue tumor [SH59W62_Cell1]","GSM3522267","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0353","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522267/suppl/GSM3522267_SH59W62_Cell1.txt.gz","2540","62","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522268","Malignant bone and soft tissue tumor [SH59W62_Cell2]","GSM3522268","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0354","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522268/suppl/GSM3522268_SH59W62_Cell2.txt.gz","2540","68","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522269","Malignant bone and soft tissue tumor [SH59W62_Cell3]","GSM3522269","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageX","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0355","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522269/suppl/GSM3522269_SH59W62_Cell3.txt.gz","2540","56","Male","Malignant bone and soft tissue tumor","Serum","StageX"
"GSM3522270","Malignant bone and soft tissue tumor [SH59W62_Cell4]","GSM3522270","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0356","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522270/suppl/GSM3522270_SH59W62_Cell4.txt.gz","2540","48","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522271","Malignant bone and soft tissue tumor [SH59X01_Cell2]","GSM3522271","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 86","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0358","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522271/suppl/GSM3522271_SH59X01_Cell2.txt.gz","2540","86","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522272","Malignant bone and soft tissue tumor [SH59X01_Cell3]","GSM3522272","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0359","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522272/suppl/GSM3522272_SH59X01_Cell3.txt.gz","2540","71","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522273","Malignant bone and soft tissue tumor [SH59X01_Cell4]","GSM3522273","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 80","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0360","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522273/suppl/GSM3522273_SH59X01_Cell4.txt.gz","2540","80","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522274","Malignant bone and soft tissue tumor [SH59X02_Cell1]","GSM3522274","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0361","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522274/suppl/GSM3522274_SH59X02_Cell1.txt.gz","2540","44","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522275","Malignant bone and soft tissue tumor [SH59X02_Cell2]","GSM3522275","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0362","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522275/suppl/GSM3522275_SH59X02_Cell2.txt.gz","2540","32","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522276","Malignant bone and soft tissue tumor [SH59X02_Cell3]","GSM3522276","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0363","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522276/suppl/GSM3522276_SH59X02_Cell3.txt.gz","2540","17","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522277","Malignant bone and soft tissue tumor [SH59X02_Cell4]","GSM3522277","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVB","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0364","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522277/suppl/GSM3522277_SH59X02_Cell4.txt.gz","2540","59","Male","Malignant bone and soft tissue tumor","Serum","StageIVB"
"GSM3522278","Malignant bone and soft tissue tumor [SH59X03_Cell1]","GSM3522278","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0365","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522278/suppl/GSM3522278_SH59X03_Cell1.txt.gz","2540","68","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522279","Malignant bone and soft tissue tumor [SH59X03_Cell2]","GSM3522279","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 11","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0366","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522279/suppl/GSM3522279_SH59X03_Cell2.txt.gz","2540","11","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522280","Malignant bone and soft tissue tumor [SH59X03_Cell4]","GSM3522280","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0368","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522280/suppl/GSM3522280_SH59X03_Cell4.txt.gz","2540","36","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522281","Malignant bone and soft tissue tumor [SH59X04_Cell1]","GSM3522281","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0369","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522281/suppl/GSM3522281_SH59X04_Cell1.txt.gz","2540","67","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522283","Malignant bone and soft tissue tumor [SH59X04_Cell4]","GSM3522283","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0373","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522283/suppl/GSM3522283_SH59X04_Cell4.txt.gz","2540","39","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522284","Malignant bone and soft tissue tumor [SH59X05_Cell1]","GSM3522284","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIVA","age: 13","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0374","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522284/suppl/GSM3522284_SH59X05_Cell1.txt.gz","2540","13","Female","Malignant bone and soft tissue tumor","Serum","StageIVA"
"GSM3522285","Malignant bone and soft tissue tumor [SH59X05_Cell2]","GSM3522285","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0375","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522285/suppl/GSM3522285_SH59X05_Cell2.txt.gz","2540","17","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522286","Malignant bone and soft tissue tumor [SH59X05_Cell3]","GSM3522286","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVA","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0376","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522286/suppl/GSM3522286_SH59X05_Cell3.txt.gz","2540","17","Male","Malignant bone and soft tissue tumor","Serum","StageIVA"
"GSM3522287","Malignant bone and soft tissue tumor [SH59X05_Cell4]","GSM3522287","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0377","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522287/suppl/GSM3522287_SH59X05_Cell4.txt.gz","2540","17","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522288","Malignant bone and soft tissue tumor [SH59X06_Cell1]","GSM3522288","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVA","age: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0378","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522288/suppl/GSM3522288_SH59X06_Cell1.txt.gz","2540","25","Male","Malignant bone and soft tissue tumor","Serum","StageIVA"
"GSM3522289","Malignant bone and soft tissue tumor [SH59X06_Cell2]","GSM3522289","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 20","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0379","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522289/suppl/GSM3522289_SH59X06_Cell2.txt.gz","2540","20","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522290","Malignant bone and soft tissue tumor [SH59X06_Cell3]","GSM3522290","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0380","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522290/suppl/GSM3522290_SH59X06_Cell3.txt.gz","2540","27","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522291","Malignant bone and soft tissue tumor [SH59X07_Cell1]","GSM3522291","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0382","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522291/suppl/GSM3522291_SH59X07_Cell1.txt.gz","2540","14","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522292","Malignant bone and soft tissue tumor [SH59X07_Cell2]","GSM3522292","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 16","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0383","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522292/suppl/GSM3522292_SH59X07_Cell2.txt.gz","2540","16","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522293","Malignant bone and soft tissue tumor [SH59X07_Cell3]","GSM3522293","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 20","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0384","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522293/suppl/GSM3522293_SH59X07_Cell3.txt.gz","2540","20","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522294","Malignant bone and soft tissue tumor [SH59X08_Cell1]","GSM3522294","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0386","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522294/suppl/GSM3522294_SH59X08_Cell1.txt.gz","2540","19","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522295","Malignant bone and soft tissue tumor [SH59X08_Cell2]","GSM3522295","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 11","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0387","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522295/suppl/GSM3522295_SH59X08_Cell2.txt.gz","2540","11","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522296","Malignant bone and soft tissue tumor [SH59X08_Cell3]","GSM3522296","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVB","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0388","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522296/suppl/GSM3522296_SH59X08_Cell3.txt.gz","2540","17","Male","Malignant bone and soft tissue tumor","Serum","StageIVB"
"GSM3522297","Malignant bone and soft tissue tumor [SH59X08_Cell4]","GSM3522297","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0389","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522297/suppl/GSM3522297_SH59X08_Cell4.txt.gz","2540","18","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522298","Malignant bone and soft tissue tumor [SH59X09_Cell3]","GSM3522298","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0393","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522298/suppl/GSM3522298_SH59X09_Cell3.txt.gz","2540","14","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522299","Malignant bone and soft tissue tumor [SH59X09_Cell4]","GSM3522299","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0394","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522299/suppl/GSM3522299_SH59X09_Cell4.txt.gz","2540","25","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522300","Malignant bone and soft tissue tumor [SH59X11_Cell2]","GSM3522300","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0396","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522300/suppl/GSM3522300_SH59X11_Cell2.txt.gz","2540","15","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522301","Malignant bone and soft tissue tumor [SH59X11_Cell3]","GSM3522301","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 10","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0397","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522301/suppl/GSM3522301_SH59X11_Cell3.txt.gz","2540","10","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522302","Malignant bone and soft tissue tumor [SH59X11_Cell4]","GSM3522302","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 11","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0398","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522302/suppl/GSM3522302_SH59X11_Cell4.txt.gz","2540","11","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522303","Malignant bone and soft tissue tumor [SH59X12_Cell1]","GSM3522303","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0399","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522303/suppl/GSM3522303_SH59X12_Cell1.txt.gz","2540","28","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522304","Malignant bone and soft tissue tumor [SH59X12_Cell2]","GSM3522304","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0400","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522304/suppl/GSM3522304_SH59X12_Cell2.txt.gz","2540","12","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522305","Malignant bone and soft tissue tumor [SH59X12_Cell3]","GSM3522305","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVA","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0401","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522305/suppl/GSM3522305_SH59X12_Cell3.txt.gz","2540","17","Male","Malignant bone and soft tissue tumor","Serum","StageIVA"
"GSM3522306","Malignant bone and soft tissue tumor [SH59X12_Cell4]","GSM3522306","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 16","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0402","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522306/suppl/GSM3522306_SH59X12_Cell4.txt.gz","2540","16","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522307","Malignant bone and soft tissue tumor [SH59X13_Cell1]","GSM3522307","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 10","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0403","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522307/suppl/GSM3522307_SH59X13_Cell1.txt.gz","2540","10","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522308","Malignant bone and soft tissue tumor [SH59X13_Cell2]","GSM3522308","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 11","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0404","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522308/suppl/GSM3522308_SH59X13_Cell2.txt.gz","2540","11","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522309","Malignant bone and soft tissue tumor [SH59X13_Cell3]","GSM3522309","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0405","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522309/suppl/GSM3522309_SH59X13_Cell3.txt.gz","2540","63","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522310","Malignant bone and soft tissue tumor [SH59X13_Cell4]","GSM3522310","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVA","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0406","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522310/suppl/GSM3522310_SH59X13_Cell4.txt.gz","2540","17","Male","Malignant bone and soft tissue tumor","Serum","StageIVA"
"GSM3522311","Malignant bone and soft tissue tumor [SH59X14_Cell1]","GSM3522311","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIVB","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0407","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522311/suppl/GSM3522311_SH59X14_Cell1.txt.gz","2540","35","Female","Malignant bone and soft tissue tumor","Serum","StageIVB"
"GSM3522312","Malignant bone and soft tissue tumor [SH59X14_Cell2]","GSM3522312","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0408","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522312/suppl/GSM3522312_SH59X14_Cell2.txt.gz","2540","72","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522313","Malignant bone and soft tissue tumor [SH59X14_Cell3]","GSM3522313","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0409","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522313/suppl/GSM3522313_SH59X14_Cell3.txt.gz","2540","31","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522314","Malignant bone and soft tissue tumor [SH59X14_Cell4]","GSM3522314","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0410","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522314/suppl/GSM3522314_SH59X14_Cell4.txt.gz","2540","64","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522315","Malignant bone and soft tissue tumor [SH59X15_Cell2]","GSM3522315","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 16","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0412","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522315/suppl/GSM3522315_SH59X15_Cell2.txt.gz","2540","16","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522316","Malignant bone and soft tissue tumor [SH59X15_Cell3]","GSM3522316","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0414","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522316/suppl/GSM3522316_SH59X15_Cell3.txt.gz","2540","34","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522317","Malignant bone and soft tissue tumor [SH59X15_Cell4]","GSM3522317","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0415","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522317/suppl/GSM3522317_SH59X15_Cell4.txt.gz","2540","15","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522318","Malignant bone and soft tissue tumor [SH59X16_Cell1]","GSM3522318","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 24","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0416","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522318/suppl/GSM3522318_SH59X16_Cell1.txt.gz","2540","24","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522319","Malignant bone and soft tissue tumor [SH59X16_Cell2]","GSM3522319","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0417","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522319/suppl/GSM3522319_SH59X16_Cell2.txt.gz","2540","18","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522320","Malignant bone and soft tissue tumor [SH59X16_Cell3]","GSM3522320","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0418","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522320/suppl/GSM3522320_SH59X16_Cell3.txt.gz","2540","37","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522321","Malignant bone and soft tissue tumor [SH59X16_Cell4]","GSM3522321","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0419","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522321/suppl/GSM3522321_SH59X16_Cell4.txt.gz","2540","18","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522322","Malignant bone and soft tissue tumor [SH59X17_Cell1]","GSM3522322","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 3","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0420","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522322/suppl/GSM3522322_SH59X17_Cell1.txt.gz","2540","3","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522323","Malignant bone and soft tissue tumor [SH59X17_Cell3]","GSM3522323","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0422","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522323/suppl/GSM3522323_SH59X17_Cell3.txt.gz","2540","19","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522324","Malignant bone and soft tissue tumor [SH59X17_Cell4]","GSM3522324","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 16","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0423","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522324/suppl/GSM3522324_SH59X17_Cell4.txt.gz","2540","16","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522325","Malignant bone and soft tissue tumor [SH59X18_Cell1]","GSM3522325","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0424","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522325/suppl/GSM3522325_SH59X18_Cell1.txt.gz","2540","8","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522326","Malignant bone and soft tissue tumor [SH59X18_Cell2]","GSM3522326","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0425","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522326/suppl/GSM3522326_SH59X18_Cell2.txt.gz","2540","19","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522327","Malignant bone and soft tissue tumor [SH59X18_Cell3]","GSM3522327","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0426","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522327/suppl/GSM3522327_SH59X18_Cell3.txt.gz","2540","8","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522328","Malignant bone and soft tissue tumor [SH59X18_Cell4]","GSM3522328","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0427","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522328/suppl/GSM3522328_SH59X18_Cell4.txt.gz","2540","8","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522329","Malignant bone and soft tissue tumor [SH59X19_Cell2]","GSM3522329","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 20","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0429","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522329/suppl/GSM3522329_SH59X19_Cell2.txt.gz","2540","20","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522330","Malignant bone and soft tissue tumor [SH59X19_Cell3]","GSM3522330","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 16","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0430","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522330/suppl/GSM3522330_SH59X19_Cell3.txt.gz","2540","16","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522331","Malignant bone and soft tissue tumor [SH59X19_Cell4]","GSM3522331","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 1","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0431","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522331/suppl/GSM3522331_SH59X19_Cell4.txt.gz","2540","1","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522332","Malignant bone and soft tissue tumor [SH59X20_Cell2]","GSM3522332","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 16","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0434","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522332/suppl/GSM3522332_SH59X20_Cell2.txt.gz","2540","16","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522333","Malignant bone and soft tissue tumor [SH59X20_Cell3]","GSM3522333","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 5","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0436","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522333/suppl/GSM3522333_SH59X20_Cell3.txt.gz","2540","5","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522334","Malignant bone and soft tissue tumor [SH59X20_Cell4]","GSM3522334","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 13","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0438","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522334/suppl/GSM3522334_SH59X20_Cell4.txt.gz","2540","13","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522335","Malignant bone and soft tissue tumor [SH59X21_Cell1]","GSM3522335","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0439","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522335/suppl/GSM3522335_SH59X21_Cell1.txt.gz","2540","40","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522336","Malignant bone and soft tissue tumor [SH59X21_Cell2]","GSM3522336","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0440","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522336/suppl/GSM3522336_SH59X21_Cell2.txt.gz","2540","47","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522337","Malignant bone and soft tissue tumor [SH59X21_Cell3]","GSM3522337","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0441","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522337/suppl/GSM3522337_SH59X21_Cell3.txt.gz","2540","68","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522338","Malignant bone and soft tissue tumor [SH59X21_Cell4]","GSM3522338","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0442","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522338/suppl/GSM3522338_SH59X21_Cell4.txt.gz","2540","41","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522339","Malignant bone and soft tissue tumor [SH59X22_Cell1]","GSM3522339","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0443","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522339/suppl/GSM3522339_SH59X22_Cell1.txt.gz","2540","26","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522340","Malignant bone and soft tissue tumor [SH59X22_Cell2]","GSM3522340","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0444","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522340/suppl/GSM3522340_SH59X22_Cell2.txt.gz","2540","53","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522341","Malignant bone and soft tissue tumor [SH59X22_Cell3]","GSM3522341","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0445","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522341/suppl/GSM3522341_SH59X22_Cell3.txt.gz","2540","41","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522342","Malignant bone and soft tissue tumor [SH59X22_Cell4]","GSM3522342","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0446","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522342/suppl/GSM3522342_SH59X22_Cell4.txt.gz","2540","30","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522343","Malignant bone and soft tissue tumor [SH59X23_Cell1]","GSM3522343","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0447","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522343/suppl/GSM3522343_SH59X23_Cell1.txt.gz","2540","36","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522344","Malignant bone and soft tissue tumor [SH59X23_Cell2]","GSM3522344","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0448","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522344/suppl/GSM3522344_SH59X23_Cell2.txt.gz","2540","50","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522345","Malignant bone and soft tissue tumor [SH59X23_Cell3]","GSM3522345","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0449","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522345/suppl/GSM3522345_SH59X23_Cell3.txt.gz","2540","59","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522346","Malignant bone and soft tissue tumor [SH59X23_Cell4]","GSM3522346","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0450","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522346/suppl/GSM3522346_SH59X23_Cell4.txt.gz","2540","27","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522347","Malignant bone and soft tissue tumor [SH59X24_Cell1]","GSM3522347","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0451","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522347/suppl/GSM3522347_SH59X24_Cell1.txt.gz","2540","49","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522348","Malignant bone and soft tissue tumor [SH59X24_Cell2]","GSM3522348","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0452","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522348/suppl/GSM3522348_SH59X24_Cell2.txt.gz","2540","40","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522349","Malignant bone and soft tissue tumor [SH59X24_Cell3]","GSM3522349","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0453","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522349/suppl/GSM3522349_SH59X24_Cell3.txt.gz","2540","26","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522350","Malignant bone and soft tissue tumor [SH59X24_Cell4]","GSM3522350","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0454","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522350/suppl/GSM3522350_SH59X24_Cell4.txt.gz","2540","56","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522351","Malignant bone and soft tissue tumor [SH59X25_Cell1]","GSM3522351","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 22","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0455","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522351/suppl/GSM3522351_SH59X25_Cell1.txt.gz","2540","22","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522352","Malignant bone and soft tissue tumor [SH59X25_Cell2]","GSM3522352","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0456","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522352/suppl/GSM3522352_SH59X25_Cell2.txt.gz","2540","40","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522353","Malignant bone and soft tissue tumor [SH59X25_Cell3]","GSM3522353","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 20","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0457","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522353/suppl/GSM3522353_SH59X25_Cell3.txt.gz","2540","20","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522354","Malignant bone and soft tissue tumor [SH59X25_Cell4]","GSM3522354","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0458","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522354/suppl/GSM3522354_SH59X25_Cell4.txt.gz","2540","46","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522355","Malignant bone and soft tissue tumor [SH59X26_Cell1]","GSM3522355","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0459","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522355/suppl/GSM3522355_SH59X26_Cell1.txt.gz","2540","38","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522356","Malignant bone and soft tissue tumor [SH59X26_Cell2]","GSM3522356","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0460","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522356/suppl/GSM3522356_SH59X26_Cell2.txt.gz","2540","27","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522357","Malignant bone and soft tissue tumor [SH59X26_Cell3]","GSM3522357","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0461","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522357/suppl/GSM3522357_SH59X26_Cell3.txt.gz","2540","62","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522358","Malignant bone and soft tissue tumor [SH59X26_Cell4]","GSM3522358","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0462","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522358/suppl/GSM3522358_SH59X26_Cell4.txt.gz","2540","40","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522359","Malignant bone and soft tissue tumor [SH59X27_Cell1]","GSM3522359","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0463","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522359/suppl/GSM3522359_SH59X27_Cell1.txt.gz","2540","61","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522360","Malignant bone and soft tissue tumor [SH59X27_Cell2]","GSM3522360","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0464","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522360/suppl/GSM3522360_SH59X27_Cell2.txt.gz","2540","69","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522361","Malignant bone and soft tissue tumor [SH59X27_Cell3]","GSM3522361","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0465","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522361/suppl/GSM3522361_SH59X27_Cell3.txt.gz","2540","60","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522362","Malignant bone and soft tissue tumor [SH59X27_Cell4]","GSM3522362","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0466","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522362/suppl/GSM3522362_SH59X27_Cell4.txt.gz","2540","27","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522363","Malignant bone and soft tissue tumor [SH59X28_Cell1]","GSM3522363","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0467","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522363/suppl/GSM3522363_SH59X28_Cell1.txt.gz","2540","67","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522364","Malignant bone and soft tissue tumor [SH59X28_Cell2]","GSM3522364","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0468","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522364/suppl/GSM3522364_SH59X28_Cell2.txt.gz","2540","71","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522365","Malignant bone and soft tissue tumor [SH59X28_Cell3]","GSM3522365","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0469","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522365/suppl/GSM3522365_SH59X28_Cell3.txt.gz","2540","63","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522366","Malignant bone and soft tissue tumor [SH59X29_Cell1]","GSM3522366","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0471","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522366/suppl/GSM3522366_SH59X29_Cell1.txt.gz","2540","56","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522367","Benign bone and soft tissue tumor [SH51Z19_Cell1]","GSM3522367","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0472","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522367/suppl/GSM3522367_SH51Z19_Cell1.txt.gz","2540","58","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522368","Benign bone and soft tissue tumor [SH51Z19_Cell2]","GSM3522368","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0473","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522368/suppl/GSM3522368_SH51Z19_Cell2.txt.gz","2540","57","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522369","Benign bone and soft tissue tumor [SH51Z19_Cell3]","GSM3522369","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0474","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522369/suppl/GSM3522369_SH51Z19_Cell3.txt.gz","2540","57","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522370","Benign bone and soft tissue tumor [SH51Z19_Cell4]","GSM3522370","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0475","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522370/suppl/GSM3522370_SH51Z19_Cell4.txt.gz","2540","26","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522371","Intermediate bone and soft tissue tumor [SH51Z20_Cell1]","GSM3522371","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0476","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522371/suppl/GSM3522371_SH51Z20_Cell1.txt.gz","2540","34","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522372","Benign bone and soft tissue tumor [SH51Z20_Cell2]","GSM3522372","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0477","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522372/suppl/GSM3522372_SH51Z20_Cell2.txt.gz","2540","45","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522373","Intermediate bone and soft tissue tumor [SH51Z20_Cell3]","GSM3522373","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0478","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522373/suppl/GSM3522373_SH51Z20_Cell3.txt.gz","2540","27","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522374","Benign bone and soft tissue tumor [SH51Z20_Cell4]","GSM3522374","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0479","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522374/suppl/GSM3522374_SH51Z20_Cell4.txt.gz","2540","35","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522375","Benign bone and soft tissue tumor [SH51Z21_Cell1]","GSM3522375","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 11","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0480","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522375/suppl/GSM3522375_SH51Z21_Cell1.txt.gz","2540","11","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522376","Intermediate bone and soft tissue tumor [SH51Z21_Cell2]","GSM3522376","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0481","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522376/suppl/GSM3522376_SH51Z21_Cell2.txt.gz","2540","32","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522377","Benign bone and soft tissue tumor [SH51Z21_Cell3]","GSM3522377","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0482","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522377/suppl/GSM3522377_SH51Z21_Cell3.txt.gz","2540","73","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522378","Benign bone and soft tissue tumor [SH51Z21_Cell4]","GSM3522378","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0483","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522378/suppl/GSM3522378_SH51Z21_Cell4.txt.gz","2540","77","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522379","Intermediate bone and soft tissue tumor [SH51Z23_Cell1]","GSM3522379","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0484","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522379/suppl/GSM3522379_SH51Z23_Cell1.txt.gz","2540","34","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522380","Benign bone and soft tissue tumor [SH51Z23_Cell2]","GSM3522380","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0485","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522380/suppl/GSM3522380_SH51Z23_Cell2.txt.gz","2540","35","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522381","Benign bone and soft tissue tumor [SH51Z23_Cell3]","GSM3522381","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 82","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0486","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522381/suppl/GSM3522381_SH51Z23_Cell3.txt.gz","2540","82","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522382","Intermediate bone and soft tissue tumor [SH51Z23_Cell4]","GSM3522382","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 20","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0487","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522382/suppl/GSM3522382_SH51Z23_Cell4.txt.gz","2540","20","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522383","Benign bone and soft tissue tumor [SH51Z27_Cell1]","GSM3522383","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0488","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522383/suppl/GSM3522383_SH51Z27_Cell1.txt.gz","2540","56","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522384","Benign bone and soft tissue tumor [SH51Z27_Cell2]","GSM3522384","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 13","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0489","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522384/suppl/GSM3522384_SH51Z27_Cell2.txt.gz","2540","13","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522385","Benign bone and soft tissue tumor [SH51Z27_Cell3]","GSM3522385","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0490","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522385/suppl/GSM3522385_SH51Z27_Cell3.txt.gz","2540","53","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522386","Benign bone and soft tissue tumor [SH51Z27_Cell4]","GSM3522386","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0491","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522386/suppl/GSM3522386_SH51Z27_Cell4.txt.gz","2540","42","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522387","Intermediate bone and soft tissue tumor [SH51Z39_Cell1]","GSM3522387","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0492","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522387/suppl/GSM3522387_SH51Z39_Cell1.txt.gz","2540","31","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522388","Benign bone and soft tissue tumor [SH51Z39_Cell2]","GSM3522388","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0493","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522388/suppl/GSM3522388_SH51Z39_Cell2.txt.gz","2540","37","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522389","Benign bone and soft tissue tumor [SH51Z39_Cell3]","GSM3522389","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0494","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522389/suppl/GSM3522389_SH51Z39_Cell3.txt.gz","2540","46","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522390","Benign bone and soft tissue tumor [SH51Z39_Cell4]","GSM3522390","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0495","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522390/suppl/GSM3522390_SH51Z39_Cell4.txt.gz","2540","62","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522391","Benign bone and soft tissue tumor [SH51Z46_Cell1]","GSM3522391","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0496","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522391/suppl/GSM3522391_SH51Z46_Cell1.txt.gz","2540","40","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522392","Intermediate bone and soft tissue tumor [SH51Z46_Cell2]","GSM3522392","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0497","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522392/suppl/GSM3522392_SH51Z46_Cell2.txt.gz","2540","37","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522393","Benign bone and soft tissue tumor [SH51Z46_Cell3]","GSM3522393","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 6","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0498","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522393/suppl/GSM3522393_SH51Z46_Cell3.txt.gz","2540","6","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522394","Benign bone and soft tissue tumor [SH51Z46_Cell4]","GSM3522394","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0499","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522394/suppl/GSM3522394_SH51Z46_Cell4.txt.gz","2540","36","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522395","Benign bone and soft tissue tumor [SH51Z47_Cell1]","GSM3522395","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 81","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0500","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522395/suppl/GSM3522395_SH51Z47_Cell1.txt.gz","2540","81","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522396","Benign bone and soft tissue tumor [SH51Z47_Cell2]","GSM3522396","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0501","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522396/suppl/GSM3522396_SH51Z47_Cell2.txt.gz","2540","53","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522397","Benign bone and soft tissue tumor [SH51Z47_Cell3]","GSM3522397","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0502","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522397/suppl/GSM3522397_SH51Z47_Cell3.txt.gz","2540","28","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522398","Benign bone and soft tissue tumor [SH51Z47_Cell4]","GSM3522398","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0503","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522398/suppl/GSM3522398_SH51Z47_Cell4.txt.gz","2540","36","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522399","Intermediate bone and soft tissue tumor [SH51Z48_Cell1]","GSM3522399","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0504","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522399/suppl/GSM3522399_SH51Z48_Cell1.txt.gz","2540","21","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522400","Benign bone and soft tissue tumor [SH51Z48_Cell2]","GSM3522400","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0505","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522400/suppl/GSM3522400_SH51Z48_Cell2.txt.gz","2540","25","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522401","Benign bone and soft tissue tumor [SH51Z48_Cell3]","GSM3522401","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0506","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522401/suppl/GSM3522401_SH51Z48_Cell3.txt.gz","2540","32","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522402","Benign bone and soft tissue tumor [SH51Z48_Cell4]","GSM3522402","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0507","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522402/suppl/GSM3522402_SH51Z48_Cell4.txt.gz","2540","67","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522403","Benign bone and soft tissue tumor [SH51Z57_Cell1]","GSM3522403","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0508","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522403/suppl/GSM3522403_SH51Z57_Cell1.txt.gz","2540","33","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522404","Benign bone and soft tissue tumor [SH51Z57_Cell2]","GSM3522404","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0509","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522404/suppl/GSM3522404_SH51Z57_Cell2.txt.gz","2540","43","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522405","Intermediate bone and soft tissue tumor [SH51Z57_Cell3]","GSM3522405","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0510","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522405/suppl/GSM3522405_SH51Z57_Cell3.txt.gz","2540","18","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522406","Benign bone and soft tissue tumor [SH51Z57_Cell4]","GSM3522406","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0511","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522406/suppl/GSM3522406_SH51Z57_Cell4.txt.gz","2540","75","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522407","Benign bone and soft tissue tumor [SH51Z58_Cell1]","GSM3522407","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0512","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522407/suppl/GSM3522407_SH51Z58_Cell1.txt.gz","2540","39","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522408","Intermediate bone and soft tissue tumor [SH51Z58_Cell2]","GSM3522408","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0513","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522408/suppl/GSM3522408_SH51Z58_Cell2.txt.gz","2540","67","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522409","Benign bone and soft tissue tumor [SH51Z58_Cell3]","GSM3522409","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0514","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522409/suppl/GSM3522409_SH51Z58_Cell3.txt.gz","2540","64","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522410","Benign bone and soft tissue tumor [SH51Z58_Cell4]","GSM3522410","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 76","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0515","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522410/suppl/GSM3522410_SH51Z58_Cell4.txt.gz","2540","76","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522411","Benign bone and soft tissue tumor [SH51Z59_Cell1]","GSM3522411","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0516","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522411/suppl/GSM3522411_SH51Z59_Cell1.txt.gz","2540","54","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522412","Benign bone and soft tissue tumor [SH51Z59_Cell2]","GSM3522412","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 22","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0517","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522412/suppl/GSM3522412_SH51Z59_Cell2.txt.gz","2540","22","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522413","Benign bone and soft tissue tumor [SH51Z59_Cell3]","GSM3522413","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0518","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522413/suppl/GSM3522413_SH51Z59_Cell3.txt.gz","2540","31","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522414","Intermediate bone and soft tissue tumor [SH51Z59_Cell4]","GSM3522414","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0519","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522414/suppl/GSM3522414_SH51Z59_Cell4.txt.gz","2540","61","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522415","Benign bone and soft tissue tumor [SH52102_Cell1]","GSM3522415","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0520","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522415/suppl/GSM3522415_SH52102_Cell1.txt.gz","2540","54","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522416","Benign bone and soft tissue tumor [SH52102_Cell2]","GSM3522416","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0521","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522416/suppl/GSM3522416_SH52102_Cell2.txt.gz","2540","47","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522417","Benign bone and soft tissue tumor [SH52102_Cell3]","GSM3522417","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0522","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522417/suppl/GSM3522417_SH52102_Cell3.txt.gz","2540","44","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522418","Benign bone and soft tissue tumor [SH52102_Cell4]","GSM3522418","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0523","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522418/suppl/GSM3522418_SH52102_Cell4.txt.gz","2540","46","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522419","Benign bone and soft tissue tumor [SH52105_Cell1]","GSM3522419","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0524","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522419/suppl/GSM3522419_SH52105_Cell1.txt.gz","2540","50","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522420","Benign bone and soft tissue tumor [SH52105_Cell2]","GSM3522420","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0525","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522420/suppl/GSM3522420_SH52105_Cell2.txt.gz","2540","28","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522421","Benign bone and soft tissue tumor [SH52105_Cell3]","GSM3522421","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0526","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522421/suppl/GSM3522421_SH52105_Cell3.txt.gz","2540","71","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522422","Intermediate bone and soft tissue tumor [SH52105_Cell4]","GSM3522422","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0527","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522422/suppl/GSM3522422_SH52105_Cell4.txt.gz","2540","37","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522423","Benign bone and soft tissue tumor [SH52107_Cell1]","GSM3522423","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0528","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522423/suppl/GSM3522423_SH52107_Cell1.txt.gz","2540","15","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522424","Intermediate bone and soft tissue tumor [SH52107_Cell2]","GSM3522424","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0529","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522424/suppl/GSM3522424_SH52107_Cell2.txt.gz","2540","36","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522425","Benign bone and soft tissue tumor [SH52107_Cell3]","GSM3522425","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0530","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522425/suppl/GSM3522425_SH52107_Cell3.txt.gz","2540","53","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522426","Benign bone and soft tissue tumor [SH52107_Cell4]","GSM3522426","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0531","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522426/suppl/GSM3522426_SH52107_Cell4.txt.gz","2540","59","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522427","Benign bone and soft tissue tumor [SH52108_Cell1]","GSM3522427","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0532","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522427/suppl/GSM3522427_SH52108_Cell1.txt.gz","2540","30","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522428","Benign bone and soft tissue tumor [SH52108_Cell2]","GSM3522428","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0533","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522428/suppl/GSM3522428_SH52108_Cell2.txt.gz","2540","73","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522429","Benign bone and soft tissue tumor [SH52108_Cell3]","GSM3522429","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 13","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0534","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522429/suppl/GSM3522429_SH52108_Cell3.txt.gz","2540","13","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522430","Malignant bone and soft tissue tumor [SH52108_Cell4]","GSM3522430","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0535","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522430/suppl/GSM3522430_SH52108_Cell4.txt.gz","2540","50","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522431","Benign bone and soft tissue tumor [SH52113_Cell1]","GSM3522431","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0536","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522431/suppl/GSM3522431_SH52113_Cell1.txt.gz","2540","14","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522432","Benign bone and soft tissue tumor [SH52113_Cell2]","GSM3522432","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0537","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522432/suppl/GSM3522432_SH52113_Cell2.txt.gz","2540","57","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522433","Benign bone and soft tissue tumor [SH52113_Cell3]","GSM3522433","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0538","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522433/suppl/GSM3522433_SH52113_Cell3.txt.gz","2540","15","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522434","Benign bone and soft tissue tumor [SH52113_Cell4]","GSM3522434","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 80","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0539","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522434/suppl/GSM3522434_SH52113_Cell4.txt.gz","2540","80","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522435","Intermediate bone and soft tissue tumor [SH52117_Cell1]","GSM3522435","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 13","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0540","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522435/suppl/GSM3522435_SH52117_Cell1.txt.gz","2540","13","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522436","Benign bone and soft tissue tumor [SH52117_Cell2]","GSM3522436","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0541","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522436/suppl/GSM3522436_SH52117_Cell2.txt.gz","2540","25","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522437","Benign bone and soft tissue tumor [SH52117_Cell3]","GSM3522437","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0542","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522437/suppl/GSM3522437_SH52117_Cell3.txt.gz","2540","19","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522438","Benign bone and soft tissue tumor [SH52117_Cell4]","GSM3522438","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0543","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522438/suppl/GSM3522438_SH52117_Cell4.txt.gz","2540","32","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522439","Benign bone and soft tissue tumor [SH52118_Cell1]","GSM3522439","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0544","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522439/suppl/GSM3522439_SH52118_Cell1.txt.gz","2540","78","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522440","Benign bone and soft tissue tumor [SH52118_Cell2]","GSM3522440","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0545","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522440/suppl/GSM3522440_SH52118_Cell2.txt.gz","2540","64","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522441","Benign bone and soft tissue tumor [SH52118_Cell3]","GSM3522441","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0546","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522441/suppl/GSM3522441_SH52118_Cell3.txt.gz","2540","12","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522442","Benign bone and soft tissue tumor [SH52118_Cell4]","GSM3522442","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0547","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522442/suppl/GSM3522442_SH52118_Cell4.txt.gz","2540","29","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522443","Benign bone and soft tissue tumor [SH52121_Cell1]","GSM3522443","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0548","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522443/suppl/GSM3522443_SH52121_Cell1.txt.gz","2540","60","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522444","Benign bone and soft tissue tumor [SH52121_Cell2]","GSM3522444","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0549","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522444/suppl/GSM3522444_SH52121_Cell2.txt.gz","2540","61","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522445","Intermediate bone and soft tissue tumor [SH52121_Cell3]","GSM3522445","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0550","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522445/suppl/GSM3522445_SH52121_Cell3.txt.gz","2540","44","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522446","Intermediate bone and soft tissue tumor [SH52121_Cell4]","GSM3522446","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0551","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522446/suppl/GSM3522446_SH52121_Cell4.txt.gz","2540","50","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522447","Benign bone and soft tissue tumor [SH52122_Cell1]","GSM3522447","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0552","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522447/suppl/GSM3522447_SH52122_Cell1.txt.gz","2540","29","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522448","Intermediate bone and soft tissue tumor [SH52122_Cell2]","GSM3522448","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0553","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522448/suppl/GSM3522448_SH52122_Cell2.txt.gz","2540","55","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522449","Benign bone and soft tissue tumor [SH52122_Cell3]","GSM3522449","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0554","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522449/suppl/GSM3522449_SH52122_Cell3.txt.gz","2540","54","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522450","Intermediate bone and soft tissue tumor [SH52122_Cell4]","GSM3522450","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0555","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522450/suppl/GSM3522450_SH52122_Cell4.txt.gz","2540","37","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522451","Benign bone and soft tissue tumor [SH52123_Cell1]","GSM3522451","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0556","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522451/suppl/GSM3522451_SH52123_Cell1.txt.gz","2540","54","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522452","Intermediate bone and soft tissue tumor [SH52123_Cell2]","GSM3522452","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0557","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522452/suppl/GSM3522452_SH52123_Cell2.txt.gz","2540","34","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522453","Intermediate bone and soft tissue tumor [SH52123_Cell3]","GSM3522453","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0558","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522453/suppl/GSM3522453_SH52123_Cell3.txt.gz","2540","38","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522454","Benign bone and soft tissue tumor [SH52123_Cell4]","GSM3522454","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0559","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522454/suppl/GSM3522454_SH52123_Cell4.txt.gz","2540","69","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522455","Benign bone and soft tissue tumor [SH52125_Cell1]","GSM3522455","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0560","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522455/suppl/GSM3522455_SH52125_Cell1.txt.gz","2540","35","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522456","Benign bone and soft tissue tumor [SH52125_Cell2]","GSM3522456","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0561","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522456/suppl/GSM3522456_SH52125_Cell2.txt.gz","2540","69","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522457","Benign bone and soft tissue tumor [SH52125_Cell3]","GSM3522457","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0562","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522457/suppl/GSM3522457_SH52125_Cell3.txt.gz","2540","37","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522458","Benign bone and soft tissue tumor [SH52125_Cell4]","GSM3522458","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0563","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522458/suppl/GSM3522458_SH52125_Cell4.txt.gz","2540","48","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522459","Benign bone and soft tissue tumor [SH52126_Cell1]","GSM3522459","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0564","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522459/suppl/GSM3522459_SH52126_Cell1.txt.gz","2540","17","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522460","Benign bone and soft tissue tumor [SH52126_Cell2]","GSM3522460","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0565","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522460/suppl/GSM3522460_SH52126_Cell2.txt.gz","2540","56","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522461","Benign bone and soft tissue tumor [SH52126_Cell3]","GSM3522461","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0566","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522461/suppl/GSM3522461_SH52126_Cell3.txt.gz","2540","72","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522462","Intermediate bone and soft tissue tumor [SH52126_Cell4]","GSM3522462","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 13","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0567","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522462/suppl/GSM3522462_SH52126_Cell4.txt.gz","2540","13","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522463","Benign bone and soft tissue tumor [SH52127_Cell1]","GSM3522463","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0568","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522463/suppl/GSM3522463_SH52127_Cell1.txt.gz","2540","43","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522464","Benign bone and soft tissue tumor [SH52127_Cell2]","GSM3522464","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0569","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522464/suppl/GSM3522464_SH52127_Cell2.txt.gz","2540","62","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522465","Benign bone and soft tissue tumor [SH52127_Cell3]","GSM3522465","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0570","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522465/suppl/GSM3522465_SH52127_Cell3.txt.gz","2540","51","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522466","Benign bone and soft tissue tumor [SH52127_Cell4]","GSM3522466","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0571","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522466/suppl/GSM3522466_SH52127_Cell4.txt.gz","2540","37","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522467","Benign bone and soft tissue tumor [SH52129_Cell1]","GSM3522467","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0572","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522467/suppl/GSM3522467_SH52129_Cell1.txt.gz","2540","14","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522468","Benign bone and soft tissue tumor [SH52129_Cell2]","GSM3522468","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0573","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522468/suppl/GSM3522468_SH52129_Cell2.txt.gz","2540","59","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522469","Benign bone and soft tissue tumor [SH52129_Cell3]","GSM3522469","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0574","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522469/suppl/GSM3522469_SH52129_Cell3.txt.gz","2540","39","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522470","Benign bone and soft tissue tumor [SH52129_Cell4]","GSM3522470","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 9","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0575","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522470/suppl/GSM3522470_SH52129_Cell4.txt.gz","2540","9","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522471","Benign bone and soft tissue tumor [SH52133_Cell1]","GSM3522471","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0576","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522471/suppl/GSM3522471_SH52133_Cell1.txt.gz","2540","53","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522472","Benign bone and soft tissue tumor [SH52133_Cell2]","GSM3522472","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0577","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522472/suppl/GSM3522472_SH52133_Cell2.txt.gz","2540","19","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522473","Benign bone and soft tissue tumor [SH52133_Cell3]","GSM3522473","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0578","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522473/suppl/GSM3522473_SH52133_Cell3.txt.gz","2540","39","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522474","Benign bone and soft tissue tumor [SH52133_Cell4]","GSM3522474","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 10","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0579","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522474/suppl/GSM3522474_SH52133_Cell4.txt.gz","2540","10","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522475","Intermediate bone and soft tissue tumor [SH52134_Cell1]","GSM3522475","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0580","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522475/suppl/GSM3522475_SH52134_Cell1.txt.gz","2540","45","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522476","Intermediate bone and soft tissue tumor [SH52134_Cell2]","GSM3522476","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 22","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0581","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522476/suppl/GSM3522476_SH52134_Cell2.txt.gz","2540","22","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522477","Benign bone and soft tissue tumor [SH52134_Cell3]","GSM3522477","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0582","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522477/suppl/GSM3522477_SH52134_Cell3.txt.gz","2540","36","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522478","Benign bone and soft tissue tumor [SH52134_Cell4]","GSM3522478","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0583","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522478/suppl/GSM3522478_SH52134_Cell4.txt.gz","2540","69","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522479","Intermediate bone and soft tissue tumor [SH52135_Cell1]","GSM3522479","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0584","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522479/suppl/GSM3522479_SH52135_Cell1.txt.gz","2540","8","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522480","Intermediate bone and soft tissue tumor [SH52135_Cell2]","GSM3522480","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0585","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522480/suppl/GSM3522480_SH52135_Cell2.txt.gz","2540","29","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522481","Intermediate bone and soft tissue tumor [SH52135_Cell3]","GSM3522481","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0586","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522481/suppl/GSM3522481_SH52135_Cell3.txt.gz","2540","63","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522482","Benign bone and soft tissue tumor [SH52135_Cell4]","GSM3522482","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0587","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522482/suppl/GSM3522482_SH52135_Cell4.txt.gz","2540","35","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522483","Benign bone and soft tissue tumor [SH52141_Cell1]","GSM3522483","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0588","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522483/suppl/GSM3522483_SH52141_Cell1.txt.gz","2540","50","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522484","Benign bone and soft tissue tumor [SH52141_Cell2]","GSM3522484","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0589","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522484/suppl/GSM3522484_SH52141_Cell2.txt.gz","2540","27","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522485","Benign bone and soft tissue tumor [SH52141_Cell3]","GSM3522485","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0590","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522485/suppl/GSM3522485_SH52141_Cell3.txt.gz","2540","21","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522486","Benign bone and soft tissue tumor [SH52141_Cell4]","GSM3522486","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0591","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522486/suppl/GSM3522486_SH52141_Cell4.txt.gz","2540","45","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522487","Benign bone and soft tissue tumor [SH52145_Cell1]","GSM3522487","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0592","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522487/suppl/GSM3522487_SH52145_Cell1.txt.gz","2540","37","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522488","Benign bone and soft tissue tumor [SH52145_Cell2]","GSM3522488","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0593","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522488/suppl/GSM3522488_SH52145_Cell2.txt.gz","2540","78","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522489","Benign bone and soft tissue tumor [SH52145_Cell3]","GSM3522489","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0594","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522489/suppl/GSM3522489_SH52145_Cell3.txt.gz","2540","48","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522490","Benign bone and soft tissue tumor [SH52145_Cell4]","GSM3522490","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0595","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522490/suppl/GSM3522490_SH52145_Cell4.txt.gz","2540","58","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522491","Benign bone and soft tissue tumor [SH52152_Cell1]","GSM3522491","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0596","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522491/suppl/GSM3522491_SH52152_Cell1.txt.gz","2540","33","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522492","Intermediate bone and soft tissue tumor [SH52152_Cell2]","GSM3522492","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0597","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522492/suppl/GSM3522492_SH52152_Cell2.txt.gz","2540","15","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522493","Benign bone and soft tissue tumor [SH52152_Cell3]","GSM3522493","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0598","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522493/suppl/GSM3522493_SH52152_Cell3.txt.gz","2540","52","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522494","Benign bone and soft tissue tumor [SH52152_Cell4]","GSM3522494","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0599","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522494/suppl/GSM3522494_SH52152_Cell4.txt.gz","2540","45","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522495","Benign bone and soft tissue tumor [SH52156_Cell1]","GSM3522495","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0600","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522495/suppl/GSM3522495_SH52156_Cell1.txt.gz","2540","68","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522496","Intermediate bone and soft tissue tumor [SH52156_Cell2]","GSM3522496","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0601","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522496/suppl/GSM3522496_SH52156_Cell2.txt.gz","2540","38","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522497","Intermediate bone and soft tissue tumor [SH52156_Cell3]","GSM3522497","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0602","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522497/suppl/GSM3522497_SH52156_Cell3.txt.gz","2540","55","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522498","Intermediate bone and soft tissue tumor [SH52156_Cell4]","GSM3522498","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0603","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522498/suppl/GSM3522498_SH52156_Cell4.txt.gz","2540","18","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522499","Benign bone and soft tissue tumor [SH52157_Cell1]","GSM3522499","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0604","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522499/suppl/GSM3522499_SH52157_Cell1.txt.gz","2540","60","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522500","Benign bone and soft tissue tumor [SH52157_Cell2]","GSM3522500","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0605","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522500/suppl/GSM3522500_SH52157_Cell2.txt.gz","2540","75","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522501","Benign bone and soft tissue tumor [SH52157_Cell3]","GSM3522501","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 24","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0606","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522501/suppl/GSM3522501_SH52157_Cell3.txt.gz","2540","24","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522502","Benign bone and soft tissue tumor [SH52157_Cell4]","GSM3522502","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0607","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522502/suppl/GSM3522502_SH52157_Cell4.txt.gz","2540","34","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522503","Benign bone and soft tissue tumor [SH52160_Cell1]","GSM3522503","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0608","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522503/suppl/GSM3522503_SH52160_Cell1.txt.gz","2540","64","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522504","Benign bone and soft tissue tumor [SH52160_Cell2]","GSM3522504","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0609","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522504/suppl/GSM3522504_SH52160_Cell2.txt.gz","2540","30","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522505","Benign bone and soft tissue tumor [SH52160_Cell3]","GSM3522505","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0610","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522505/suppl/GSM3522505_SH52160_Cell3.txt.gz","2540","50","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522506","Benign bone and soft tissue tumor [SH52160_Cell4]","GSM3522506","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0611","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522506/suppl/GSM3522506_SH52160_Cell4.txt.gz","2540","32","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522507","Benign bone and soft tissue tumor [SH52164_Cell1]","GSM3522507","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0612","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522507/suppl/GSM3522507_SH52164_Cell1.txt.gz","2540","44","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522508","Benign bone and soft tissue tumor [SH52164_Cell2]","GSM3522508","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0613","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522508/suppl/GSM3522508_SH52164_Cell2.txt.gz","2540","56","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522509","Benign bone and soft tissue tumor [SH52164_Cell3]","GSM3522509","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0614","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522509/suppl/GSM3522509_SH52164_Cell3.txt.gz","2540","15","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522510","Benign bone and soft tissue tumor [SH52164_Cell4]","GSM3522510","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0615","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522510/suppl/GSM3522510_SH52164_Cell4.txt.gz","2540","50","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522511","Benign bone and soft tissue tumor [SH52165_Cell1]","GSM3522511","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0616","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522511/suppl/GSM3522511_SH52165_Cell1.txt.gz","2540","34","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522512","Benign bone and soft tissue tumor [SH52165_Cell2]","GSM3522512","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0617","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522512/suppl/GSM3522512_SH52165_Cell2.txt.gz","2540","53","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522513","Benign bone and soft tissue tumor [SH52165_Cell3]","GSM3522513","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0618","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522513/suppl/GSM3522513_SH52165_Cell3.txt.gz","2540","31","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522514","Benign bone and soft tissue tumor [SH52165_Cell4]","GSM3522514","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0619","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522514/suppl/GSM3522514_SH52165_Cell4.txt.gz","2540","72","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522515","Intermediate bone and soft tissue tumor [SH52166_Cell1]","GSM3522515","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0620","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522515/suppl/GSM3522515_SH52166_Cell1.txt.gz","2540","32","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522516","Benign bone and soft tissue tumor [SH52166_Cell2]","GSM3522516","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0621","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522516/suppl/GSM3522516_SH52166_Cell2.txt.gz","2540","45","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522517","Benign bone and soft tissue tumor [SH52166_Cell3]","GSM3522517","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0622","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522517/suppl/GSM3522517_SH52166_Cell3.txt.gz","2540","12","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522518","Intermediate bone and soft tissue tumor [SH52166_Cell4]","GSM3522518","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0623","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522518/suppl/GSM3522518_SH52166_Cell4.txt.gz","2540","18","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522519","Benign bone and soft tissue tumor [SH52167_Cell1]","GSM3522519","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0624","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522519/suppl/GSM3522519_SH52167_Cell1.txt.gz","2540","46","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522520","Benign bone and soft tissue tumor [SH52167_Cell2]","GSM3522520","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0625","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522520/suppl/GSM3522520_SH52167_Cell2.txt.gz","2540","26","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522521","Benign bone and soft tissue tumor [SH52167_Cell3]","GSM3522521","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0626","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522521/suppl/GSM3522521_SH52167_Cell3.txt.gz","2540","33","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522522","Benign bone and soft tissue tumor [SH52167_Cell4]","GSM3522522","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0627","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522522/suppl/GSM3522522_SH52167_Cell4.txt.gz","2540","61","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522523","Benign bone and soft tissue tumor [SH52213_Cell1]","GSM3522523","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 20","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0628","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522523/suppl/GSM3522523_SH52213_Cell1.txt.gz","2540","20","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522524","Benign bone and soft tissue tumor [SH52213_Cell2]","GSM3522524","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0629","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522524/suppl/GSM3522524_SH52213_Cell2.txt.gz","2540","41","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522525","Benign bone and soft tissue tumor [SH52213_Cell3]","GSM3522525","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0630","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522525/suppl/GSM3522525_SH52213_Cell3.txt.gz","2540","45","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522526","Intermediate bone and soft tissue tumor [SH52213_Cell4]","GSM3522526","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0631","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522526/suppl/GSM3522526_SH52213_Cell4.txt.gz","2540","19","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522527","Benign bone and soft tissue tumor [SH52217_Cell1]","GSM3522527","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0632","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522527/suppl/GSM3522527_SH52217_Cell1.txt.gz","2540","8","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522528","Benign bone and soft tissue tumor [SH52217_Cell2]","GSM3522528","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0633","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522528/suppl/GSM3522528_SH52217_Cell2.txt.gz","2540","55","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522529","Intermediate bone and soft tissue tumor [SH52217_Cell3]","GSM3522529","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0634","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522529/suppl/GSM3522529_SH52217_Cell3.txt.gz","2540","33","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522530","Benign bone and soft tissue tumor [SH52217_Cell4]","GSM3522530","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0635","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522530/suppl/GSM3522530_SH52217_Cell4.txt.gz","2540","61","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522531","Benign bone and soft tissue tumor [SH52218_Cell1]","GSM3522531","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0636","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522531/suppl/GSM3522531_SH52218_Cell1.txt.gz","2540","50","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522532","Benign bone and soft tissue tumor [SH52218_Cell2]","GSM3522532","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0637","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522532/suppl/GSM3522532_SH52218_Cell2.txt.gz","2540","21","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522533","Benign bone and soft tissue tumor [SH52218_Cell3]","GSM3522533","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0638","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522533/suppl/GSM3522533_SH52218_Cell3.txt.gz","2540","61","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522534","Benign bone and soft tissue tumor [SH52218_Cell4]","GSM3522534","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0639","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522534/suppl/GSM3522534_SH52218_Cell4.txt.gz","2540","43","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522535","Benign bone and soft tissue tumor [SH52219_Cell1]","GSM3522535","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0640","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522535/suppl/GSM3522535_SH52219_Cell1.txt.gz","2540","55","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522536","Benign bone and soft tissue tumor [SH52219_Cell2]","GSM3522536","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0641","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522536/suppl/GSM3522536_SH52219_Cell2.txt.gz","2540","67","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522537","Benign bone and soft tissue tumor [SH52219_Cell3]","GSM3522537","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0642","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522537/suppl/GSM3522537_SH52219_Cell3.txt.gz","2540","69","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522538","Benign bone and soft tissue tumor [SH52219_Cell4]","GSM3522538","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0643","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522538/suppl/GSM3522538_SH52219_Cell4.txt.gz","2540","41","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522539","Benign bone and soft tissue tumor [SH52223_Cell1]","GSM3522539","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0644","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522539/suppl/GSM3522539_SH52223_Cell1.txt.gz","2540","54","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522540","Benign bone and soft tissue tumor [SH52223_Cell2]","GSM3522540","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0645","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522540/suppl/GSM3522540_SH52223_Cell2.txt.gz","2540","26","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522541","Intermediate bone and soft tissue tumor [SH52223_Cell3]","GSM3522541","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0646","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522541/suppl/GSM3522541_SH52223_Cell3.txt.gz","2540","58","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522542","Benign bone and soft tissue tumor [SH52223_Cell4]","GSM3522542","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0647","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522542/suppl/GSM3522542_SH52223_Cell4.txt.gz","2540","48","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522543","Benign bone and soft tissue tumor [SH52224_Cell1]","GSM3522543","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0648","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522543/suppl/GSM3522543_SH52224_Cell1.txt.gz","2540","57","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522544","Benign bone and soft tissue tumor [SH52224_Cell2]","GSM3522544","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0649","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522544/suppl/GSM3522544_SH52224_Cell2.txt.gz","2540","36","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522545","Benign bone and soft tissue tumor [SH52224_Cell3]","GSM3522545","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0650","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522545/suppl/GSM3522545_SH52224_Cell3.txt.gz","2540","36","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522546","Benign bone and soft tissue tumor [SH52224_Cell4]","GSM3522546","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0651","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522546/suppl/GSM3522546_SH52224_Cell4.txt.gz","2540","72","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522547","Benign bone and soft tissue tumor [SH4YE08_Cell1]","GSM3522547","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0652","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522547/suppl/GSM3522547_SH4YE08_Cell1.txt.gz","2540","31","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522548","Benign bone and soft tissue tumor [SH4YE08_Cell2]","GSM3522548","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0653","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522548/suppl/GSM3522548_SH4YE08_Cell2.txt.gz","2540","17","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522549","Benign bone and soft tissue tumor [SH4YE08_Cell3]","GSM3522549","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0654","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522549/suppl/GSM3522549_SH4YE08_Cell3.txt.gz","2540","40","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522550","Benign bone and soft tissue tumor [SH51P15_Cell2]","GSM3522550","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0655","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522550/suppl/GSM3522550_SH51P15_Cell2.txt.gz","2540","62","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522551","Benign bone and soft tissue tumor [SH4YE17_Cell1]","GSM3522551","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0656","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522551/suppl/GSM3522551_SH4YE17_Cell1.txt.gz","2540","62","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522552","Intermediate bone and soft tissue tumor [SH4YE17_Cell2]","GSM3522552","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0657","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522552/suppl/GSM3522552_SH4YE17_Cell2.txt.gz","2540","50","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522553","Benign bone and soft tissue tumor [SH4YE17_Cell3]","GSM3522553","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0658","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522553/suppl/GSM3522553_SH4YE17_Cell3.txt.gz","2540","42","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522554","Benign bone and soft tissue tumor [SH4YE17_Cell4]","GSM3522554","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0659","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522554/suppl/GSM3522554_SH4YE17_Cell4.txt.gz","2540","45","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522555","Benign bone and soft tissue tumor [SH4YE32_Cell1]","GSM3522555","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0660","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522555/suppl/GSM3522555_SH4YE32_Cell1.txt.gz","2540","72","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522556","Benign bone and soft tissue tumor [SH4YE32_Cell2]","GSM3522556","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0661","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522556/suppl/GSM3522556_SH4YE32_Cell2.txt.gz","2540","38","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522557","Benign bone and soft tissue tumor [SH4YE32_Cell3]","GSM3522557","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0662","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522557/suppl/GSM3522557_SH4YE32_Cell3.txt.gz","2540","38","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522558","Benign bone and soft tissue tumor [SH4YE32_Cell4]","GSM3522558","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0663","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522558/suppl/GSM3522558_SH4YE32_Cell4.txt.gz","2540","67","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522559","Benign bone and soft tissue tumor [SH4YE33_Cell1]","GSM3522559","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 80","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0664","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522559/suppl/GSM3522559_SH4YE33_Cell1.txt.gz","2540","80","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522560","Benign bone and soft tissue tumor [SH4YE33_Cell2]","GSM3522560","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0665","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522560/suppl/GSM3522560_SH4YE33_Cell2.txt.gz","2540","60","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522561","Benign bone and soft tissue tumor [SH4YE33_Cell3]","GSM3522561","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 6","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0666","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522561/suppl/GSM3522561_SH4YE33_Cell3.txt.gz","2540","6","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522562","Benign bone and soft tissue tumor [SH4YE33_Cell4]","GSM3522562","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0667","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522562/suppl/GSM3522562_SH4YE33_Cell4.txt.gz","2540","41","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522563","Benign bone and soft tissue tumor [SH4YE34_Cell1]","GSM3522563","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0668","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522563/suppl/GSM3522563_SH4YE34_Cell1.txt.gz","2540","26","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522564","Benign bone and soft tissue tumor [SH4YE34_Cell2]","GSM3522564","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 13","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0669","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522564/suppl/GSM3522564_SH4YE34_Cell2.txt.gz","2540","13","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522565","Benign bone and soft tissue tumor [SH4YE34_Cell3]","GSM3522565","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0670","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522565/suppl/GSM3522565_SH4YE34_Cell3.txt.gz","2540","49","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522566","Benign bone and soft tissue tumor [SH4YE34_Cell4]","GSM3522566","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 80","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0671","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522566/suppl/GSM3522566_SH4YE34_Cell4.txt.gz","2540","80","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522567","Benign bone and soft tissue tumor [SH4YE39_Cell1]","GSM3522567","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0672","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522567/suppl/GSM3522567_SH4YE39_Cell1.txt.gz","2540","26","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522568","Benign bone and soft tissue tumor [SH4YE39_Cell2]","GSM3522568","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0673","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522568/suppl/GSM3522568_SH4YE39_Cell2.txt.gz","2540","59","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522569","Benign bone and soft tissue tumor [SH4YE39_Cell3]","GSM3522569","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 22","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0674","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522569/suppl/GSM3522569_SH4YE39_Cell3.txt.gz","2540","22","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522570","Benign bone and soft tissue tumor [SH4YE39_Cell4]","GSM3522570","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0675","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522570/suppl/GSM3522570_SH4YE39_Cell4.txt.gz","2540","12","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522571","Benign bone and soft tissue tumor [SH4YE40_Cell1]","GSM3522571","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0676","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522571/suppl/GSM3522571_SH4YE40_Cell1.txt.gz","2540","60","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522572","Benign bone and soft tissue tumor [SH4YE40_Cell2]","GSM3522572","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0677","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522572/suppl/GSM3522572_SH4YE40_Cell2.txt.gz","2540","55","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522573","Benign bone and soft tissue tumor [SH4YE40_Cell3]","GSM3522573","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0678","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522573/suppl/GSM3522573_SH4YE40_Cell3.txt.gz","2540","45","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522574","Benign bone and soft tissue tumor [SH51P15_Cell3]","GSM3522574","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0679","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522574/suppl/GSM3522574_SH51P15_Cell3.txt.gz","2540","75","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522575","Benign bone and soft tissue tumor [SH4YE45_Cell1]","GSM3522575","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0680","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522575/suppl/GSM3522575_SH4YE45_Cell1.txt.gz","2540","33","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522576","Benign bone and soft tissue tumor [SH4YE45_Cell2]","GSM3522576","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0681","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522576/suppl/GSM3522576_SH4YE45_Cell2.txt.gz","2540","37","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522577","Intermediate bone and soft tissue tumor [SH4YE45_Cell3]","GSM3522577","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0682","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522577/suppl/GSM3522577_SH4YE45_Cell3.txt.gz","2540","49","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522578","Benign bone and soft tissue tumor [SH4YE45_Cell4]","GSM3522578","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0683","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522578/suppl/GSM3522578_SH4YE45_Cell4.txt.gz","2540","14","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522579","Benign bone and soft tissue tumor [SH4YE49_Cell1]","GSM3522579","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0684","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522579/suppl/GSM3522579_SH4YE49_Cell1.txt.gz","2540","63","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522580","Benign bone and soft tissue tumor [SH4YE49_Cell2]","GSM3522580","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0685","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522580/suppl/GSM3522580_SH4YE49_Cell2.txt.gz","2540","42","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522581","Benign bone and soft tissue tumor [SH4YE49_Cell3]","GSM3522581","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 22","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0686","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522581/suppl/GSM3522581_SH4YE49_Cell3.txt.gz","2540","22","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522582","Benign bone and soft tissue tumor [SH4YE49_Cell4]","GSM3522582","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0687","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522582/suppl/GSM3522582_SH4YE49_Cell4.txt.gz","2540","30","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522583","Benign bone and soft tissue tumor [SH4YE56_Cell1]","GSM3522583","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0688","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522583/suppl/GSM3522583_SH4YE56_Cell1.txt.gz","2540","72","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522584","Benign bone and soft tissue tumor [SH4YE56_Cell2]","GSM3522584","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0689","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522584/suppl/GSM3522584_SH4YE56_Cell2.txt.gz","2540","47","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522585","Benign bone and soft tissue tumor [SH4YE56_Cell3]","GSM3522585","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0690","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522585/suppl/GSM3522585_SH4YE56_Cell3.txt.gz","2540","19","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522586","Intermediate bone and soft tissue tumor [SH4YE56_Cell4]","GSM3522586","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 4","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0691","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522586/suppl/GSM3522586_SH4YE56_Cell4.txt.gz","2540","4","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522587","Intermediate bone and soft tissue tumor [SH4YH14_Cell3]","GSM3522587","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0692","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522587/suppl/GSM3522587_SH4YH14_Cell3.txt.gz","2540","33","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522588","Benign bone and soft tissue tumor [SH4YH14_Cell4]","GSM3522588","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0693","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522588/suppl/GSM3522588_SH4YH14_Cell4.txt.gz","2540","48","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522589","Intermediate bone and soft tissue tumor [SH4YH40_Cell1]","GSM3522589","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0694","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522589/suppl/GSM3522589_SH4YH40_Cell1.txt.gz","2540","21","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522590","Benign bone and soft tissue tumor [SH4YH40_Cell2]","GSM3522590","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 6","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0695","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522590/suppl/GSM3522590_SH4YH40_Cell2.txt.gz","2540","6","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522591","Benign bone and soft tissue tumor [SH4YH40_Cell3]","GSM3522591","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 23","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0696","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522591/suppl/GSM3522591_SH4YH40_Cell3.txt.gz","2540","23","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522592","Intermediate bone and soft tissue tumor [SH4YH40_Cell4]","GSM3522592","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0697","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522592/suppl/GSM3522592_SH4YH40_Cell4.txt.gz","2540","39","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522593","Benign bone and soft tissue tumor [SH4YJ47_Cell1]","GSM3522593","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0698","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522593/suppl/GSM3522593_SH4YJ47_Cell1.txt.gz","2540","8","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522594","Benign bone and soft tissue tumor [SH4YJ47_Cell2]","GSM3522594","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0699","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522594/suppl/GSM3522594_SH4YJ47_Cell2.txt.gz","2540","61","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522595","Benign bone and soft tissue tumor [SH4YJ47_Cell3]","GSM3522595","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0700","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522595/suppl/GSM3522595_SH4YJ47_Cell3.txt.gz","2540","58","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522596","Intermediate bone and soft tissue tumor [SH4YJ47_Cell4]","GSM3522596","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0701","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522596/suppl/GSM3522596_SH4YJ47_Cell4.txt.gz","2540","35","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522597","Benign bone and soft tissue tumor [SH4YL19_Cell1]","GSM3522597","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0702","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522597/suppl/GSM3522597_SH4YL19_Cell1.txt.gz","2540","41","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522598","Benign bone and soft tissue tumor [SH4YL19_Cell2]","GSM3522598","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0703","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522598/suppl/GSM3522598_SH4YL19_Cell2.txt.gz","2540","40","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522599","Benign bone and soft tissue tumor [SH4YL19_Cell3]","GSM3522599","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0704","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522599/suppl/GSM3522599_SH4YL19_Cell3.txt.gz","2540","41","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522600","Benign bone and soft tissue tumor [SH4YL19_Cell4]","GSM3522600","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0705","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522600/suppl/GSM3522600_SH4YL19_Cell4.txt.gz","2540","44","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522601","Intermediate bone and soft tissue tumor [SH4YS63_Cell1]","GSM3522601","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0706","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522601/suppl/GSM3522601_SH4YS63_Cell1.txt.gz","2540","60","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522602","Benign bone and soft tissue tumor [SH4YS63_Cell2]","GSM3522602","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0707","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522602/suppl/GSM3522602_SH4YS63_Cell2.txt.gz","2540","40","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522603","Benign bone and soft tissue tumor [SH4YS63_Cell3]","GSM3522603","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0708","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522603/suppl/GSM3522603_SH4YS63_Cell3.txt.gz","2540","36","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522604","Benign bone and soft tissue tumor [SH4YS63_Cell4]","GSM3522604","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0709","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522604/suppl/GSM3522604_SH4YS63_Cell4.txt.gz","2540","39","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522605","Benign bone and soft tissue tumor [SH4YS64_Cell1]","GSM3522605","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0710","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522605/suppl/GSM3522605_SH4YS64_Cell1.txt.gz","2540","54","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522606","Benign bone and soft tissue tumor [SH4YS64_Cell2]","GSM3522606","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0711","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522606/suppl/GSM3522606_SH4YS64_Cell2.txt.gz","2540","48","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522607","Intermediate bone and soft tissue tumor [SH51P15_Cell4]","GSM3522607","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0712","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522607/suppl/GSM3522607_SH51P15_Cell4.txt.gz","2540","15","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522608","Benign bone and soft tissue tumor [SH51P17_Cell1]","GSM3522608","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0713","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522608/suppl/GSM3522608_SH51P17_Cell1.txt.gz","2540","60","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522609","Benign bone and soft tissue tumor [SH4YT01_Cell1]","GSM3522609","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0714","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522609/suppl/GSM3522609_SH4YT01_Cell1.txt.gz","2540","57","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522610","Benign bone and soft tissue tumor [SH4YT01_Cell2]","GSM3522610","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0715","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522610/suppl/GSM3522610_SH4YT01_Cell2.txt.gz","2540","44","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522611","Benign bone and soft tissue tumor [SH4YT01_Cell3]","GSM3522611","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0716","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522611/suppl/GSM3522611_SH4YT01_Cell3.txt.gz","2540","17","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522612","Benign bone and soft tissue tumor [SH4YT01_Cell4]","GSM3522612","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0717","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522612/suppl/GSM3522612_SH4YT01_Cell4.txt.gz","2540","66","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522613","Intermediate bone and soft tissue tumor [SH4YT02_Cell1]","GSM3522613","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0718","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522613/suppl/GSM3522613_SH4YT02_Cell1.txt.gz","2540","36","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522614","Benign bone and soft tissue tumor [SH4YT02_Cell2]","GSM3522614","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0719","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522614/suppl/GSM3522614_SH4YT02_Cell2.txt.gz","2540","34","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522615","Benign bone and soft tissue tumor [SH4YT02_Cell3]","GSM3522615","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 24","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0720","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522615/suppl/GSM3522615_SH4YT02_Cell3.txt.gz","2540","24","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522616","Benign bone and soft tissue tumor [SH4YT02_Cell4]","GSM3522616","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0721","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522616/suppl/GSM3522616_SH4YT02_Cell4.txt.gz","2540","61","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522617","Benign bone and soft tissue tumor [SH4YT03_Cell1]","GSM3522617","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 70","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0722","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522617/suppl/GSM3522617_SH4YT03_Cell1.txt.gz","2540","70","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522618","Benign bone and soft tissue tumor [SH4YT03_Cell2]","GSM3522618","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0723","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522618/suppl/GSM3522618_SH4YT03_Cell2.txt.gz","2540","74","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522619","Benign bone and soft tissue tumor [SH4YT03_Cell3]","GSM3522619","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0724","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522619/suppl/GSM3522619_SH4YT03_Cell3.txt.gz","2540","26","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522620","Benign bone and soft tissue tumor [SH4YT03_Cell4]","GSM3522620","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0725","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522620/suppl/GSM3522620_SH4YT03_Cell4.txt.gz","2540","63","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522621","Benign bone and soft tissue tumor [SH4YT04_Cell1]","GSM3522621","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0726","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522621/suppl/GSM3522621_SH4YT04_Cell1.txt.gz","2540","39","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522622","Benign bone and soft tissue tumor [SH4YT04_Cell2]","GSM3522622","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0727","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522622/suppl/GSM3522622_SH4YT04_Cell2.txt.gz","2540","46","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522623","Intermediate bone and soft tissue tumor [SH4YT04_Cell3]","GSM3522623","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0728","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522623/suppl/GSM3522623_SH4YT04_Cell3.txt.gz","2540","19","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522624","Benign bone and soft tissue tumor [SH4YT04_Cell4]","GSM3522624","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 22","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0729","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522624/suppl/GSM3522624_SH4YT04_Cell4.txt.gz","2540","22","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522625","Benign bone and soft tissue tumor [SH4YT05_Cell1]","GSM3522625","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0730","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522625/suppl/GSM3522625_SH4YT05_Cell1.txt.gz","2540","34","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522626","Intermediate bone and soft tissue tumor [SH4YT05_Cell2]","GSM3522626","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0731","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522626/suppl/GSM3522626_SH4YT05_Cell2.txt.gz","2540","32","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522627","Benign bone and soft tissue tumor [SH4YT05_Cell3]","GSM3522627","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0732","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522627/suppl/GSM3522627_SH4YT05_Cell3.txt.gz","2540","50","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522628","Intermediate bone and soft tissue tumor [SH51P17_Cell3]","GSM3522628","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0734","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522628/suppl/GSM3522628_SH51P17_Cell3.txt.gz","2540","48","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522629","Benign bone and soft tissue tumor [SH4YT06_Cell3]","GSM3522629","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0736","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522629/suppl/GSM3522629_SH4YT06_Cell3.txt.gz","2540","42","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522630","Benign bone and soft tissue tumor [SH51P18_Cell1]","GSM3522630","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0737","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522630/suppl/GSM3522630_SH51P18_Cell1.txt.gz","2540","26","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522631","Intermediate bone and soft tissue tumor [SH51P18_Cell2]","GSM3522631","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0738","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522631/suppl/GSM3522631_SH51P18_Cell2.txt.gz","2540","58","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522632","Malignant bone and soft tissue tumor [SH51P18_Cell3]","GSM3522632","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIA","age: 22","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0739","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522632/suppl/GSM3522632_SH51P18_Cell3.txt.gz","2540","22","Female","Malignant bone and soft tissue tumor","Serum","StageIA"
"GSM3522633","Benign bone and soft tissue tumor [SH4YT07_Cell3]","GSM3522633","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0740","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522633/suppl/GSM3522633_SH4YT07_Cell3.txt.gz","2540","60","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522634","Intermediate bone and soft tissue tumor [SH4YT07_Cell4]","GSM3522634","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 17","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0741","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522634/suppl/GSM3522634_SH4YT07_Cell4.txt.gz","2540","17","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522635","Benign bone and soft tissue tumor [SH51P18_Cell4]","GSM3522635","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0742","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522635/suppl/GSM3522635_SH51P18_Cell4.txt.gz","2540","74","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522636","Benign bone and soft tissue tumor [SH51P19_Cell1]","GSM3522636","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0743","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522636/suppl/GSM3522636_SH51P19_Cell1.txt.gz","2540","64","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522637","Benign bone and soft tissue tumor [SH4YT09_Cell3]","GSM3522637","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0744","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522637/suppl/GSM3522637_SH4YT09_Cell3.txt.gz","2540","12","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522638","Benign bone and soft tissue tumor [SH4YT09_Cell4]","GSM3522638","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0745","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522638/suppl/GSM3522638_SH4YT09_Cell4.txt.gz","2540","69","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522639","Intermediate bone and soft tissue tumor [SH51P19_Cell2]","GSM3522639","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0746","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522639/suppl/GSM3522639_SH51P19_Cell2.txt.gz","2540","54","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522640","Benign bone and soft tissue tumor [SH4YT11_Cell2]","GSM3522640","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0747","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522640/suppl/GSM3522640_SH4YT11_Cell2.txt.gz","2540","54","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522641","Intermediate bone and soft tissue tumor [SH4YT11_Cell3]","GSM3522641","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0748","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522641/suppl/GSM3522641_SH4YT11_Cell3.txt.gz","2540","68","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522642","Intermediate bone and soft tissue tumor [SH51P19_Cell3]","GSM3522642","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 33","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0749","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522642/suppl/GSM3522642_SH51P19_Cell3.txt.gz","2540","33","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522643","Benign bone and soft tissue tumor [SH4YT14_Cell1]","GSM3522643","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0750","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522643/suppl/GSM3522643_SH4YT14_Cell1.txt.gz","2540","21","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522644","Benign bone and soft tissue tumor [SH51P19_Cell4]","GSM3522644","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 24","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0751","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522644/suppl/GSM3522644_SH51P19_Cell4.txt.gz","2540","24","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522645","Benign bone and soft tissue tumor [SH4YT14_Cell3]","GSM3522645","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0752","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522645/suppl/GSM3522645_SH4YT14_Cell3.txt.gz","2540","59","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522646","Benign bone and soft tissue tumor [SH4YT14_Cell4]","GSM3522646","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0753","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522646/suppl/GSM3522646_SH4YT14_Cell4.txt.gz","2540","54","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522647","Benign bone and soft tissue tumor [SH51P20_Cell1]","GSM3522647","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0754","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522647/suppl/GSM3522647_SH51P20_Cell1.txt.gz","2540","30","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522648","Benign bone and soft tissue tumor [SH51P20_Cell2]","GSM3522648","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0755","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522648/suppl/GSM3522648_SH51P20_Cell2.txt.gz","2540","48","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522649","Benign bone and soft tissue tumor [SH4YT15_Cell3]","GSM3522649","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0756","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522649/suppl/GSM3522649_SH4YT15_Cell3.txt.gz","2540","43","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522650","Malignant bone and soft tissue tumor [SH51P20_Cell3]","GSM3522650","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0757","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522650/suppl/GSM3522650_SH51P20_Cell3.txt.gz","2540","63","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522651","Benign bone and soft tissue tumor [SH4YT16_Cell1]","GSM3522651","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0758","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522651/suppl/GSM3522651_SH4YT16_Cell1.txt.gz","2540","47","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522652","Benign bone and soft tissue tumor [SH4YT16_Cell2]","GSM3522652","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0759","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522652/suppl/GSM3522652_SH4YT16_Cell2.txt.gz","2540","59","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522653","Benign bone and soft tissue tumor [SH4YT16_Cell3]","GSM3522653","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0760","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522653/suppl/GSM3522653_SH4YT16_Cell3.txt.gz","2540","39","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522654","Benign bone and soft tissue tumor [SH51P20_Cell4]","GSM3522654","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0761","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522654/suppl/GSM3522654_SH51P20_Cell4.txt.gz","2540","47","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522655","Benign bone and soft tissue tumor [SH51P21_Cell1]","GSM3522655","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0762","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522655/suppl/GSM3522655_SH51P21_Cell1.txt.gz","2540","26","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522656","Intermediate bone and soft tissue tumor [SH51P21_Cell2]","GSM3522656","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0763","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522656/suppl/GSM3522656_SH51P21_Cell2.txt.gz","2540","36","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522657","Intermediate bone and soft tissue tumor [SH51P21_Cell3]","GSM3522657","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0764","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522657/suppl/GSM3522657_SH51P21_Cell3.txt.gz","2540","55","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522658","Benign bone and soft tissue tumor [SH51P21_Cell4]","GSM3522658","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0765","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522658/suppl/GSM3522658_SH51P21_Cell4.txt.gz","2540","21","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522659","Benign bone and soft tissue tumor [SH4YT18_Cell1]","GSM3522659","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0766","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522659/suppl/GSM3522659_SH4YT18_Cell1.txt.gz","2540","14","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522660","Benign bone and soft tissue tumor [SH4YT18_Cell2]","GSM3522660","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0767","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522660/suppl/GSM3522660_SH4YT18_Cell2.txt.gz","2540","43","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522661","Benign bone and soft tissue tumor [SH51P22_Cell2]","GSM3522661","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0769","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522661/suppl/GSM3522661_SH51P22_Cell2.txt.gz","2540","78","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522662","Benign bone and soft tissue tumor [SH4YT19_Cell1]","GSM3522662","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0770","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522662/suppl/GSM3522662_SH4YT19_Cell1.txt.gz","2540","35","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522663","Benign bone and soft tissue tumor [SH51P22_Cell3]","GSM3522663","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0771","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522663/suppl/GSM3522663_SH51P22_Cell3.txt.gz","2540","34","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522664","Benign bone and soft tissue tumor [SH51P22_Cell4]","GSM3522664","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0772","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522664/suppl/GSM3522664_SH51P22_Cell4.txt.gz","2540","30","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522665","Benign bone and soft tissue tumor [SH51P23_Cell1]","GSM3522665","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0773","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522665/suppl/GSM3522665_SH51P23_Cell1.txt.gz","2540","59","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522666","Benign bone and soft tissue tumor [SH4YT20_Cell1]","GSM3522666","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0774","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522666/suppl/GSM3522666_SH4YT20_Cell1.txt.gz","2540","35","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522667","Benign bone and soft tissue tumor [SH51P23_Cell2]","GSM3522667","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0775","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522667/suppl/GSM3522667_SH51P23_Cell2.txt.gz","2540","50","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522668","Benign bone and soft tissue tumor [SH51P23_Cell3]","GSM3522668","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0776","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522668/suppl/GSM3522668_SH51P23_Cell3.txt.gz","2540","31","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522669","Intermediate bone and soft tissue tumor [SH51P23_Cell4]","GSM3522669","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 23","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0777","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522669/suppl/GSM3522669_SH51P23_Cell4.txt.gz","2540","23","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522670","Benign bone and soft tissue tumor [SH4YT21_Cell1]","GSM3522670","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0778","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522670/suppl/GSM3522670_SH4YT21_Cell1.txt.gz","2540","72","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522671","Benign bone and soft tissue tumor [SH4YT21_Cell2]","GSM3522671","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 7","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0779","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522671/suppl/GSM3522671_SH4YT21_Cell2.txt.gz","2540","7","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522672","Benign bone and soft tissue tumor [SH4YT21_Cell3]","GSM3522672","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0780","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522672/suppl/GSM3522672_SH4YT21_Cell3.txt.gz","2540","53","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522673","Intermediate bone and soft tissue tumor [SH51P24_Cell1]","GSM3522673","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 4","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0781","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522673/suppl/GSM3522673_SH51P24_Cell1.txt.gz","2540","4","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522674","Benign bone and soft tissue tumor [SH4YT22_Cell1]","GSM3522674","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 7","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0782","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522674/suppl/GSM3522674_SH4YT22_Cell1.txt.gz","2540","7","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522675","Benign bone and soft tissue tumor [SH51P24_Cell2]","GSM3522675","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0783","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522675/suppl/GSM3522675_SH51P24_Cell2.txt.gz","2540","48","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522676","Benign bone and soft tissue tumor [SH51P24_Cell3]","GSM3522676","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0784","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522676/suppl/GSM3522676_SH51P24_Cell3.txt.gz","2540","64","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522677","Benign bone and soft tissue tumor [SH51P24_Cell4]","GSM3522677","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0785","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522677/suppl/GSM3522677_SH51P24_Cell4.txt.gz","2540","42","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522678","Benign bone and soft tissue tumor [SH4YT23_Cell1]","GSM3522678","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0786","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522678/suppl/GSM3522678_SH4YT23_Cell1.txt.gz","2540","51","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522679","Benign bone and soft tissue tumor [SH4YT23_Cell2]","GSM3522679","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0787","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522679/suppl/GSM3522679_SH4YT23_Cell2.txt.gz","2540","28","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522680","Benign bone and soft tissue tumor [SH51P25_Cell1]","GSM3522680","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0788","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522680/suppl/GSM3522680_SH51P25_Cell1.txt.gz","2540","48","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522681","Benign bone and soft tissue tumor [SH51P25_Cell2]","GSM3522681","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 8","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0789","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522681/suppl/GSM3522681_SH51P25_Cell2.txt.gz","2540","8","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522682","Benign bone and soft tissue tumor [SH51P25_Cell3]","GSM3522682","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0790","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522682/suppl/GSM3522682_SH51P25_Cell3.txt.gz","2540","53","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522683","Benign bone and soft tissue tumor [SH51P25_Cell4]","GSM3522683","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0791","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522683/suppl/GSM3522683_SH51P25_Cell4.txt.gz","2540","29","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522684","Benign bone and soft tissue tumor [SH51P28_Cell1]","GSM3522684","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0792","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522684/suppl/GSM3522684_SH51P28_Cell1.txt.gz","2540","62","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522685","Intermediate bone and soft tissue tumor [SH51P28_Cell2]","GSM3522685","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0793","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522685/suppl/GSM3522685_SH51P28_Cell2.txt.gz","2540","51","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522686","Benign bone and soft tissue tumor [SH4YT26_Cell1]","GSM3522686","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0794","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522686/suppl/GSM3522686_SH4YT26_Cell1.txt.gz","2540","69","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522687","Benign bone and soft tissue tumor [SH51P28_Cell3]","GSM3522687","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0795","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522687/suppl/GSM3522687_SH51P28_Cell3.txt.gz","2540","75","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522688","Benign bone and soft tissue tumor [SH51P28_Cell4]","GSM3522688","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0796","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522688/suppl/GSM3522688_SH51P28_Cell4.txt.gz","2540","64","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522689","Benign bone and soft tissue tumor [SH51P29_Cell1]","GSM3522689","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0797","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522689/suppl/GSM3522689_SH51P29_Cell1.txt.gz","2540","56","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522690","Benign bone and soft tissue tumor [SH4YT27_Cell1]","GSM3522690","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0798","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522690/suppl/GSM3522690_SH4YT27_Cell1.txt.gz","2540","58","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522691","Intermediate bone and soft tissue tumor [SH4YT27_Cell2]","GSM3522691","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0799","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522691/suppl/GSM3522691_SH4YT27_Cell2.txt.gz","2540","30","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522692","Benign bone and soft tissue tumor [SH51P29_Cell2]","GSM3522692","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0800","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522692/suppl/GSM3522692_SH51P29_Cell2.txt.gz","2540","42","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522693","Benign bone and soft tissue tumor [SH51P29_Cell3]","GSM3522693","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0801","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522693/suppl/GSM3522693_SH51P29_Cell3.txt.gz","2540","61","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522694","Intermediate bone and soft tissue tumor [SH4YT28_Cell1]","GSM3522694","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0802","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522694/suppl/GSM3522694_SH4YT28_Cell1.txt.gz","2540","31","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522695","Benign bone and soft tissue tumor [SH4YT28_Cell2]","GSM3522695","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0803","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522695/suppl/GSM3522695_SH4YT28_Cell2.txt.gz","2540","44","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522696","Benign bone and soft tissue tumor [SH51P29_Cell4]","GSM3522696","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 23","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0804","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522696/suppl/GSM3522696_SH51P29_Cell4.txt.gz","2540","23","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522697","Benign bone and soft tissue tumor [SH4YT29_Cell1]","GSM3522697","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0806","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522697/suppl/GSM3522697_SH4YT29_Cell1.txt.gz","2540","31","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522698","Benign bone and soft tissue tumor [SH4YT29_Cell2]","GSM3522698","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0807","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522698/suppl/GSM3522698_SH4YT29_Cell2.txt.gz","2540","50","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522699","Benign bone and soft tissue tumor [SH51P31_Cell2]","GSM3522699","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0808","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522699/suppl/GSM3522699_SH51P31_Cell2.txt.gz","2540","48","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522700","Benign bone and soft tissue tumor [SH51P31_Cell3]","GSM3522700","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0809","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522700/suppl/GSM3522700_SH51P31_Cell3.txt.gz","2540","25","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522701","Benign bone and soft tissue tumor [SH4YT30_Cell1]","GSM3522701","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0810","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522701/suppl/GSM3522701_SH4YT30_Cell1.txt.gz","2540","68","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522702","Intermediate bone and soft tissue tumor [SH4YT30_Cell2]","GSM3522702","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 7","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0811","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522702/suppl/GSM3522702_SH4YT30_Cell2.txt.gz","2540","7","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522703","Benign bone and soft tissue tumor [SH4YT30_Cell3]","GSM3522703","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0812","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522703/suppl/GSM3522703_SH4YT30_Cell3.txt.gz","2540","61","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522704","Benign bone and soft tissue tumor [SH51P31_Cell4]","GSM3522704","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0813","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522704/suppl/GSM3522704_SH51P31_Cell4.txt.gz","2540","34","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522705","Benign bone and soft tissue tumor [SH4YT31_Cell1]","GSM3522705","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0814","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522705/suppl/GSM3522705_SH4YT31_Cell1.txt.gz","2540","71","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522706","Intermediate bone and soft tissue tumor [SH4YT52_Cell1]","GSM3522706","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0815","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522706/suppl/GSM3522706_SH4YT52_Cell1.txt.gz","2540","18","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522707","Benign bone and soft tissue tumor [SH4YT31_Cell2]","GSM3522707","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0816","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522707/suppl/GSM3522707_SH4YT31_Cell2.txt.gz","2540","37","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522708","Benign bone and soft tissue tumor [SH51P32_Cell1]","GSM3522708","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0817","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522708/suppl/GSM3522708_SH51P32_Cell1.txt.gz","2540","68","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522709","Benign bone and soft tissue tumor [SH51P32_Cell2]","GSM3522709","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0818","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522709/suppl/GSM3522709_SH51P32_Cell2.txt.gz","2540","73","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522710","Intermediate bone and soft tissue tumor [SH4YT33_Cell1]","GSM3522710","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 24","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0819","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522710/suppl/GSM3522710_SH4YT33_Cell1.txt.gz","2540","24","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522711","Benign bone and soft tissue tumor [SH4YT33_Cell2]","GSM3522711","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0820","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522711/suppl/GSM3522711_SH4YT33_Cell2.txt.gz","2540","25","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522712","Benign bone and soft tissue tumor [SH4YT33_Cell3]","GSM3522712","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0821","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522712/suppl/GSM3522712_SH4YT33_Cell3.txt.gz","2540","65","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522713","Benign bone and soft tissue tumor [SH4YT33_Cell4]","GSM3522713","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0822","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522713/suppl/GSM3522713_SH4YT33_Cell4.txt.gz","2540","62","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522714","Benign bone and soft tissue tumor [SH4YT34_Cell1]","GSM3522714","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0823","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522714/suppl/GSM3522714_SH4YT34_Cell1.txt.gz","2540","59","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522715","Benign bone and soft tissue tumor [SH51P32_Cell3]","GSM3522715","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0824","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522715/suppl/GSM3522715_SH51P32_Cell3.txt.gz","2540","32","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522716","Benign bone and soft tissue tumor [SH51P32_Cell4]","GSM3522716","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0825","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522716/suppl/GSM3522716_SH51P32_Cell4.txt.gz","2540","37","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522717","Intermediate bone and soft tissue tumor [SH4YT34_Cell4]","GSM3522717","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 10","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0826","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522717/suppl/GSM3522717_SH4YT34_Cell4.txt.gz","2540","10","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522718","Benign bone and soft tissue tumor [SH4YT35_Cell1]","GSM3522718","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0827","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522718/suppl/GSM3522718_SH4YT35_Cell1.txt.gz","2540","64","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522719","Malignant bone and soft tissue tumor [SH51P33_Cell1]","GSM3522719","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0828","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522719/suppl/GSM3522719_SH51P33_Cell1.txt.gz","2540","29","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522720","Intermediate bone and soft tissue tumor [SH4YT35_Cell3]","GSM3522720","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0829","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522720/suppl/GSM3522720_SH4YT35_Cell3.txt.gz","2540","46","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522721","Benign bone and soft tissue tumor [SH4YT35_Cell4]","GSM3522721","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0830","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522721/suppl/GSM3522721_SH4YT35_Cell4.txt.gz","2540","60","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522722","Intermediate bone and soft tissue tumor [SH4YT38_Cell1]","GSM3522722","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0831","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522722/suppl/GSM3522722_SH4YT38_Cell1.txt.gz","2540","71","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522723","Malignant bone and soft tissue tumor [SH4YT38_Cell2]","GSM3522723","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0832","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522723/suppl/GSM3522723_SH4YT38_Cell2.txt.gz","2540","50","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522724","Benign bone and soft tissue tumor [SH4YT38_Cell3]","GSM3522724","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0833","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522724/suppl/GSM3522724_SH4YT38_Cell3.txt.gz","2540","54","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522725","Benign bone and soft tissue tumor [SH4YT38_Cell4]","GSM3522725","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0834","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522725/suppl/GSM3522725_SH4YT38_Cell4.txt.gz","2540","34","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522726","Malignant bone and soft tissue tumor [SH51P33_Cell2]","GSM3522726","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0835","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522726/suppl/GSM3522726_SH51P33_Cell2.txt.gz","2540","52","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522727","Benign bone and soft tissue tumor [SH51P33_Cell3]","GSM3522727","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0836","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522727/suppl/GSM3522727_SH51P33_Cell3.txt.gz","2540","47","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522728","Benign bone and soft tissue tumor [SH4YT39_Cell3]","GSM3522728","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0837","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522728/suppl/GSM3522728_SH4YT39_Cell3.txt.gz","2540","66","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522729","Benign bone and soft tissue tumor [SH4YT40_Cell3]","GSM3522729","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0840","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522729/suppl/GSM3522729_SH4YT40_Cell3.txt.gz","2540","44","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522730","Benign bone and soft tissue tumor [SH4YT40_Cell4]","GSM3522730","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0841","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522730/suppl/GSM3522730_SH4YT40_Cell4.txt.gz","2540","48","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522731","Benign bone and soft tissue tumor [SH4YT41_Cell1]","GSM3522731","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0842","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522731/suppl/GSM3522731_SH4YT41_Cell1.txt.gz","2540","55","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522732","Benign bone and soft tissue tumor [SH4YT41_Cell2]","GSM3522732","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 24","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0843","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522732/suppl/GSM3522732_SH4YT41_Cell2.txt.gz","2540","24","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522733","Benign bone and soft tissue tumor [SH4YT41_Cell3]","GSM3522733","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0844","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522733/suppl/GSM3522733_SH4YT41_Cell3.txt.gz","2540","15","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522734","Benign bone and soft tissue tumor [SH51P33_Cell4]","GSM3522734","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0845","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522734/suppl/GSM3522734_SH51P33_Cell4.txt.gz","2540","39","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522735","Intermediate bone and soft tissue tumor [SH4YT42_Cell1]","GSM3522735","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0846","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522735/suppl/GSM3522735_SH4YT42_Cell1.txt.gz","2540","40","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522736","Malignant bone and soft tissue tumor [SH4YT42_Cell2]","GSM3522736","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0847","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522736/suppl/GSM3522736_SH4YT42_Cell2.txt.gz","2540","14","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522737","Intermediate bone and soft tissue tumor [SH4YT42_Cell3]","GSM3522737","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 25","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0848","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522737/suppl/GSM3522737_SH4YT42_Cell3.txt.gz","2540","25","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522738","Malignant bone and soft tissue tumor [SH4YT42_Cell4]","GSM3522738","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0849","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522738/suppl/GSM3522738_SH4YT42_Cell4.txt.gz","2540","55","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522739","Malignant bone and soft tissue tumor [SH4YT43_Cell1]","GSM3522739","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0850","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522739/suppl/GSM3522739_SH4YT43_Cell1.txt.gz","2540","26","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522740","Intermediate bone and soft tissue tumor [SH4YT43_Cell2]","GSM3522740","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0851","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522740/suppl/GSM3522740_SH4YT43_Cell2.txt.gz","2540","53","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522741","Benign bone and soft tissue tumor [SH4YT43_Cell3]","GSM3522741","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0852","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522741/suppl/GSM3522741_SH4YT43_Cell3.txt.gz","2540","38","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522742","Intermediate bone and soft tissue tumor [SH51P36_Cell1]","GSM3522742","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0853","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522742/suppl/GSM3522742_SH51P36_Cell1.txt.gz","2540","43","Female","Intermediate bone and soft tissue tumor","Serum","StageIIB"
"GSM3522743","Benign bone and soft tissue tumor [SH4YT45_Cell1]","GSM3522743","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0854","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522743/suppl/GSM3522743_SH4YT45_Cell1.txt.gz","2540","54","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522744","Benign bone and soft tissue tumor [SH4YT45_Cell2]","GSM3522744","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0855","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522744/suppl/GSM3522744_SH4YT45_Cell2.txt.gz","2540","32","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522745","Malignant bone and soft tissue tumor [SH51P36_Cell2]","GSM3522745","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0856","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522745/suppl/GSM3522745_SH51P36_Cell2.txt.gz","2540","30","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522746","Benign bone and soft tissue tumor [SH51P36_Cell3]","GSM3522746","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 3","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0857","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522746/suppl/GSM3522746_SH51P36_Cell3.txt.gz","2540","3","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522747","Benign bone and soft tissue tumor [SH51P36_Cell4]","GSM3522747","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0858","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522747/suppl/GSM3522747_SH51P36_Cell4.txt.gz","2540","74","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522748","Intermediate bone and soft tissue tumor [SH4YT46_Cell2]","GSM3522748","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0859","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522748/suppl/GSM3522748_SH4YT46_Cell2.txt.gz","2540","57","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522749","Benign bone and soft tissue tumor [SH4YT46_Cell3]","GSM3522749","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0860","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522749/suppl/GSM3522749_SH4YT46_Cell3.txt.gz","2540","65","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522750","Benign bone and soft tissue tumor [SH4YT46_Cell4]","GSM3522750","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0861","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522750/suppl/GSM3522750_SH4YT46_Cell4.txt.gz","2540","36","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522751","Intermediate bone and soft tissue tumor [SH4YT47_Cell1]","GSM3522751","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0862","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522751/suppl/GSM3522751_SH4YT47_Cell1.txt.gz","2540","21","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522752","Malignant bone and soft tissue tumor [SH4YT47_Cell2]","GSM3522752","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 48","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0863","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522752/suppl/GSM3522752_SH4YT47_Cell2.txt.gz","2540","48","Female","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522753","Malignant bone and soft tissue tumor [SH4YT47_Cell3]","GSM3522753","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0864","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522753/suppl/GSM3522753_SH4YT47_Cell3.txt.gz","2540","62","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522754","Intermediate bone and soft tissue tumor [SH4YT47_Cell4]","GSM3522754","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0865","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522754/suppl/GSM3522754_SH4YT47_Cell4.txt.gz","2540","26","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522755","Malignant bone and soft tissue tumor [SH4YT49_Cell1]","GSM3522755","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0866","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522755/suppl/GSM3522755_SH4YT49_Cell1.txt.gz","2540","53","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522756","Malignant bone and soft tissue tumor [SH4YT49_Cell2]","GSM3522756","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 88","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0867","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522756/suppl/GSM3522756_SH4YT49_Cell2.txt.gz","2540","88","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522757","Malignant bone and soft tissue tumor [SH4YT49_Cell3]","GSM3522757","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0868","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522757/suppl/GSM3522757_SH4YT49_Cell3.txt.gz","2540","56","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522758","Benign bone and soft tissue tumor [SH4YT49_Cell4]","GSM3522758","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0869","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522758/suppl/GSM3522758_SH4YT49_Cell4.txt.gz","2540","26","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522759","Malignant bone and soft tissue tumor [SH4YT50_Cell1]","GSM3522759","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0870","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522759/suppl/GSM3522759_SH4YT50_Cell1.txt.gz","2540","41","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522760","Malignant bone and soft tissue tumor [SH4YT50_Cell3]","GSM3522760","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 76","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0872","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522760/suppl/GSM3522760_SH4YT50_Cell3.txt.gz","2540","76","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522761","Benign bone and soft tissue tumor [SH4YT50_Cell4]","GSM3522761","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0873","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522761/suppl/GSM3522761_SH4YT50_Cell4.txt.gz","2540","40","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522762","Malignant bone and soft tissue tumor [SH51P39_Cell2]","GSM3522762","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0874","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522762/suppl/GSM3522762_SH51P39_Cell2.txt.gz","2540","65","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522763","Benign bone and soft tissue tumor [SH4YT51_Cell2]","GSM3522763","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0875","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522763/suppl/GSM3522763_SH4YT51_Cell2.txt.gz","2540","37","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522764","Benign bone and soft tissue tumor [SH4YT51_Cell3]","GSM3522764","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0876","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522764/suppl/GSM3522764_SH4YT51_Cell3.txt.gz","2540","12","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522765","Malignant bone and soft tissue tumor [SH4YT51_Cell4]","GSM3522765","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 80","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0877","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522765/suppl/GSM3522765_SH4YT51_Cell4.txt.gz","2540","80","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522766","Malignant bone and soft tissue tumor [SH4YT39_Cell4]","GSM3522766","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 22","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0878","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522766/suppl/GSM3522766_SH4YT39_Cell4.txt.gz","2540","22","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522767","Intermediate bone and soft tissue tumor [SH4YT52_Cell2]","GSM3522767","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0879","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522767/suppl/GSM3522767_SH4YT52_Cell2.txt.gz","2540","62","Female","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522768","Intermediate bone and soft tissue tumor [SH4YT52_Cell3]","GSM3522768","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0880","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522768/suppl/GSM3522768_SH4YT52_Cell3.txt.gz","2540","28","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522769","Malignant bone and soft tissue tumor [SH4YT52_Cell4]","GSM3522769","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0881","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522769/suppl/GSM3522769_SH4YT52_Cell4.txt.gz","2540","72","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522770","Malignant bone and soft tissue tumor [SH4YT53_Cell1]","GSM3522770","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0882","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522770/suppl/GSM3522770_SH4YT53_Cell1.txt.gz","2540","14","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522771","Malignant bone and soft tissue tumor [SH4YT53_Cell2]","GSM3522771","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0883","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522771/suppl/GSM3522771_SH4YT53_Cell2.txt.gz","2540","31","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522772","Intermediate bone and soft tissue tumor [SH4YT53_Cell3]","GSM3522772","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0884","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522772/suppl/GSM3522772_SH4YT53_Cell3.txt.gz","2540","59","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522773","Malignant bone and soft tissue tumor [SH51P39_Cell3]","GSM3522773","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 85","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0885","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522773/suppl/GSM3522773_SH51P39_Cell3.txt.gz","2540","85","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522774","Malignant bone and soft tissue tumor [SH4YT54_Cell1]","GSM3522774","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 84","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0886","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522774/suppl/GSM3522774_SH4YT54_Cell1.txt.gz","2540","84","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522775","Malignant bone and soft tissue tumor [SH4YT54_Cell2]","GSM3522775","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0887","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522775/suppl/GSM3522775_SH4YT54_Cell2.txt.gz","2540","47","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522776","Malignant bone and soft tissue tumor [SH4YT54_Cell3]","GSM3522776","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 85","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0888","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522776/suppl/GSM3522776_SH4YT54_Cell3.txt.gz","2540","85","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522777","Malignant bone and soft tissue tumor [SH4YT54_Cell4]","GSM3522777","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0889","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522777/suppl/GSM3522777_SH4YT54_Cell4.txt.gz","2540","61","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522778","Malignant bone and soft tissue tumor [SH4YT56_Cell1]","GSM3522778","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0890","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522778/suppl/GSM3522778_SH4YT56_Cell1.txt.gz","2540","49","Female","Malignant bone and soft tissue tumor","Serum","StageIA"
"GSM3522779","Malignant bone and soft tissue tumor [SH4YT56_Cell2]","GSM3522779","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0891","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522779/suppl/GSM3522779_SH4YT56_Cell2.txt.gz","2540","18","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522780","Intermediate bone and soft tissue tumor [SH4YT56_Cell3]","GSM3522780","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0892","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522780/suppl/GSM3522780_SH4YT56_Cell3.txt.gz","2540","64","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522781","Malignant bone and soft tissue tumor [SH4YT56_Cell4]","GSM3522781","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0893","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522781/suppl/GSM3522781_SH4YT56_Cell4.txt.gz","2540","55","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522782","Malignant bone and soft tissue tumor [SH4YT57_Cell1]","GSM3522782","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 10","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0894","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522782/suppl/GSM3522782_SH4YT57_Cell1.txt.gz","2540","10","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522783","Benign bone and soft tissue tumor [SH4YT57_Cell2]","GSM3522783","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0895","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522783/suppl/GSM3522783_SH4YT57_Cell2.txt.gz","2540","41","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522784","Benign bone and soft tissue tumor [SH4YT57_Cell3]","GSM3522784","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 7","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0896","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522784/suppl/GSM3522784_SH4YT57_Cell3.txt.gz","2540","7","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522785","Malignant bone and soft tissue tumor [SH4YT58_Cell1]","GSM3522785","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0898","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522785/suppl/GSM3522785_SH4YT58_Cell1.txt.gz","2540","45","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522786","Benign bone and soft tissue tumor [SH4YT58_Cell2]","GSM3522786","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0899","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522786/suppl/GSM3522786_SH4YT58_Cell2.txt.gz","2540","56","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522787","Malignant bone and soft tissue tumor [SH4YT58_Cell3]","GSM3522787","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0900","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522787/suppl/GSM3522787_SH4YT58_Cell3.txt.gz","2540","21","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522788","Malignant bone and soft tissue tumor [SH51P39_Cell4]","GSM3522788","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0901","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522788/suppl/GSM3522788_SH51P39_Cell4.txt.gz","2540","28","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522789","Malignant bone and soft tissue tumor [SH4YT59_Cell1]","GSM3522789","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 19","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0902","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522789/suppl/GSM3522789_SH4YT59_Cell1.txt.gz","2540","19","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522790","Malignant bone and soft tissue tumor [SH4YT59_Cell2]","GSM3522790","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0903","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522790/suppl/GSM3522790_SH4YT59_Cell2.txt.gz","2540","65","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522791","Benign bone and soft tissue tumor [SH4YT59_Cell4]","GSM3522791","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 26","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0905","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522791/suppl/GSM3522791_SH4YT59_Cell4.txt.gz","2540","26","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522792","Malignant bone and soft tissue tumor [SH4YT61_Cell1]","GSM3522792","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0906","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522792/suppl/GSM3522792_SH4YT61_Cell1.txt.gz","2540","69","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522793","Malignant bone and soft tissue tumor [SH4YT61_Cell2]","GSM3522793","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0907","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522793/suppl/GSM3522793_SH4YT61_Cell2.txt.gz","2540","46","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522794","Intermediate bone and soft tissue tumor [SH4YT61_Cell3]","GSM3522794","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0908","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522794/suppl/GSM3522794_SH4YT61_Cell3.txt.gz","2540","66","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522795","Benign bone and soft tissue tumor [SH4YT61_Cell4]","GSM3522795","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0909","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522795/suppl/GSM3522795_SH4YT61_Cell4.txt.gz","2540","40","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522796","Malignant bone and soft tissue tumor [SH51P35_Cell1]","GSM3522796","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0910","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522796/suppl/GSM3522796_SH51P35_Cell1.txt.gz","2540","18","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522797","Benign bone and soft tissue tumor [SH4YT62_Cell2]","GSM3522797","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0911","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522797/suppl/GSM3522797_SH4YT62_Cell2.txt.gz","2540","49","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522798","Malignant bone and soft tissue tumor [SH51P35_Cell2]","GSM3522798","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0912","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522798/suppl/GSM3522798_SH51P35_Cell2.txt.gz","2540","78","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522799","Benign bone and soft tissue tumor [SH51P35_Cell3]","GSM3522799","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0913","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522799/suppl/GSM3522799_SH51P35_Cell3.txt.gz","2540","59","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522800","Benign bone and soft tissue tumor [SH4YT63_Cell1]","GSM3522800","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0914","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522800/suppl/GSM3522800_SH4YT63_Cell1.txt.gz","2540","62","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522801","Benign bone and soft tissue tumor [SH51P35_Cell4]","GSM3522801","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 32","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0915","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522801/suppl/GSM3522801_SH51P35_Cell4.txt.gz","2540","32","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522802","Benign bone and soft tissue tumor [SH4YT63_Cell3]","GSM3522802","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0916","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522802/suppl/GSM3522802_SH4YT63_Cell3.txt.gz","2540","40","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522803","Intermediate bone and soft tissue tumor [SH4YT64_Cell1]","GSM3522803","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0918","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522803/suppl/GSM3522803_SH4YT64_Cell1.txt.gz","2540","63","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522804","Malignant bone and soft tissue tumor [SH4YT64_Cell2]","GSM3522804","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 5","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0919","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522804/suppl/GSM3522804_SH4YT64_Cell2.txt.gz","2540","5","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522805","Benign bone and soft tissue tumor [SH51P47_Cell2]","GSM3522805","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 11","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0920","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522805/suppl/GSM3522805_SH51P47_Cell2.txt.gz","2540","11","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522806","Malignant bone and soft tissue tumor [SH4YT64_Cell4]","GSM3522806","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 27","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0921","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522806/suppl/GSM3522806_SH4YT64_Cell4.txt.gz","2540","27","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522807","Malignant bone and soft tissue tumor [SH51840_Cell1]","GSM3522807","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0922","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522807/suppl/GSM3522807_SH51840_Cell1.txt.gz","2540","56","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522808","Malignant bone and soft tissue tumor [SH51840_Cell2]","GSM3522808","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0923","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522808/suppl/GSM3522808_SH51840_Cell2.txt.gz","2540","30","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522809","Benign bone and soft tissue tumor [SH51840_Cell3]","GSM3522809","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 29","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0924","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522809/suppl/GSM3522809_SH51840_Cell3.txt.gz","2540","29","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522810","Benign bone and soft tissue tumor [SH51840_Cell4]","GSM3522810","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0925","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522810/suppl/GSM3522810_SH51840_Cell4.txt.gz","2540","58","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522811","Benign bone and soft tissue tumor [SH51841_Cell1]","GSM3522811","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 7","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0926","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522811/suppl/GSM3522811_SH51841_Cell1.txt.gz","2540","7","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522812","Benign bone and soft tissue tumor [SH51841_Cell2]","GSM3522812","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0927","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522812/suppl/GSM3522812_SH51841_Cell2.txt.gz","2540","65","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522813","Benign bone and soft tissue tumor [SH51841_Cell3]","GSM3522813","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 23","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0928","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522813/suppl/GSM3522813_SH51841_Cell3.txt.gz","2540","23","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522814","Malignant bone and soft tissue tumor [SH51841_Cell4]","GSM3522814","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0929","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522814/suppl/GSM3522814_SH51841_Cell4.txt.gz","2540","73","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522815","Intermediate bone and soft tissue tumor [SH51843_Cell1]","GSM3522815","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 76","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0930","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522815/suppl/GSM3522815_SH51843_Cell1.txt.gz","2540","76","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522816","Benign bone and soft tissue tumor [SH51843_Cell2]","GSM3522816","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 5","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0931","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522816/suppl/GSM3522816_SH51843_Cell2.txt.gz","2540","5","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522817","Benign bone and soft tissue tumor [SH51843_Cell3]","GSM3522817","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0932","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522817/suppl/GSM3522817_SH51843_Cell3.txt.gz","2540","41","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522818","Benign bone and soft tissue tumor [SH51843_Cell4]","GSM3522818","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0933","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522818/suppl/GSM3522818_SH51843_Cell4.txt.gz","2540","36","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522819","Benign bone and soft tissue tumor [SH51845_Cell1]","GSM3522819","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0934","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522819/suppl/GSM3522819_SH51845_Cell1.txt.gz","2540","34","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522820","Malignant bone and soft tissue tumor [SH51845_Cell2]","GSM3522820","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 21","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0935","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522820/suppl/GSM3522820_SH51845_Cell2.txt.gz","2540","21","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522821","Intermediate bone and soft tissue tumor [SH51845_Cell3]","GSM3522821","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 28","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0936","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522821/suppl/GSM3522821_SH51845_Cell3.txt.gz","2540","28","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522822","Malignant bone and soft tissue tumor [SH51845_Cell4]","GSM3522822","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0937","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522822/suppl/GSM3522822_SH51845_Cell4.txt.gz","2540","72","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522823","Intermediate bone and soft tissue tumor [SH51846_Cell1]","GSM3522823","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0938","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522823/suppl/GSM3522823_SH51846_Cell1.txt.gz","2540","60","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522824","Benign bone and soft tissue tumor [SH51846_Cell2]","GSM3522824","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0939","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522824/suppl/GSM3522824_SH51846_Cell2.txt.gz","2540","37","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522825","Intermediate bone and soft tissue tumor [SH51846_Cell3]","GSM3522825","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0940","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522825/suppl/GSM3522825_SH51846_Cell3.txt.gz","2540","65","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522826","Benign bone and soft tissue tumor [SH51846_Cell4]","GSM3522826","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0941","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522826/suppl/GSM3522826_SH51846_Cell4.txt.gz","2540","53","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522827","Malignant bone and soft tissue tumor [SH51847_Cell1]","GSM3522827","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0942","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522827/suppl/GSM3522827_SH51847_Cell1.txt.gz","2540","65","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522828","Malignant bone and soft tissue tumor [SH51847_Cell2]","GSM3522828","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0943","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522828/suppl/GSM3522828_SH51847_Cell2.txt.gz","2540","61","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522829","Malignant bone and soft tissue tumor [SH51847_Cell3]","GSM3522829","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0944","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522829/suppl/GSM3522829_SH51847_Cell3.txt.gz","2540","41","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522830","Malignant bone and soft tissue tumor [SH51847_Cell4]","GSM3522830","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0945","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522830/suppl/GSM3522830_SH51847_Cell4.txt.gz","2540","72","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522831","Malignant bone and soft tissue tumor [SH51848_Cell1]","GSM3522831","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0946","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522831/suppl/GSM3522831_SH51848_Cell1.txt.gz","2540","31","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522832","Malignant bone and soft tissue tumor [SH51848_Cell2]","GSM3522832","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 30","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0947","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522832/suppl/GSM3522832_SH51848_Cell2.txt.gz","2540","30","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522833","Intermediate bone and soft tissue tumor [SH51848_Cell3]","GSM3522833","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: StageIB","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0948","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522833/suppl/GSM3522833_SH51848_Cell3.txt.gz","2540","59","Female","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522834","Malignant bone and soft tissue tumor [SH51848_Cell4]","GSM3522834","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 84","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0949","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522834/suppl/GSM3522834_SH51848_Cell4.txt.gz","2540","84","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522835","Intermediate bone and soft tissue tumor [SH51849_Cell1]","GSM3522835","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0950","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522835/suppl/GSM3522835_SH51849_Cell1.txt.gz","2540","40","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522836","Benign bone and soft tissue tumor [SH51849_Cell3]","GSM3522836","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0952","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522836/suppl/GSM3522836_SH51849_Cell3.txt.gz","2540","60","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522837","Intermediate bone and soft tissue tumor [SH51849_Cell4]","GSM3522837","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0953","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522837/suppl/GSM3522837_SH51849_Cell4.txt.gz","2540","59","Female","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522838","Malignant bone and soft tissue tumor [SH51851_Cell1]","GSM3522838","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0954","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522838/suppl/GSM3522838_SH51851_Cell1.txt.gz","2540","71","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522839","Malignant bone and soft tissue tumor [SH51851_Cell2]","GSM3522839","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0955","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522839/suppl/GSM3522839_SH51851_Cell2.txt.gz","2540","55","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522840","Intermediate bone and soft tissue tumor [SH51851_Cell3]","GSM3522840","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 80","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0956","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522840/suppl/GSM3522840_SH51851_Cell3.txt.gz","2540","80","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522841","Malignant bone and soft tissue tumor [SH51851_Cell4]","GSM3522841","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 81","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0957","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522841/suppl/GSM3522841_SH51851_Cell4.txt.gz","2540","81","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522842","Malignant bone and soft tissue tumor [SH51852_Cell1]","GSM3522842","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 23","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0958","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522842/suppl/GSM3522842_SH51852_Cell1.txt.gz","2540","23","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522843","Benign bone and soft tissue tumor [SH51852_Cell2]","GSM3522843","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0959","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522843/suppl/GSM3522843_SH51852_Cell2.txt.gz","2540","39","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522844","Benign bone and soft tissue tumor [SH51854_Cell1]","GSM3522844","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0962","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522844/suppl/GSM3522844_SH51854_Cell1.txt.gz","2540","60","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522845","Intermediate bone and soft tissue tumor [SH51P47_Cell3]","GSM3522845","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 10","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0963","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522845/suppl/GSM3522845_SH51P47_Cell3.txt.gz","2540","10","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522846","Intermediate bone and soft tissue tumor [SH51854_Cell3]","GSM3522846","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0964","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522846/suppl/GSM3522846_SH51854_Cell3.txt.gz","2540","65","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522847","Malignant bone and soft tissue tumor [SH51854_Cell4]","GSM3522847","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0965","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522847/suppl/GSM3522847_SH51854_Cell4.txt.gz","2540","71","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522848","Intermediate bone and soft tissue tumor [SH51856_Cell1]","GSM3522848","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 14","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0966","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522848/suppl/GSM3522848_SH51856_Cell1.txt.gz","2540","14","Male","Intermediate bone and soft tissue tumor","Serum","NA"
"GSM3522849","Malignant bone and soft tissue tumor [SH51856_Cell2]","GSM3522849","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0967","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522849/suppl/GSM3522849_SH51856_Cell2.txt.gz","2540","31","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522850","Malignant bone and soft tissue tumor [SH51856_Cell3]","GSM3522850","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 84","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0968","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522850/suppl/GSM3522850_SH51856_Cell3.txt.gz","2540","84","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522851","Malignant bone and soft tissue tumor [SH51856_Cell4]","GSM3522851","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 31","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0969","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522851/suppl/GSM3522851_SH51856_Cell4.txt.gz","2540","31","Male","Malignant bone and soft tissue tumor","Serum","StageIB"
"GSM3522852","Benign bone and soft tissue tumor [SH51857_Cell1]","GSM3522852","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0970","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522852/suppl/GSM3522852_SH51857_Cell1.txt.gz","2540","64","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522853","Malignant bone and soft tissue tumor [SH51857_Cell2]","GSM3522853","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0971","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522853/suppl/GSM3522853_SH51857_Cell2.txt.gz","2540","68","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522854","Benign bone and soft tissue tumor [SH51857_Cell3]","GSM3522854","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0972","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522854/suppl/GSM3522854_SH51857_Cell3.txt.gz","2540","53","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522855","Malignant bone and soft tissue tumor [SH51857_Cell4]","GSM3522855","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 34","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0973","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522855/suppl/GSM3522855_SH51857_Cell4.txt.gz","2540","34","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522856","Intermediate bone and soft tissue tumor [SH51858_Cell2]","GSM3522856","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0975","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522856/suppl/GSM3522856_SH51858_Cell2.txt.gz","2540","36","Male","Intermediate bone and soft tissue tumor","Serum","StageIIB"
"GSM3522857","Malignant bone and soft tissue tumor [SH51858_Cell3]","GSM3522857","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0976","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522857/suppl/GSM3522857_SH51858_Cell3.txt.gz","2540","66","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522858","Benign bone and soft tissue tumor [SH51858_Cell4]","GSM3522858","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0977","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522858/suppl/GSM3522858_SH51858_Cell4.txt.gz","2540","36","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522859","Intermediate bone and soft tissue tumor [SH51860_Cell1]","GSM3522859","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIB","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0978","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522859/suppl/GSM3522859_SH51860_Cell1.txt.gz","2540","71","Male","Intermediate bone and soft tissue tumor","Serum","StageIB"
"GSM3522860","Malignant bone and soft tissue tumor [SH51860_Cell2]","GSM3522860","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0979","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522860/suppl/GSM3522860_SH51860_Cell2.txt.gz","2540","61","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522861","Benign bone and soft tissue tumor [SH51860_Cell3]","GSM3522861","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0980","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522861/suppl/GSM3522861_SH51860_Cell3.txt.gz","2540","50","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522862","Malignant bone and soft tissue tumor [SH51P47_Cell4]","GSM3522862","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0981","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522862/suppl/GSM3522862_SH51P47_Cell4.txt.gz","2540","61","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522863","Intermediate bone and soft tissue tumor [SH51861_Cell1]","GSM3522863","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Intermediate bone and soft tissue tumor","gender: Male","tumor stage: StageIA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0982","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522863/suppl/GSM3522863_SH51861_Cell1.txt.gz","2540","78","Male","Intermediate bone and soft tissue tumor","Serum","StageIA"
"GSM3522864","Benign bone and soft tissue tumor [SH51861_Cell2]","GSM3522864","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0983","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522864/suppl/GSM3522864_SH51861_Cell2.txt.gz","2540","74","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522865","Benign bone and soft tissue tumor [SH51861_Cell3]","GSM3522865","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Male","tumor stage: NA","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0984","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522865/suppl/GSM3522865_SH51861_Cell3.txt.gz","2540","71","Male","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522866","Malignant bone and soft tissue tumor [SH51861_Cell4]","GSM3522866","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0985","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522866/suppl/GSM3522866_SH51861_Cell4.txt.gz","2540","52","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522867","Malignant bone and soft tissue tumor [SH51863_Cell1]","GSM3522867","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIVB","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0986","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522867/suppl/GSM3522867_SH51863_Cell1.txt.gz","2540","63","Male","Malignant bone and soft tissue tumor","Serum","StageIVB"
"GSM3522868","Malignant bone and soft tissue tumor [SH51863_Cell2]","GSM3522868","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIV","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0987","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522868/suppl/GSM3522868_SH51863_Cell2.txt.gz","2540","54","Female","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522869","Malignant bone and soft tissue tumor [SH51863_Cell3]","GSM3522869","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 81","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0988","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522869/suppl/GSM3522869_SH51863_Cell3.txt.gz","2540","81","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522870","Benign bone and soft tissue tumor [SH51863_Cell4]","GSM3522870","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Benign bone and soft tissue tumor","gender: Female","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0989","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522870/suppl/GSM3522870_SH51863_Cell4.txt.gz","2540","41","Female","Benign bone and soft tissue tumor","Serum","NA"
"GSM3522871","Malignant bone and soft tissue tumor [SH51864_Cell1]","GSM3522871","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0990","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522871/suppl/GSM3522871_SH51864_Cell1.txt.gz","2540","60","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522872","Malignant bone and soft tissue tumor [SH51864_Cell3]","GSM3522872","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0992","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522872/suppl/GSM3522872_SH51864_Cell3.txt.gz","2540","58","Female","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522873","Malignant bone and soft tissue tumor [SH51864_Cell4]","GSM3522873","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0993","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522873/suppl/GSM3522873_SH51864_Cell4.txt.gz","2540","60","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522874","Malignant bone and soft tissue tumor [SH51867_Cell1]","GSM3522874","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0994","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522874/suppl/GSM3522874_SH51867_Cell1.txt.gz","2540","46","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522875","Malignant bone and soft tissue tumor [SH51867_Cell2]","GSM3522875","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0995","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522875/suppl/GSM3522875_SH51867_Cell2.txt.gz","2540","51","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522876","Malignant bone and soft tissue tumor [SH51867_Cell3]","GSM3522876","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIII","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0996","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522876/suppl/GSM3522876_SH51867_Cell3.txt.gz","2540","44","Female","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522877","Malignant bone and soft tissue tumor [SH51867_Cell4]","GSM3522877","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0997","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522877/suppl/GSM3522877_SH51867_Cell4.txt.gz","2540","77","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522878","Malignant bone and soft tissue tumor [SH51903_Cell1]","GSM3522878","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0998","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522878/suppl/GSM3522878_SH51903_Cell1.txt.gz","2540","66","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522879","Malignant bone and soft tissue tumor [SH51903_Cell2]","GSM3522879","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA0999","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522879/suppl/GSM3522879_SH51903_Cell2.txt.gz","2540","72","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522880","Malignant bone and soft tissue tumor [SH51903_Cell3]","GSM3522880","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1000","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522880/suppl/GSM3522880_SH51903_Cell3.txt.gz","2540","68","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522881","Malignant bone and soft tissue tumor [SH51903_Cell4]","GSM3522881","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1001","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522881/suppl/GSM3522881_SH51903_Cell4.txt.gz","2540","72","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522882","Malignant bone and soft tissue tumor [SH51904_Cell1]","GSM3522882","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1002","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522882/suppl/GSM3522882_SH51904_Cell1.txt.gz","2540","63","Male","Malignant bone and soft tissue tumor","Serum","StageIIA"
"GSM3522883","Malignant bone and soft tissue tumor [SH51904_Cell2]","GSM3522883","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIV","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1003","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522883/suppl/GSM3522883_SH51904_Cell2.txt.gz","2540","74","Male","Malignant bone and soft tissue tumor","Serum","StageIV"
"GSM3522884","Malignant bone and soft tissue tumor [SH51904_Cell3]","GSM3522884","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 15","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1004","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522884/suppl/GSM3522884_SH51904_Cell3.txt.gz","2540","15","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522885","Malignant bone and soft tissue tumor [SH51904_Cell4]","GSM3522885","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 12","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1005","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522885/suppl/GSM3522885_SH51904_Cell4.txt.gz","2540","12","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522886","Malignant bone and soft tissue tumor [SH51905_Cell1]","GSM3522886","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIIB","age: 11","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1006","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522886/suppl/GSM3522886_SH51905_Cell1.txt.gz","2540","11","Male","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522887","Malignant bone and soft tissue tumor [SH51905_Cell2]","GSM3522887","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Female","tumor stage: StageIIB","age: 13","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1007","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522887/suppl/GSM3522887_SH51905_Cell2.txt.gz","2540","13","Female","Malignant bone and soft tissue tumor","Serum","StageIIB"
"GSM3522888","Malignant bone and soft tissue tumor [SH51905_Cell3]","GSM3522888","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1008","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522888/suppl/GSM3522888_SH51905_Cell3.txt.gz","2540","73","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522889","Malignant bone and soft tissue tumor [SH51905_Cell4]","GSM3522889","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Malignant bone and soft tissue tumor","gender: Male","tumor stage: StageIII","age: 18","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","SA1009","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522889/suppl/GSM3522889_SH51905_Cell4.txt.gz","2540","18","Male","Malignant bone and soft tissue tumor","Serum","StageIII"
"GSM3522890","Healthy [SH4Z127_Cell1]","GSM3522890","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0001","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522890/suppl/GSM3522890_SH4Z127_Cell1.txt.gz","2540","50","Female","Healthy","Serum","NA"
"GSM3522891","Healthy [SH5XD28_Cell4]","GSM3522891","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268084","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522891/suppl/GSM3522891_SH5XD28_Cell4.txt.gz","2540","47","Female","Healthy","Serum","NA"
"GSM3522892","Healthy [SH4Z127_Cell3]","GSM3522892","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0003","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522892/suppl/GSM3522892_SH4Z127_Cell3.txt.gz","2540","43","Female","Healthy","Serum","NA"
"GSM3522893","Healthy [SH4Z127_Cell4]","GSM3522893","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0004","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522893/suppl/GSM3522893_SH4Z127_Cell4.txt.gz","2540","58","Female","Healthy","Serum","NA"
"GSM3522894","Healthy [SH5XD29_Cell3]","GSM3522894","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268087","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522894/suppl/GSM3522894_SH5XD29_Cell3.txt.gz","2540","41","Female","Healthy","Serum","NA"
"GSM3522895","Healthy [SH4Z128_Cell2]","GSM3522895","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0006","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522895/suppl/GSM3522895_SH4Z128_Cell2.txt.gz","2540","50","Female","Healthy","Serum","NA"
"GSM3522896","Healthy [SH4Z128_Cell3]","GSM3522896","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0007","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522896/suppl/GSM3522896_SH4Z128_Cell3.txt.gz","2540","39","Female","Healthy","Serum","NA"
"GSM3522897","Healthy [SH52J15_Cell3]","GSM3522897","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268089","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522897/suppl/GSM3522897_SH52J15_Cell3.txt.gz","2540","56","Female","Healthy","Serum","NA"
"GSM3522898","Healthy [SH4Z133_Cell1]","GSM3522898","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0009","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522898/suppl/GSM3522898_SH4Z133_Cell1.txt.gz","2540","44","Female","Healthy","Serum","NA"
"GSM3522899","Healthy [SH4Z133_Cell2]","GSM3522899","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469941","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522899/suppl/GSM3522899_SH4Z133_Cell2.txt.gz","2540","39","Female","Healthy","Serum","NA"
"GSM3522900","Healthy [SH4Z133_Cell3]","GSM3522900","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0011","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522900/suppl/GSM3522900_SH4Z133_Cell3.txt.gz","2540","40","Female","Healthy","Serum","NA"
"GSM3522901","Healthy [SH4Z133_Cell4]","GSM3522901","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469939","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522901/suppl/GSM3522901_SH4Z133_Cell4.txt.gz","2540","37","Female","Healthy","Serum","NA"
"GSM3522902","Healthy [SH5XD31_Cell1]","GSM3522902","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268092","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522902/suppl/GSM3522902_SH5XD31_Cell1.txt.gz","2540","43","Female","Healthy","Serum","NA"
"GSM3522903","Healthy [SH4Z135_Cell2]","GSM3522903","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0014","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522903/suppl/GSM3522903_SH4Z135_Cell2.txt.gz","2540","54","Female","Healthy","Serum","NA"
"GSM3522904","Healthy [SH5XD31_Cell3]","GSM3522904","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268094","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522904/suppl/GSM3522904_SH5XD31_Cell3.txt.gz","2540","49","Female","Healthy","Serum","NA"
"GSM3522905","Healthy [SH4Z135_Cell4]","GSM3522905","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0016","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522905/suppl/GSM3522905_SH4Z135_Cell4.txt.gz","2540","63","Female","Healthy","Serum","NA"
"GSM3522906","Healthy [SH4Z136_Cell1]","GSM3522906","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0017","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522906/suppl/GSM3522906_SH4Z136_Cell1.txt.gz","2540","46","Female","Healthy","Serum","NA"
"GSM3522907","Healthy [SH4Z136_Cell2]","GSM3522907","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0018","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522907/suppl/GSM3522907_SH4Z136_Cell2.txt.gz","2540","66","Female","Healthy","Serum","NA"
"GSM3522908","Healthy [SH4Z136_Cell3]","GSM3522908","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0019","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522908/suppl/GSM3522908_SH4Z136_Cell3.txt.gz","2540","37","Female","Healthy","Serum","NA"
"GSM3522909","Healthy [SH5XD32_Cell4]","GSM3522909","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268098","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522909/suppl/GSM3522909_SH5XD32_Cell4.txt.gz","2540","66","Female","Healthy","Serum","NA"
"GSM3522910","Healthy [SH5XD33_Cell1]","GSM3522910","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268099","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522910/suppl/GSM3522910_SH5XD33_Cell1.txt.gz","2540","51","Female","Healthy","Serum","NA"
"GSM3522911","Healthy [SH4Z201_Cell2]","GSM3522911","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268100","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522911/suppl/GSM3522911_SH4Z201_Cell2.txt.gz","2540","40","Female","Healthy","Serum","NA"
"GSM3522912","Healthy [SH4Z201_Cell3]","GSM3522912","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0023","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522912/suppl/GSM3522912_SH4Z201_Cell3.txt.gz","2540","41","Female","Healthy","Serum","NA"
"GSM3522913","Healthy [SH4Z201_Cell4]","GSM3522913","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0024","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522913/suppl/GSM3522913_SH4Z201_Cell4.txt.gz","2540","39","Female","Healthy","Serum","NA"
"GSM3522914","Healthy [SH4Z202_Cell1]","GSM3522914","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0025","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522914/suppl/GSM3522914_SH4Z202_Cell1.txt.gz","2540","51","Female","Healthy","Serum","NA"
"GSM3522915","Healthy [SH4Z202_Cell2]","GSM3522915","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0026","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522915/suppl/GSM3522915_SH4Z202_Cell2.txt.gz","2540","58","Female","Healthy","Serum","NA"
"GSM3522916","Healthy [SH5XD34_Cell3]","GSM3522916","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268104","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522916/suppl/GSM3522916_SH5XD34_Cell3.txt.gz","2540","46","Female","Healthy","Serum","NA"
"GSM3522917","Healthy [SH4Z202_Cell4]","GSM3522917","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0028","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522917/suppl/GSM3522917_SH4Z202_Cell4.txt.gz","2540","50","Female","Healthy","Serum","NA"
"GSM3522918","Healthy [SH5XD35_Cell1]","GSM3522918","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268106","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522918/suppl/GSM3522918_SH5XD35_Cell1.txt.gz","2540","42","Female","Healthy","Serum","NA"
"GSM3522919","Healthy [SH4Z203_Cell2]","GSM3522919","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 72","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0030","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522919/suppl/GSM3522919_SH4Z203_Cell2.txt.gz","2540","72","Female","Healthy","Serum","NA"
"GSM3522920","Healthy [SH4Z203_Cell3]","GSM3522920","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0031","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522920/suppl/GSM3522920_SH4Z203_Cell3.txt.gz","2540","44","Female","Healthy","Serum","NA"
"GSM3522921","Healthy [SH5XD35_Cell4]","GSM3522921","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268109","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522921/suppl/GSM3522921_SH5XD35_Cell4.txt.gz","2540","47","Female","Healthy","Serum","NA"
"GSM3522922","Healthy [SH4Z204_Cell1]","GSM3522922","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0033","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522922/suppl/GSM3522922_SH4Z204_Cell1.txt.gz","2540","46","Female","Healthy","Serum","NA"
"GSM3522923","Healthy [SH5XD37_Cell2]","GSM3522923","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268111","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522923/suppl/GSM3522923_SH5XD37_Cell2.txt.gz","2540","46","Female","Healthy","Serum","NA"
"GSM3522924","Healthy [SH5XD37_Cell3]","GSM3522924","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268112","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522924/suppl/GSM3522924_SH5XD37_Cell3.txt.gz","2540","41","Female","Healthy","Serum","NA"
"GSM3522925","Healthy [SH4Z204_Cell4]","GSM3522925","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0036","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522925/suppl/GSM3522925_SH4Z204_Cell4.txt.gz","2540","46","Female","Healthy","Serum","NA"
"GSM3522926","Healthy [SH5XD38_Cell1]","GSM3522926","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268114","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522926/suppl/GSM3522926_SH5XD38_Cell1.txt.gz","2540","58","Female","Healthy","Serum","NA"
"GSM3522927","Healthy [SH4Z205_Cell2]","GSM3522927","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0038","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522927/suppl/GSM3522927_SH4Z205_Cell2.txt.gz","2540","57","Female","Healthy","Serum","NA"
"GSM3522928","Healthy [SH5XD38_Cell3]","GSM3522928","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268116","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522928/suppl/GSM3522928_SH5XD38_Cell3.txt.gz","2540","52","Female","Healthy","Serum","NA"
"GSM3522929","Healthy [SH5XD38_Cell4]","GSM3522929","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268117","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522929/suppl/GSM3522929_SH5XD38_Cell4.txt.gz","2540","50","Female","Healthy","Serum","NA"
"GSM3522930","Healthy [SH4Z206_Cell1]","GSM3522930","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0041","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522930/suppl/GSM3522930_SH4Z206_Cell1.txt.gz","2540","53","Female","Healthy","Serum","NA"
"GSM3522931","Healthy [SH5XD39_Cell2]","GSM3522931","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268119","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522931/suppl/GSM3522931_SH5XD39_Cell2.txt.gz","2540","46","Female","Healthy","Serum","NA"
"GSM3522932","Healthy [SH5XD39_Cell3]","GSM3522932","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268120","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522932/suppl/GSM3522932_SH5XD39_Cell3.txt.gz","2540","52","Female","Healthy","Serum","NA"
"GSM3522933","Healthy [SH4Z206_Cell4]","GSM3522933","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0044","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522933/suppl/GSM3522933_SH4Z206_Cell4.txt.gz","2540","44","Female","Healthy","Serum","NA"
"GSM3522934","Healthy [SH5XD40_Cell1]","GSM3522934","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268122","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522934/suppl/GSM3522934_SH5XD40_Cell1.txt.gz","2540","47","Female","Healthy","Serum","NA"
"GSM3522935","Healthy [SH4Z207_Cell2]","GSM3522935","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268123","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522935/suppl/GSM3522935_SH4Z207_Cell2.txt.gz","2540","49","Female","Healthy","Serum","NA"
"GSM3522936","Healthy [SH5XD40_Cell3]","GSM3522936","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268124","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522936/suppl/GSM3522936_SH5XD40_Cell3.txt.gz","2540","41","Female","Healthy","Serum","NA"
"GSM3522937","Healthy [SH5XD40_Cell4]","GSM3522937","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268125","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522937/suppl/GSM3522937_SH5XD40_Cell4.txt.gz","2540","49","Female","Healthy","Serum","NA"
"GSM3522938","Healthy [SH4Z208_Cell2]","GSM3522938","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0050","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522938/suppl/GSM3522938_SH4Z208_Cell2.txt.gz","2540","45","Female","Healthy","Serum","NA"
"GSM3522939","Healthy [SH5XE24_Cell4]","GSM3522939","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469900","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522939/suppl/GSM3522939_SH5XE24_Cell4.txt.gz","2540","39","Female","Healthy","Serum","NA"
"GSM3522940","Healthy [SH4Z208_Cell4]","GSM3522940","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268128","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522940/suppl/GSM3522940_SH4Z208_Cell4.txt.gz","2540","45","Female","Healthy","Serum","NA"
"GSM3522941","Healthy [SH4Z209_Cell1]","GSM3522941","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268129","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522941/suppl/GSM3522941_SH4Z209_Cell1.txt.gz","2540","45","Female","Healthy","Serum","NA"
"GSM3522942","Healthy [SH4Z209_Cell2]","GSM3522942","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268130","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522942/suppl/GSM3522942_SH4Z209_Cell2.txt.gz","2540","40","Female","Healthy","Serum","NA"
"GSM3522943","Healthy [SH4Z209_Cell3]","GSM3522943","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268131","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522943/suppl/GSM3522943_SH4Z209_Cell3.txt.gz","2540","43","Female","Healthy","Serum","NA"
"GSM3522944","Healthy [SH4Z210_Cell1]","GSM3522944","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268133","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522944/suppl/GSM3522944_SH4Z210_Cell1.txt.gz","2540","45","Female","Healthy","Serum","NA"
"GSM3522945","Healthy [SH4Z210_Cell2]","GSM3522945","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268134","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522945/suppl/GSM3522945_SH4Z210_Cell2.txt.gz","2540","45","Female","Healthy","Serum","NA"
"GSM3522946","Healthy [SH52J15_Cell4]","GSM3522946","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268135","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522946/suppl/GSM3522946_SH52J15_Cell4.txt.gz","2540","56","Female","Healthy","Serum","NA"
"GSM3522947","Healthy [SH4Z210_Cell4]","GSM3522947","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469891","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522947/suppl/GSM3522947_SH4Z210_Cell4.txt.gz","2540","37","Female","Healthy","Serum","NA"
"GSM3522948","Healthy [SH4Z211_Cell1]","GSM3522948","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469890","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522948/suppl/GSM3522948_SH4Z211_Cell1.txt.gz","2540","36","Female","Healthy","Serum","NA"
"GSM3522949","Healthy [SH4Z211_Cell2]","GSM3522949","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268136","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522949/suppl/GSM3522949_SH4Z211_Cell2.txt.gz","2540","53","Female","Healthy","Serum","NA"
"GSM3522950","Healthy [SH4Z211_Cell3]","GSM3522950","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268137","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522950/suppl/GSM3522950_SH4Z211_Cell3.txt.gz","2540","42","Female","Healthy","Serum","NA"
"GSM3522951","Healthy [SH4Z212_Cell4]","GSM3522951","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268142","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522951/suppl/GSM3522951_SH4Z212_Cell4.txt.gz","2540","61","Female","Healthy","Serum","NA"
"GSM3522952","Healthy [SH4Z213_Cell1]","GSM3522952","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469882","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522952/suppl/GSM3522952_SH4Z213_Cell1.txt.gz","2540","39","Female","Healthy","Serum","NA"
"GSM3522953","Healthy [SH4Z213_Cell2]","GSM3522953","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268143","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522953/suppl/GSM3522953_SH4Z213_Cell2.txt.gz","2540","40","Female","Healthy","Serum","NA"
"GSM3522954","Healthy [SH4Z215_Cell2]","GSM3522954","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268147","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522954/suppl/GSM3522954_SH4Z215_Cell2.txt.gz","2540","53","Female","Healthy","Serum","NA"
"GSM3522955","Healthy [SH4Z215_Cell3]","GSM3522955","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469876","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522955/suppl/GSM3522955_SH4Z215_Cell3.txt.gz","2540","38","Female","Healthy","Serum","NA"
"GSM3522956","Healthy [SH5XD42_Cell1]","GSM3522956","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469869","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522956/suppl/GSM3522956_SH5XD42_Cell1.txt.gz","2540","39","Female","Healthy","Serum","NA"
"GSM3522957","Healthy [SH5XD44_Cell1]","GSM3522957","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268159","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522957/suppl/GSM3522957_SH5XD44_Cell1.txt.gz","2540","73","Female","Healthy","Serum","NA"
"GSM3522958","Healthy [SH5XD44_Cell2]","GSM3522958","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469863","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522958/suppl/GSM3522958_SH5XD44_Cell2.txt.gz","2540","36","Female","Healthy","Serum","NA"
"GSM3522959","Healthy [SH5XD45_Cell1]","GSM3522959","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268163","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522959/suppl/GSM3522959_SH5XD45_Cell1.txt.gz","2540","40","Female","Healthy","Serum","NA"
"GSM3522960","Healthy [SH4Z223_Cell3]","GSM3522960","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469849","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522960/suppl/GSM3522960_SH4Z223_Cell3.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522961","Healthy [SH5XD49_Cell1]","GSM3522961","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469848","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522961/suppl/GSM3522961_SH5XD49_Cell1.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522962","Healthy [SH4Z228_Cell1]","GSM3522962","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0109","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522962/suppl/GSM3522962_SH4Z228_Cell1.txt.gz","2540","51","Female","Healthy","Serum","NA"
"GSM3522963","Healthy [SH4Z228_Cell3]","GSM3522963","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0111","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522963/suppl/GSM3522963_SH4Z228_Cell3.txt.gz","2540","62","Female","Healthy","Serum","NA"
"GSM3522964","Healthy [SH4Z229_Cell1]","GSM3522964","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 75","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0113","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522964/suppl/GSM3522964_SH4Z229_Cell1.txt.gz","2540","75","Female","Healthy","Serum","NA"
"GSM3522965","Healthy [SH52J19_Cell1]","GSM3522965","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 68","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268175","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522965/suppl/GSM3522965_SH52J19_Cell1.txt.gz","2540","68","Female","Healthy","Serum","NA"
"GSM3522966","Healthy [SH4Z233_Cell2]","GSM3522966","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0126","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522966/suppl/GSM3522966_SH4Z233_Cell2.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522967","Healthy [SH4Z239_Cell3]","GSM3522967","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0135","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522967/suppl/GSM3522967_SH4Z239_Cell3.txt.gz","2540","56","Female","Healthy","Serum","NA"
"GSM3522968","Healthy [SH5XD58_Cell2]","GSM3522968","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268191","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522968/suppl/GSM3522968_SH5XD58_Cell2.txt.gz","2540","54","Female","Healthy","Serum","NA"
"GSM3522969","Healthy [SH4Z243_Cell3]","GSM3522969","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469810","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522969/suppl/GSM3522969_SH4Z243_Cell3.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522970","Healthy [SH4Z245_Cell3]","GSM3522970","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0155","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522970/suppl/GSM3522970_SH4Z245_Cell3.txt.gz","2540","53","Female","Healthy","Serum","NA"
"GSM3522971","Healthy [SH4Z248_Cell3]","GSM3522971","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0163","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522971/suppl/GSM3522971_SH4Z248_Cell3.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522972","Healthy [SH5XE03_Cell1]","GSM3522972","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268205","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522972/suppl/GSM3522972_SH5XE03_Cell1.txt.gz","2540","58","Female","Healthy","Serum","NA"
"GSM3522973","Healthy [SH5XE03_Cell2]","GSM3522973","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469788","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522973/suppl/GSM3522973_SH5XE03_Cell2.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522974","Healthy [SH4Z256_Cell1]","GSM3522974","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0181","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522974/suppl/GSM3522974_SH4Z256_Cell1.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522975","Healthy [SH4Z256_Cell2]","GSM3522975","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 79","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0182","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522975/suppl/GSM3522975_SH4Z256_Cell2.txt.gz","2540","79","Female","Healthy","Serum","NA"
"GSM3522976","Healthy [SH5XE06_Cell4]","GSM3522976","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268217","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522976/suppl/GSM3522976_SH5XE06_Cell4.txt.gz","2540","51","Female","Healthy","Serum","NA"
"GSM3522977","Healthy [SH5XE08_Cell4]","GSM3522977","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268224","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522977/suppl/GSM3522977_SH5XE08_Cell4.txt.gz","2540","69","Female","Healthy","Serum","NA"
"GSM3522978","Healthy [SH4Z260_Cell3]","GSM3522978","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0199","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522978/suppl/GSM3522978_SH4Z260_Cell3.txt.gz","2540","52","Female","Healthy","Serum","NA"
"GSM3522979","Healthy [SH4Z263_Cell3]","GSM3522979","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0207","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522979/suppl/GSM3522979_SH4Z263_Cell3.txt.gz","2540","60","Female","Healthy","Serum","NA"
"GSM3522980","Healthy [SH5XE11_Cell3]","GSM3522980","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268234","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522980/suppl/GSM3522980_SH5XE11_Cell3.txt.gz","2540","51","Female","Healthy","Serum","NA"
"GSM3522981","Healthy [SH4Z264_Cell1]","GSM3522981","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0209","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522981/suppl/GSM3522981_SH4Z264_Cell1.txt.gz","2540","63","Female","Healthy","Serum","NA"
"GSM3522982","Healthy [SH4Z264_Cell3]","GSM3522982","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268236","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522982/suppl/GSM3522982_SH4Z264_Cell3.txt.gz","2540","63","Female","Healthy","Serum","NA"
"GSM3522983","Healthy [SH4Z303_Cell1]","GSM3522983","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0213","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522983/suppl/GSM3522983_SH4Z303_Cell1.txt.gz","2540","63","Female","Healthy","Serum","NA"
"GSM3522984","Healthy [SH4Z303_Cell2]","GSM3522984","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0214","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522984/suppl/GSM3522984_SH4Z303_Cell2.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522985","Healthy [SH5XE14_Cell4]","GSM3522985","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268242","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522985/suppl/GSM3522985_SH5XE14_Cell4.txt.gz","2540","55","Female","Healthy","Serum","NA"
"GSM3522986","Healthy [SH5XE16_Cell3]","GSM3522986","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268245","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522986/suppl/GSM3522986_SH5XE16_Cell3.txt.gz","2540","52","Female","Healthy","Serum","NA"
"GSM3522987","Healthy [SH5XE17_Cell1]","GSM3522987","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268247","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522987/suppl/GSM3522987_SH5XE17_Cell1.txt.gz","2540","60","Female","Healthy","Serum","NA"
"GSM3522988","Healthy [SH4Z309_Cell4]","GSM3522988","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","XA0228","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522988/suppl/GSM3522988_SH4Z309_Cell4.txt.gz","2540","60","Female","Healthy","Serum","NA"
"GSM3522989","Healthy [SH5XE18_Cell4]","GSM3522989","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268253","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522989/suppl/GSM3522989_SH5XE18_Cell4.txt.gz","2540","57","Female","Healthy","Serum","NA"
"GSM3522990","Healthy [SH5XE19_Cell1]","GSM3522990","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 80","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268254","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522990/suppl/GSM3522990_SH5XE19_Cell1.txt.gz","2540","80","Female","Healthy","Serum","NA"
"GSM3522991","Healthy [SH5XE20_Cell2]","GSM3522991","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268258","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522991/suppl/GSM3522991_SH5XE20_Cell2.txt.gz","2540","58","Female","Healthy","Serum","NA"
"GSM3522992","Healthy [SH5XE20_Cell4]","GSM3522992","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469728","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522992/suppl/GSM3522992_SH5XE20_Cell4.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3522993","Healthy [SH5XE22_Cell4]","GSM3522993","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268267","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522993/suppl/GSM3522993_SH5XE22_Cell4.txt.gz","2540","61","Female","Healthy","Serum","NA"
"GSM3522994","Healthy [SH4ZP47_Cell2]","GSM3522994","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268276","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522994/suppl/GSM3522994_SH4ZP47_Cell2.txt.gz","2540","57","Female","Healthy","Serum","NA"
"GSM3522995","Healthy [SH4ZP47_Cell4]","GSM3522995","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268278","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522995/suppl/GSM3522995_SH4ZP47_Cell4.txt.gz","2540","69","Female","Healthy","Serum","NA"
"GSM3522996","Healthy [SH4ZP48_Cell3]","GSM3522996","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268281","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522996/suppl/GSM3522996_SH4ZP48_Cell3.txt.gz","2540","67","Female","Healthy","Serum","NA"
"GSM3522997","Healthy [SH4ZP50_Cell3]","GSM3522997","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268289","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522997/suppl/GSM3522997_SH4ZP50_Cell3.txt.gz","2540","69","Female","Healthy","Serum","NA"
"GSM3522998","Healthy [SH4ZP51_Cell3]","GSM3522998","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268293","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522998/suppl/GSM3522998_SH4ZP51_Cell3.txt.gz","2540","65","Female","Healthy","Serum","NA"
"GSM3522999","Healthy [SH4ZP52_Cell1]","GSM3522999","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268295","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3522nnn/GSM3522999/suppl/GSM3522999_SH4ZP52_Cell1.txt.gz","2540","66","Female","Healthy","Serum","NA"
"GSM3523000","Healthy [SH4ZP54_Cell1]","GSM3523000","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268303","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523000/suppl/GSM3523000_SH4ZP54_Cell1.txt.gz","2540","65","Female","Healthy","Serum","NA"
"GSM3523001","Healthy [SH4ZP55_Cell1]","GSM3523001","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469675","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523001/suppl/GSM3523001_SH4ZP55_Cell1.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3523002","Healthy [SH4ZP55_Cell3]","GSM3523002","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 76","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268308","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523002/suppl/GSM3523002_SH4ZP55_Cell3.txt.gz","2540","76","Female","Healthy","Serum","NA"
"GSM3523003","Healthy [SH4ZP55_Cell4]","GSM3523003","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268309","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523003/suppl/GSM3523003_SH4ZP55_Cell4.txt.gz","2540","74","Female","Healthy","Serum","NA"
"GSM3523004","Healthy [SH4ZP56_Cell1]","GSM3523004","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268310","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523004/suppl/GSM3523004_SH4ZP56_Cell1.txt.gz","2540","74","Female","Healthy","Serum","NA"
"GSM3523005","Healthy [SH4ZP56_Cell3]","GSM3523005","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268312","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523005/suppl/GSM3523005_SH4ZP56_Cell3.txt.gz","2540","71","Female","Healthy","Serum","NA"
"GSM3523006","Healthy [SH4ZP59_Cell2]","GSM3523006","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 62","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268321","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523006/suppl/GSM3523006_SH4ZP59_Cell2.txt.gz","2540","62","Female","Healthy","Serum","NA"
"GSM3523007","Healthy [SH4ZP60_Cell1]","GSM3523007","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268323","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523007/suppl/GSM3523007_SH4ZP60_Cell1.txt.gz","2540","67","Female","Healthy","Serum","NA"
"GSM3523008","Healthy [SH4ZP62_Cell2]","GSM3523008","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469650","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523008/suppl/GSM3523008_SH4ZP62_Cell2.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3523009","Healthy [SH4ZQ01_Cell4]","GSM3523009","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268346","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523009/suppl/GSM3523009_SH4ZQ01_Cell4.txt.gz","2540","46","Female","Healthy","Serum","NA"
"GSM3523010","Healthy [SH4ZQ18_Cell1]","GSM3523010","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268377","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523010/suppl/GSM3523010_SH4ZQ18_Cell1.txt.gz","2540","78","Female","Healthy","Serum","NA"
"GSM3523011","Healthy [SH4ZQ27_Cell1]","GSM3523011","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469563","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523011/suppl/GSM3523011_SH4ZQ27_Cell1.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3523012","Healthy [SH4ZR54_Cell2]","GSM3523012","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469457","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523012/suppl/GSM3523012_SH4ZR54_Cell2.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3523013","Healthy [SH51D12_Cell3]","GSM3523013","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469424","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523013/suppl/GSM3523013_SH51D12_Cell3.txt.gz","2540","65","Female","Healthy","Serum","NA"
"GSM3523014","Healthy [SH51D28_Cell3]","GSM3523014","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Female","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3469396","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523014/suppl/GSM3523014_SH51D28_Cell3.txt.gz","2540","35","Female","Healthy","Serum","NA"
"GSM3523015","Healthy [SH52616_Cell4]","GSM3523015","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268897","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523015/suppl/GSM3523015_SH52616_Cell4.txt.gz","2540","49","Male","Healthy","Serum","NA"
"GSM3523016","Healthy [SH52P09_Cell4]","GSM3523016","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268898","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523016/suppl/GSM3523016_SH52P09_Cell4.txt.gz","2540","45","Male","Healthy","Serum","NA"
"GSM3523017","Healthy [SH52617_Cell2]","GSM3523017","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268899","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523017/suppl/GSM3523017_SH52617_Cell2.txt.gz","2540","60","Male","Healthy","Serum","NA"
"GSM3523018","Healthy [SH52P18_Cell1]","GSM3523018","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268900","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523018/suppl/GSM3523018_SH52P18_Cell1.txt.gz","2540","51","Male","Healthy","Serum","NA"
"GSM3523019","Healthy [SH52P18_Cell2]","GSM3523019","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268901","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523019/suppl/GSM3523019_SH52P18_Cell2.txt.gz","2540","45","Male","Healthy","Serum","NA"
"GSM3523020","Healthy [SH52618_Cell1]","GSM3523020","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268902","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523020/suppl/GSM3523020_SH52618_Cell1.txt.gz","2540","44","Male","Healthy","Serum","NA"
"GSM3523021","Healthy [SH52618_Cell2]","GSM3523021","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268903","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523021/suppl/GSM3523021_SH52618_Cell2.txt.gz","2540","67","Male","Healthy","Serum","NA"
"GSM3523022","Healthy [SH52618_Cell3]","GSM3523022","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 70","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268904","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523022/suppl/GSM3523022_SH52618_Cell3.txt.gz","2540","70","Male","Healthy","Serum","NA"
"GSM3523023","Healthy [SH52618_Cell4]","GSM3523023","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268905","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523023/suppl/GSM3523023_SH52618_Cell4.txt.gz","2540","53","Male","Healthy","Serum","NA"
"GSM3523024","Healthy [SH52619_Cell1]","GSM3523024","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268906","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523024/suppl/GSM3523024_SH52619_Cell1.txt.gz","2540","56","Male","Healthy","Serum","NA"
"GSM3523025","Healthy [SH52619_Cell2]","GSM3523025","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268907","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523025/suppl/GSM3523025_SH52619_Cell2.txt.gz","2540","53","Male","Healthy","Serum","NA"
"GSM3523026","Healthy [SH52619_Cell3]","GSM3523026","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268908","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523026/suppl/GSM3523026_SH52619_Cell3.txt.gz","2540","71","Male","Healthy","Serum","NA"
"GSM3523027","Healthy [SH52619_Cell4]","GSM3523027","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268909","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523027/suppl/GSM3523027_SH52619_Cell4.txt.gz","2540","74","Male","Healthy","Serum","NA"
"GSM3523028","Healthy [SH52622_Cell1]","GSM3523028","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268910","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523028/suppl/GSM3523028_SH52622_Cell1.txt.gz","2540","66","Male","Healthy","Serum","NA"
"GSM3523029","Healthy [SH52622_Cell2]","GSM3523029","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268911","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523029/suppl/GSM3523029_SH52622_Cell2.txt.gz","2540","46","Male","Healthy","Serum","NA"
"GSM3523030","Healthy [SH52622_Cell3]","GSM3523030","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268912","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523030/suppl/GSM3523030_SH52622_Cell3.txt.gz","2540","71","Male","Healthy","Serum","NA"
"GSM3523031","Healthy [SH52622_Cell4]","GSM3523031","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268913","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523031/suppl/GSM3523031_SH52622_Cell4.txt.gz","2540","61","Male","Healthy","Serum","NA"
"GSM3523032","Healthy [SH52P18_Cell3]","GSM3523032","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268914","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523032/suppl/GSM3523032_SH52P18_Cell3.txt.gz","2540","78","Male","Healthy","Serum","NA"
"GSM3523033","Healthy [SH52624_Cell2]","GSM3523033","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268915","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523033/suppl/GSM3523033_SH52624_Cell2.txt.gz","2540","52","Male","Healthy","Serum","NA"
"GSM3523034","Healthy [SH52624_Cell3]","GSM3523034","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268916","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523034/suppl/GSM3523034_SH52624_Cell3.txt.gz","2540","65","Male","Healthy","Serum","NA"
"GSM3523035","Healthy [SH52624_Cell4]","GSM3523035","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 70","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268917","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523035/suppl/GSM3523035_SH52624_Cell4.txt.gz","2540","70","Male","Healthy","Serum","NA"
"GSM3523036","Healthy [SH52625_Cell1]","GSM3523036","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268918","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523036/suppl/GSM3523036_SH52625_Cell1.txt.gz","2540","69","Male","Healthy","Serum","NA"
"GSM3523037","Healthy [SH52625_Cell2]","GSM3523037","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268919","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523037/suppl/GSM3523037_SH52625_Cell2.txt.gz","2540","73","Male","Healthy","Serum","NA"
"GSM3523038","Healthy [SH52625_Cell3]","GSM3523038","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268920","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523038/suppl/GSM3523038_SH52625_Cell3.txt.gz","2540","66","Male","Healthy","Serum","NA"
"GSM3523039","Healthy [SH52625_Cell4]","GSM3523039","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268921","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523039/suppl/GSM3523039_SH52625_Cell4.txt.gz","2540","40","Male","Healthy","Serum","NA"
"GSM3523040","Healthy [SH52626_Cell1]","GSM3523040","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268922","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523040/suppl/GSM3523040_SH52626_Cell1.txt.gz","2540","50","Male","Healthy","Serum","NA"
"GSM3523041","Healthy [SH52626_Cell2]","GSM3523041","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468944","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523041/suppl/GSM3523041_SH52626_Cell2.txt.gz","2540","39","Male","Healthy","Serum","NA"
"GSM3523042","Healthy [SH52626_Cell3]","GSM3523042","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 67","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268923","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523042/suppl/GSM3523042_SH52626_Cell3.txt.gz","2540","67","Male","Healthy","Serum","NA"
"GSM3523043","Healthy [SH52626_Cell4]","GSM3523043","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 69","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268924","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523043/suppl/GSM3523043_SH52626_Cell4.txt.gz","2540","69","Male","Healthy","Serum","NA"
"GSM3523044","Healthy [SH52627_Cell1]","GSM3523044","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 73","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268925","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523044/suppl/GSM3523044_SH52627_Cell1.txt.gz","2540","73","Male","Healthy","Serum","NA"
"GSM3523045","Healthy [SH52627_Cell2]","GSM3523045","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 77","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268926","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523045/suppl/GSM3523045_SH52627_Cell2.txt.gz","2540","77","Male","Healthy","Serum","NA"
"GSM3523046","Healthy [SH52627_Cell3]","GSM3523046","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 70","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268927","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523046/suppl/GSM3523046_SH52627_Cell3.txt.gz","2540","70","Male","Healthy","Serum","NA"
"GSM3523047","Healthy [SH52627_Cell4]","GSM3523047","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268928","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523047/suppl/GSM3523047_SH52627_Cell4.txt.gz","2540","51","Male","Healthy","Serum","NA"
"GSM3523048","Healthy [SH52629_Cell1]","GSM3523048","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268929","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523048/suppl/GSM3523048_SH52629_Cell1.txt.gz","2540","65","Male","Healthy","Serum","NA"
"GSM3523049","Healthy [SH52629_Cell2]","GSM3523049","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268930","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523049/suppl/GSM3523049_SH52629_Cell2.txt.gz","2540","63","Male","Healthy","Serum","NA"
"GSM3523050","Healthy [SH52629_Cell3]","GSM3523050","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 61","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268931","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523050/suppl/GSM3523050_SH52629_Cell3.txt.gz","2540","61","Male","Healthy","Serum","NA"
"GSM3523051","Healthy [SH52629_Cell4]","GSM3523051","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 66","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268932","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523051/suppl/GSM3523051_SH52629_Cell4.txt.gz","2540","66","Male","Healthy","Serum","NA"
"GSM3523052","Healthy [SH52630_Cell1]","GSM3523052","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 74","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268933","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523052/suppl/GSM3523052_SH52630_Cell1.txt.gz","2540","74","Male","Healthy","Serum","NA"
"GSM3523053","Healthy [SH52630_Cell2]","GSM3523053","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 59","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268934","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523053/suppl/GSM3523053_SH52630_Cell2.txt.gz","2540","59","Male","Healthy","Serum","NA"
"GSM3523054","Healthy [SH52630_Cell3]","GSM3523054","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268935","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523054/suppl/GSM3523054_SH52630_Cell3.txt.gz","2540","63","Male","Healthy","Serum","NA"
"GSM3523055","Healthy [SH52P18_Cell4]","GSM3523055","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268936","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523055/suppl/GSM3523055_SH52P18_Cell4.txt.gz","2540","53","Male","Healthy","Serum","NA"
"GSM3523056","Healthy [SH52631_Cell1]","GSM3523056","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 54","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268937","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523056/suppl/GSM3523056_SH52631_Cell1.txt.gz","2540","54","Male","Healthy","Serum","NA"
"GSM3523057","Healthy [SH52631_Cell2]","GSM3523057","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268938","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523057/suppl/GSM3523057_SH52631_Cell2.txt.gz","2540","64","Male","Healthy","Serum","NA"
"GSM3523058","Healthy [SH52631_Cell3]","GSM3523058","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468927","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523058/suppl/GSM3523058_SH52631_Cell3.txt.gz","2540","38","Male","Healthy","Serum","NA"
"GSM3523059","Healthy [SH52631_Cell4]","GSM3523059","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268939","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523059/suppl/GSM3523059_SH52631_Cell4.txt.gz","2540","78","Male","Healthy","Serum","NA"
"GSM3523060","Healthy [SH52632_Cell1]","GSM3523060","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268940","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523060/suppl/GSM3523060_SH52632_Cell1.txt.gz","2540","41","Male","Healthy","Serum","NA"
"GSM3523061","Healthy [SH52632_Cell2]","GSM3523061","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 76","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268941","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523061/suppl/GSM3523061_SH52632_Cell2.txt.gz","2540","76","Male","Healthy","Serum","NA"
"GSM3523062","Healthy [SH52632_Cell3]","GSM3523062","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268942","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523062/suppl/GSM3523062_SH52632_Cell3.txt.gz","2540","43","Male","Healthy","Serum","NA"
"GSM3523063","Healthy [SH52632_Cell4]","GSM3523063","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468922","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523063/suppl/GSM3523063_SH52632_Cell4.txt.gz","2540","37","Male","Healthy","Serum","NA"
"GSM3523064","Healthy [SH52633_Cell1]","GSM3523064","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268943","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523064/suppl/GSM3523064_SH52633_Cell1.txt.gz","2540","47","Male","Healthy","Serum","NA"
"GSM3523065","Healthy [SH52633_Cell4]","GSM3523065","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268946","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523065/suppl/GSM3523065_SH52633_Cell4.txt.gz","2540","51","Male","Healthy","Serum","NA"
"GSM3523066","Healthy [SH52P19_Cell1]","GSM3523066","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268947","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523066/suppl/GSM3523066_SH52P19_Cell1.txt.gz","2540","60","Male","Healthy","Serum","NA"
"GSM3523067","Healthy [SH52634_Cell2]","GSM3523067","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268948","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523067/suppl/GSM3523067_SH52634_Cell2.txt.gz","2540","49","Male","Healthy","Serum","NA"
"GSM3523068","Healthy [SH52634_Cell3]","GSM3523068","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268949","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523068/suppl/GSM3523068_SH52634_Cell3.txt.gz","2540","58","Male","Healthy","Serum","NA"
"GSM3523069","Healthy [SH52634_Cell4]","GSM3523069","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268950","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523069/suppl/GSM3523069_SH52634_Cell4.txt.gz","2540","43","Male","Healthy","Serum","NA"
"GSM3523070","Healthy [SH52635_Cell1]","GSM3523070","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468913","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523070/suppl/GSM3523070_SH52635_Cell1.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523071","Healthy [SH52635_Cell2]","GSM3523071","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 53","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268951","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523071/suppl/GSM3523071_SH52635_Cell2.txt.gz","2540","53","Male","Healthy","Serum","NA"
"GSM3523072","Healthy [SH52635_Cell3]","GSM3523072","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268952","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523072/suppl/GSM3523072_SH52635_Cell3.txt.gz","2540","52","Male","Healthy","Serum","NA"
"GSM3523073","Healthy [SH52635_Cell4]","GSM3523073","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268953","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523073/suppl/GSM3523073_SH52635_Cell4.txt.gz","2540","56","Male","Healthy","Serum","NA"
"GSM3523074","Healthy [SH52637_Cell1]","GSM3523074","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268954","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523074/suppl/GSM3523074_SH52637_Cell1.txt.gz","2540","50","Male","Healthy","Serum","NA"
"GSM3523075","Healthy [SH52637_Cell2]","GSM3523075","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268955","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523075/suppl/GSM3523075_SH52637_Cell2.txt.gz","2540","60","Male","Healthy","Serum","NA"
"GSM3523076","Healthy [SH52637_Cell3]","GSM3523076","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268956","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523076/suppl/GSM3523076_SH52637_Cell3.txt.gz","2540","64","Male","Healthy","Serum","NA"
"GSM3523077","Healthy [SH52637_Cell4]","GSM3523077","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268957","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523077/suppl/GSM3523077_SH52637_Cell4.txt.gz","2540","50","Male","Healthy","Serum","NA"
"GSM3523078","Healthy [SH52657_Cell1]","GSM3523078","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 52","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268958","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523078/suppl/GSM3523078_SH52657_Cell1.txt.gz","2540","52","Male","Healthy","Serum","NA"
"GSM3523079","Healthy [SH52657_Cell2]","GSM3523079","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268959","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523079/suppl/GSM3523079_SH52657_Cell2.txt.gz","2540","56","Male","Healthy","Serum","NA"
"GSM3523080","Healthy [SH52657_Cell3]","GSM3523080","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268960","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523080/suppl/GSM3523080_SH52657_Cell3.txt.gz","2540","60","Male","Healthy","Serum","NA"
"GSM3523081","Healthy [SH52657_Cell4]","GSM3523081","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268961","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523081/suppl/GSM3523081_SH52657_Cell4.txt.gz","2540","63","Male","Healthy","Serum","NA"
"GSM3523082","Healthy [SH52658_Cell1]","GSM3523082","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268962","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523082/suppl/GSM3523082_SH52658_Cell1.txt.gz","2540","63","Male","Healthy","Serum","NA"
"GSM3523083","Healthy [SH52658_Cell2]","GSM3523083","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 65","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268963","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523083/suppl/GSM3523083_SH52658_Cell2.txt.gz","2540","65","Male","Healthy","Serum","NA"
"GSM3523084","Healthy [SH52658_Cell3]","GSM3523084","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 78","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268964","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523084/suppl/GSM3523084_SH52658_Cell3.txt.gz","2540","78","Male","Healthy","Serum","NA"
"GSM3523085","Healthy [SH52658_Cell4]","GSM3523085","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 64","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268965","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523085/suppl/GSM3523085_SH52658_Cell4.txt.gz","2540","64","Male","Healthy","Serum","NA"
"GSM3523086","Healthy [SH52659_Cell1]","GSM3523086","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268966","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523086/suppl/GSM3523086_SH52659_Cell1.txt.gz","2540","55","Male","Healthy","Serum","NA"
"GSM3523087","Healthy [SH52659_Cell3]","GSM3523087","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 57","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268968","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523087/suppl/GSM3523087_SH52659_Cell3.txt.gz","2540","57","Male","Healthy","Serum","NA"
"GSM3523088","Healthy [SH52659_Cell4]","GSM3523088","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268969","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523088/suppl/GSM3523088_SH52659_Cell4.txt.gz","2540","55","Male","Healthy","Serum","NA"
"GSM3523089","Healthy [SH52661_Cell1]","GSM3523089","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268970","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523089/suppl/GSM3523089_SH52661_Cell1.txt.gz","2540","71","Male","Healthy","Serum","NA"
"GSM3523090","Healthy [SH52661_Cell4]","GSM3523090","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 63","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268974","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523090/suppl/GSM3523090_SH52661_Cell4.txt.gz","2540","63","Male","Healthy","Serum","NA"
"GSM3523091","Healthy [SH52662_Cell3]","GSM3523091","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468886","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523091/suppl/GSM3523091_SH52662_Cell3.txt.gz","2540","39","Male","Healthy","Serum","NA"
"GSM3523092","Healthy [SH52662_Cell4]","GSM3523092","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 46","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268977","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523092/suppl/GSM3523092_SH52662_Cell4.txt.gz","2540","46","Male","Healthy","Serum","NA"
"GSM3523093","Healthy [SH52P23_Cell3]","GSM3523093","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268980","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523093/suppl/GSM3523093_SH52P23_Cell3.txt.gz","2540","47","Male","Healthy","Serum","NA"
"GSM3523094","Healthy [SH52666_Cell1]","GSM3523094","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268982","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523094/suppl/GSM3523094_SH52666_Cell1.txt.gz","2540","50","Male","Healthy","Serum","NA"
"GSM3523095","Healthy [SH52666_Cell2]","GSM3523095","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268983","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523095/suppl/GSM3523095_SH52666_Cell2.txt.gz","2540","51","Male","Healthy","Serum","NA"
"GSM3523096","Healthy [SH52666_Cell3]","GSM3523096","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268984","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523096/suppl/GSM3523096_SH52666_Cell3.txt.gz","2540","55","Male","Healthy","Serum","NA"
"GSM3523097","Healthy [SH52667_Cell1]","GSM3523097","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268986","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523097/suppl/GSM3523097_SH52667_Cell1.txt.gz","2540","49","Male","Healthy","Serum","NA"
"GSM3523098","Healthy [SH52668_Cell4]","GSM3523098","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268993","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523098/suppl/GSM3523098_SH52668_Cell4.txt.gz","2540","60","Male","Healthy","Serum","NA"
"GSM3523099","Healthy [SH52801_Cell2]","GSM3523099","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268995","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523099/suppl/GSM3523099_SH52801_Cell2.txt.gz","2540","55","Male","Healthy","Serum","NA"
"GSM3523100","Healthy [SH52801_Cell3]","GSM3523100","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 71","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268996","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523100/suppl/GSM3523100_SH52801_Cell3.txt.gz","2540","71","Male","Healthy","Serum","NA"
"GSM3523101","Healthy [SH52802_Cell2]","GSM3523101","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 55","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3268999","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523101/suppl/GSM3523101_SH52802_Cell2.txt.gz","2540","55","Male","Healthy","Serum","NA"
"GSM3523102","Healthy [SH52802_Cell3]","GSM3523102","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269000","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523102/suppl/GSM3523102_SH52802_Cell3.txt.gz","2540","51","Male","Healthy","Serum","NA"
"GSM3523103","Healthy [SH52802_Cell4]","GSM3523103","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 51","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269001","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523103/suppl/GSM3523103_SH52802_Cell4.txt.gz","2540","51","Male","Healthy","Serum","NA"
"GSM3523104","Healthy [SH52807_Cell1]","GSM3523104","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269002","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523104/suppl/GSM3523104_SH52807_Cell1.txt.gz","2540","50","Male","Healthy","Serum","NA"
"GSM3523105","Healthy [SH52807_Cell2]","GSM3523105","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468859","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523105/suppl/GSM3523105_SH52807_Cell2.txt.gz","2540","39","Male","Healthy","Serum","NA"
"GSM3523106","Healthy [SH52807_Cell3]","GSM3523106","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468858","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523106/suppl/GSM3523106_SH52807_Cell3.txt.gz","2540","38","Male","Healthy","Serum","NA"
"GSM3523107","Healthy [SH52807_Cell4]","GSM3523107","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468857","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523107/suppl/GSM3523107_SH52807_Cell4.txt.gz","2540","36","Male","Healthy","Serum","NA"
"GSM3523108","Healthy [SH53228_Cell2]","GSM3523108","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269007","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523108/suppl/GSM3523108_SH53228_Cell2.txt.gz","2540","60","Male","Healthy","Serum","NA"
"GSM3523109","Healthy [SH53230_Cell1]","GSM3523109","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 56","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269010","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523109/suppl/GSM3523109_SH53230_Cell1.txt.gz","2540","56","Male","Healthy","Serum","NA"
"GSM3523110","Healthy [SH53233_Cell2]","GSM3523110","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269019","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523110/suppl/GSM3523110_SH53233_Cell2.txt.gz","2540","45","Male","Healthy","Serum","NA"
"GSM3523111","Healthy [SH53233_Cell3]","GSM3523111","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269020","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523111/suppl/GSM3523111_SH53233_Cell3.txt.gz","2540","49","Male","Healthy","Serum","NA"
"GSM3523112","Healthy [SH53234_Cell1]","GSM3523112","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 60","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269022","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523112/suppl/GSM3523112_SH53234_Cell1.txt.gz","2540","60","Male","Healthy","Serum","NA"
"GSM3523113","Healthy [SH53234_Cell2]","GSM3523113","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269023","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523113/suppl/GSM3523113_SH53234_Cell2.txt.gz","2540","58","Male","Healthy","Serum","NA"
"GSM3523114","Healthy [SH53234_Cell3]","GSM3523114","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 58","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269024","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523114/suppl/GSM3523114_SH53234_Cell3.txt.gz","2540","58","Male","Healthy","Serum","NA"
"GSM3523115","Healthy [SH53235_Cell2]","GSM3523115","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269027","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523115/suppl/GSM3523115_SH53235_Cell2.txt.gz","2540","49","Male","Healthy","Serum","NA"
"GSM3523116","Healthy [SH53235_Cell3]","GSM3523116","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269028","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523116/suppl/GSM3523116_SH53235_Cell3.txt.gz","2540","50","Male","Healthy","Serum","NA"
"GSM3523117","Healthy [SH53B26_Cell3]","GSM3523117","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 49","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269088","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523117/suppl/GSM3523117_SH53B26_Cell3.txt.gz","2540","49","Male","Healthy","Serum","NA"
"GSM3523118","Healthy [SH53A47_Cell1]","GSM3523118","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269090","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523118/suppl/GSM3523118_SH53A47_Cell1.txt.gz","2540","50","Male","Healthy","Serum","NA"
"GSM3523119","Healthy [SH53A47_Cell3]","GSM3523119","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269092","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523119/suppl/GSM3523119_SH53A47_Cell3.txt.gz","2540","40","Male","Healthy","Serum","NA"
"GSM3523120","Healthy [SH53A49_Cell2]","GSM3523120","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269095","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523120/suppl/GSM3523120_SH53A49_Cell2.txt.gz","2540","47","Male","Healthy","Serum","NA"
"GSM3523121","Healthy [SH53A49_Cell3]","GSM3523121","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269096","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523121/suppl/GSM3523121_SH53A49_Cell3.txt.gz","2540","43","Male","Healthy","Serum","NA"
"GSM3523122","Healthy [SH53A49_Cell4]","GSM3523122","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269097","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523122/suppl/GSM3523122_SH53A49_Cell4.txt.gz","2540","44","Male","Healthy","Serum","NA"
"GSM3523123","Healthy [SH53A51_Cell1]","GSM3523123","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269098","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523123/suppl/GSM3523123_SH53A51_Cell1.txt.gz","2540","44","Male","Healthy","Serum","NA"
"GSM3523124","Healthy [SH54101_Cell1]","GSM3523124","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269099","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523124/suppl/GSM3523124_SH54101_Cell1.txt.gz","2540","40","Male","Healthy","Serum","NA"
"GSM3523125","Healthy [SH54101_Cell2]","GSM3523125","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 50","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269100","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523125/suppl/GSM3523125_SH54101_Cell2.txt.gz","2540","50","Male","Healthy","Serum","NA"
"GSM3523126","Healthy [SH53A51_Cell4]","GSM3523126","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468758","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523126/suppl/GSM3523126_SH53A51_Cell4.txt.gz","2540","39","Male","Healthy","Serum","NA"
"GSM3523127","Healthy [SH53A52_Cell1]","GSM3523127","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 39","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468757","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523127/suppl/GSM3523127_SH53A52_Cell1.txt.gz","2540","39","Male","Healthy","Serum","NA"
"GSM3523128","Healthy [SH54101_Cell3]","GSM3523128","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 47","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269101","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523128/suppl/GSM3523128_SH54101_Cell3.txt.gz","2540","47","Male","Healthy","Serum","NA"
"GSM3523129","Healthy [SH54101_Cell4]","GSM3523129","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269102","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523129/suppl/GSM3523129_SH54101_Cell4.txt.gz","2540","40","Male","Healthy","Serum","NA"
"GSM3523130","Healthy [SH53A52_Cell4]","GSM3523130","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468754","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523130/suppl/GSM3523130_SH53A52_Cell4.txt.gz","2540","37","Male","Healthy","Serum","NA"
"GSM3523131","Healthy [SH53A54_Cell3]","GSM3523131","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468751","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523131/suppl/GSM3523131_SH53A54_Cell3.txt.gz","2540","36","Male","Healthy","Serum","NA"
"GSM3523132","Healthy [SH53A54_Cell4]","GSM3523132","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269105","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523132/suppl/GSM3523132_SH53A54_Cell4.txt.gz","2540","45","Male","Healthy","Serum","NA"
"GSM3523133","Healthy [SH53A55_Cell1]","GSM3523133","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468749","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523133/suppl/GSM3523133_SH53A55_Cell1.txt.gz","2540","37","Male","Healthy","Serum","NA"
"GSM3523134","Healthy [SH53A55_Cell2]","GSM3523134","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468748","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523134/suppl/GSM3523134_SH53A55_Cell2.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523135","Healthy [SH53A56_Cell1]","GSM3523135","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269108","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523135/suppl/GSM3523135_SH53A56_Cell1.txt.gz","2540","43","Male","Healthy","Serum","NA"
"GSM3523136","Healthy [SH54102_Cell1]","GSM3523136","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 38","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468744","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523136/suppl/GSM3523136_SH54102_Cell1.txt.gz","2540","38","Male","Healthy","Serum","NA"
"GSM3523137","Healthy [SH54102_Cell2]","GSM3523137","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 43","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269109","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523137/suppl/GSM3523137_SH54102_Cell2.txt.gz","2540","43","Male","Healthy","Serum","NA"
"GSM3523138","Healthy [SH53A59_Cell1]","GSM3523138","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 36","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468741","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523138/suppl/GSM3523138_SH53A59_Cell1.txt.gz","2540","36","Male","Healthy","Serum","NA"
"GSM3523139","Healthy [SH53A59_Cell3]","GSM3523139","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 37","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468738","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523139/suppl/GSM3523139_SH53A59_Cell3.txt.gz","2540","37","Male","Healthy","Serum","NA"
"GSM3523140","Healthy [SH53A60_Cell2]","GSM3523140","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269114","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523140/suppl/GSM3523140_SH53A60_Cell2.txt.gz","2540","41","Male","Healthy","Serum","NA"
"GSM3523141","Healthy [SH53A60_Cell4]","GSM3523141","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468734","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523141/suppl/GSM3523141_SH53A60_Cell4.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523142","Healthy [SH53A61_Cell3]","GSM3523142","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269118","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523142/suppl/GSM3523142_SH53A61_Cell3.txt.gz","2540","45","Male","Healthy","Serum","NA"
"GSM3523143","Healthy [SH53A61_Cell4]","GSM3523143","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 41","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269119","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523143/suppl/GSM3523143_SH53A61_Cell4.txt.gz","2540","41","Male","Healthy","Serum","NA"
"GSM3523144","Healthy [SH53A62_Cell3]","GSM3523144","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269121","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523144/suppl/GSM3523144_SH53A62_Cell3.txt.gz","2540","42","Male","Healthy","Serum","NA"
"GSM3523145","Healthy [SH53A62_Cell4]","GSM3523145","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 40","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269122","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523145/suppl/GSM3523145_SH53A62_Cell4.txt.gz","2540","40","Male","Healthy","Serum","NA"
"GSM3523146","Healthy [SH53B03_Cell2]","GSM3523146","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269133","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523146/suppl/GSM3523146_SH53B03_Cell2.txt.gz","2540","45","Male","Healthy","Serum","NA"
"GSM3523147","Healthy [SH53B04_Cell1]","GSM3523147","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468710","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523147/suppl/GSM3523147_SH53B04_Cell1.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523148","Healthy [SH53B04_Cell3]","GSM3523148","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 45","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269137","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523148/suppl/GSM3523148_SH53B04_Cell3.txt.gz","2540","45","Male","Healthy","Serum","NA"
"GSM3523149","Healthy [SH53B04_Cell4]","GSM3523149","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 42","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269138","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523149/suppl/GSM3523149_SH53B04_Cell4.txt.gz","2540","42","Male","Healthy","Serum","NA"
"GSM3523150","Healthy [SH53B05_Cell3]","GSM3523150","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 44","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3269141","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523150/suppl/GSM3523150_SH53B05_Cell3.txt.gz","2540","44","Male","Healthy","Serum","NA"
"GSM3523151","Healthy [SH53B07_Cell2]","GSM3523151","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468697","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523151/suppl/GSM3523151_SH53B07_Cell2.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523152","Healthy [SH53B21_Cell1]","GSM3523152","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468642","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523152/suppl/GSM3523152_SH53B21_Cell1.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523153","Healthy [SH53R31_Cell3]","GSM3523153","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468581","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523153/suppl/GSM3523153_SH53R31_Cell3.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523154","Healthy [SH55B22_Cell3]","GSM3523154","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468526","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523154/suppl/GSM3523154_SH55B22_Cell3.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523155","Healthy [SH56N29_Cell2]","GSM3523155","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468477","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523155/suppl/GSM3523155_SH56N29_Cell2.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523156","Healthy [SH54933_Cell1]","GSM3523156","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468425","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523156/suppl/GSM3523156_SH54933_Cell1.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523157","Healthy [SH56N25_Cell3]","GSM3523157","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468374","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523157/suppl/GSM3523157_SH56N25_Cell3.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523158","Healthy [SH54G03_Cell3]","GSM3523158","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468343","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523158/suppl/GSM3523158_SH54G03_Cell3.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523159","Healthy [SH54G07_Cell3]","GSM3523159","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468339","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523159/suppl/GSM3523159_SH54G07_Cell3.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523160","Healthy [SH56N23_Cell4]","GSM3523160","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468335","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523160/suppl/GSM3523160_SH56N23_Cell4.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523161","Healthy [SH55B08_Cell1]","GSM3523161","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468325","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523161/suppl/GSM3523161_SH55B08_Cell1.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523162","Healthy [SH55B27_Cell1]","GSM3523162","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468321","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523162/suppl/GSM3523162_SH55B27_Cell1.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523163","Healthy [SH55B28_Cell3]","GSM3523163","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468315","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523163/suppl/GSM3523163_SH55B28_Cell3.txt.gz","2540","35","Male","Healthy","Serum","NA"
"GSM3523164","Healthy [SH56N15_Cell3]","GSM3523164","Public on Feb 14 2019","Dec 19 2018","Feb 16 2019","RNA","1","Serum","Homo sapiens","tissue: Serum","patient diagnosis: Healthy","gender: Male","tumor stage: NA","age: 35","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.). Total RNA was also obtained from the FFPE sections using the Arcturus® Paradise® Extraction and Isolation kit (Life Technologies) in accordance with the manufacturer's instructions.","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","GSM3468252","Mean and standard deviation (SD) of the 5% trimmed signals of the negative controls were calculated. Signals of miRNAs over mean+2SD of the negative controls were subtracted with the mean of the negative controls. The undetected signal was replaced with the value that was the least signal intensity on each DNA chip minus 0.1 in log2 scale followed by quantile normalization.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3523nnn/GSM3523164/suppl/GSM3523164_SH56N15_Cell3.txt.gz","2540","35","Male","Healthy","Serum","NA"
